



**BAFNA PHARMACEUTICALS LIMITED**

30th Annual Report | Financial Year 2024-25

# Exporting Excellence







## Exporting Excellence

At Bafna Pharmaceuticals, we manufacture more than prescription medicines. We produce trust in our bottles, sachets and packs. Trust that gets shipped across time zones.

And that is why we have to ensure that every microgram that leaves our plant is of the topmost quality. BAFNA PHARMA is a UK MHRA- accredited Facility.

This enables us to thrive not only in Africa and Southeast Asia, but also in the highly regulated markets like the United Kingdom, Europe and Australia, where we have to be the best.

And we can do so because of our unwavering focus on quality.

# About Bafna

Bafna Pharmaceuticals Limited (Bafna) is a leading pharmaceutical company, headquartered in Chennai, India, specializing in non-betalactum solid oral dosage forms besides other emerging and potential products and forms.

We have a strong and long legacy of delivering Generic Pharmaceutical Products for UK, Australia EU and Emerging Markets. During our journey, we have built an impeccable lineage and strong client relations as a Contract Manufacturing Organization (CMO) for leading pharmaceutical world-class players. We also have the right capabilities to manufacture high potent molecule(s).

Over the past 30+ years, we have built a reputation that is signified by strong capabilities, high integrity, strong governance, stringent compliances, excellent business relations and a growing global market presence.

We have UK-MHRA, TGA-Australia and EU-GMP certified manufacturing facility in Chennai, India. We export about 70% of our total produce to over twenty (20) countries across Asia, Africa, UK, Europe and Australia.

**The pharmaceutical services that we offer include Contract Research & Manufacturing (CRAMS), Technology transfers, Formulation and Analytical Development.**





## Vision

**“To become a leading global pharmaceutical company recognized for our specialty generics and innovative product portfolio, expanding across regulated markets and continuously moving up the pharmaceutical value chain under the banner of ‘Wellness Beyond Boundaries.’”**

## Mission

**“To deliver high quality, affordable pharmaceutical formulations to global markets, leveraging our EU GMP, UK MHRA and TGA Australia accredited facility, while maintaining cost leadership, regulatory excellence, and a deep commitment to patient wellbeing.”**

**30+**  
years of pharma  
manufacturing  
experience

**UK-MHRA, TGA-  
Australia and  
WHO-GMP** certified  
manufacturing facility  
in Chennai

**Export-led  
growth**  
model with  
presence in  
Australia, UK,  
Africa, etc.

**₹146 Cr.**  
Operating Revenue  
FY25

# KEY FACTS:

**₹57.83 Cr.**  
Net Worth FY25

**₹201 Cr.**  
Market Cap

**600+**  
Employees

**First**  
to launch generic  
Prednisolone  
Enteric Coated  
tablets in UK and  
IVAB, RECLAP and  
SITAG in emerging  
Markets

Multiple awards in 2024-25, including **“Excellence in Pharma Exports”** by Times of India and **“Top 10 Finished Dosage Formulations Manufacturer”** by India Pharma Outlook.

**CEO Mr. Bafna Mahaveer Chand** awarded with **Entrepreneur of the Year 2025** by the MSME Department, Govt. of Odisha

- **The National Level Entrepreneurship Excellence Award in 2010** from SME Chamber of Commerce
- **Udyog Rattan Award 2011**
- **Pioneers 2012 Award** from “The Times Award” for Contribution towards the success of Healthcare in Tamil Nadu.

**Continuous acknowledgments** for the Company from Government bodies including:

- **Best Supplier Awards** by Government of Sri Lanka
- **Gold Quality Excellence Award 2009**, and **Quality Excellence Award 2010** from Indian Drug Manufacturers’ Association (IDMA)
- **Excellence Award 2011** from Institute of Economic Studies (IES)
- Recognized as a **ZED Gold Category** Company by the Ministry of MSME, Government of India

**Trusted partnerships** with global distributors across UK, Australia, Europe, Asia, Africa and Rest of the World (RoW)

# ANNUAL REPORT 2024-25



Visit our Investor Relations section here  
<http://bafnapharma.com/financials.html>

#### Caution Regarding Forward-Looking Statements

We have used a few forward-looking (futuristic) statements throughout the report solely to articulate our future growth prospects and to exemplify our intended milestones. However, the actual results may vary from the forward-looking statements as the business is subject to a number of risks and uncertainties according to the market scenario.

For readers' reference, we have used words like 'anticipate', 'estimate', 'expect', 'project', 'intend', 'plan', 'believe', and words of similar nature to signify every forward-looking statement. We do not guarantee that these statements will stand true, but we believe that these are backed up by prudent assumptions.

The achievement of the results may vary due to risks, uncertainties, and inaccurate assumptions. If, in case, certain unforeseen risks or uncertainties dominate the market or any of the assumptions are proven erroneous, then the final result may vary exponentially with respect to the anticipated, estimated, or projected result.

Thus, the readers should bear this in mind. We undertake no obligation to update any forward-looking statements publicly, if there is any change in future events, there is new information, or whatsoever.

# Across the Pages

## CORPORATE OVERVIEW

01	Exporting Excellence	22	Governance-driven, sustainably inclusive
02	About Bafna	26	FY25 in Snapshot
08	Manufacturing Excellence that delivers Results	27	Financial Highlights – FY25 & Historical Performance
12	Marketing Solutions that work beyond borders	28	Vision that leads – Message from the CEO
14	Creating Products that Heal	30	Rewards & Recognitions
16	Research & Development that excels	31	Board of Directors
20	Strategy for Sustainable Growth	34	Corporate Information

## STATUTORY REPORTS

36	Notice	50	Board's Report
64	Report on Corporate Governance	76	Management Discussion and Analysis

## FINANCIAL STATEMENTS

85	Independent Auditor's Report on Standalone Financial Statements	98	Standalone Financial Statements
----	---	----	---------------------------------



# Manufacturing Excellence that delivers Results

Bafna has truly come a long way in its journey of building indigenous manufacturing capabilities and obtaining accreditations such as, UK-MHRA and Australia-TGA, DSIR- Govt of India.


This customer-aligned, compliance-led and market-driven manufacture infrastructure provides for the right platform for all the present and future growth

plans of the Company. Our facilities have met with all certifications and periodic audit requirements with satisfactory observations. Right from UK's highly-highly stringent MHRA certification to the TGA for the Australian continent and WHO-GMP, our facilities provide all the peace of mind to our customers.

## Constantly adding to Operational Strengths:



Capacity enhancements at Manufacturing Facility



Expanding the Facility with High capacity Machines.



In-house QC & QA laboratories are constantly upgraded with modern instrumentation



Constantly developing into multi products facilities



Capability to manufacture from small batches to large batches



**EU-GMP** - European Good Manufacturing Practice certified.



**UK-MHRA** - Approved by UK Medicines and Healthcare products Regulatory Agency.



**Australia-TGA** - Accredited by Australian Therapeutic Goods Administration.



**DSIR Certification** - Recognized R&D facility by Department of Scientific and Industrial Research (DSIR), Govt. of India.



**Contract Manufacturing (CMO) Capabilities:** Bafna has strong CMO capabilities and is ready to capitalize the experience, expertise and capacities for future growth plans.



Current partnerships with UK and SEA-based pharma companies



Manufacturing capacity available for third-party branded generics



Proven capability in delivering compliant, export-quality batches




## Overview of Production Infrastructure



**Manufacturing Facility at Red Hills, Chennai**  
**Expanded Formulations + Potent Drugs**  
**WHO-GMP Certified, MHRA Audit Cleared**

## Installed Manufacturing Capacities





## Quality & Regulatory Systems

### QC Infrastructure:

- High Pressure Liquid Chromatography, Infrared Spectrometer, Ultraviolet Visible Spectrophotometers, Gas chromatography, Fourier Transform Infrared spectroscopy, Atomic Absorption Spectrometer, Dissolution Testers.
- Microbiology lab for stability and sterility testing

### QA & Documentation:

- Electronic Batch Records (eBR) being implemented
- Annual Product Quality Review (APQR) integrated

## Compliance & Audit Readiness

- WHO-GMP approval renewed FY23–26
- UK MHRA audit successfully cleared in FY25
- PIC/S standard alignment for ASEAN market eligibility
- Dedicated RA cell for real-time dossier submissions and tracking



Investment Area	Purpose	Status
QC Lab Modernization	New stability chambers, digital validation	Completed
Revamping High Containment Zone-Containment Zone	Oncology / Hormonal lines	Work in Progress
Capacity Enhancement	Optimizing Production	Ongoing
ERP Rollout (Plant Module)	Inventory + batch traceability	Pilot Launched



# Marketing Solutions that work beyond borders

Bafna Pharmaceuticals is name well reckoned as an Indian player of repute, exporting excellence in form of products to various countries of significant sized markets.

Bafna's majority of Exports are most diversified market mix. From one of the most regulated U.K. markets to another high compliance market of Australia to CIS countries and Africa and South East Asia, we cater to a diverse customer base.

## Market Position

- Exports account for 70%+ of revenues
- Diversified Global Market Presence:
  - **Regulated Markets:** UK, Europe and Australia
  - **ASIA:** Sri Lanka, Philippines, Nepal
  - **CIS countries:** Ukraine, Russia, Uzbekistan, Azerbaijan
  - **Africa:** Nigeria, Kenya, Ethiopia, Rwanda, Ghana, Tanzania
- Present across 21 countries

As part of strategic growth plans, Bafna plans to enter **Latin America (LATAM), MENA, and CIS** regions.

**Key Marketing Initiatives and Strengths:**



**Expert Local Partnerships & Regulatory Consultants:** Partnering with specialized regulatory advisors and local distributors helped accelerate market entry and smoothen approval pathways.



**Strong CMO & Institutional relationships:** Bafna, with its strong 35-year legacy built impeccable relations in the capacity of Contract Manufacturing Organization with leading pharmaceutical companies and healthcare institutes. At present Bafna is working with few of the top leading global pharma company.



**Building capabilities to excel:** Bafna has built capabilities to offer multiple pharmaceutical services like Contract Research & Manufacturing (CRAMS), Technology Transfers, Formulation and Analytical Development.



# Creating Products that Heal

At Bafna, our focus has been to add difference to the daily needs of end consumers. Bafna Pharma was the first Company to launch Generic Prednisolone Eccentric Coated treating swelling, itching and allergic reactions, in UK and other markets, have been testimony to our strategy.

Over the years, we expanded our therapeutic areas of products and tried to address a large opportunity segment of lifestyle drugs and thus venturing in high potential product categories,

Today, Bafna manufactures products across following key therapeutic areas:

## Therapeutic Focus Areas:




### Cardiology

Beta blockers, ACE inhibitors, statins.



### Lifestyle & Potent Drugs

Focused pipeline in oncology, women's health, and metabolic disorders, Diabetes, Hyper-tension



### Pain Management

Neuropathic, Joint Pains, Muscular Skeleton Pains, Opioid Pains



**Specialty & Complex Generics:** In order to expand our product portfolio, we are expanding the therapeutic areas and product forms.



**Development of differentiated dosage forms – sachets and modified release tablets**



**Pipeline products include:**

- Potent formulations - oncology, hormonal therapies
- Stability-challenging molecules
- High-barrier generics for emerging and regulated markets

#### **High-value, low-volume portfolio strategy**

We are working on the strategy to build a **high-value, low-volume** specialty product pipeline. The aim is to have a qualitative growth and higher margins, going forward.

#### **Branded Generics**

We have launched our own brands in Sri Lanka, Philippines, Tanzania and Nigeria markets. Our portfolio of offerings under our own brand includes some high-demand therapies like diabetes, cardiovascular and oncology.

# Research & Development that excels

In-house FR&D center, approved by DSIR- Department of Scientific and Industrial Research (DSIR), Govt. of India, enables Bafna to develop formulations indigenously or under contract, targeting regulated markets like the U.K., Europe and other Emerging Markets.

**Our Aim:** Be a “one-stop shop” for formulation development through to commercial production, with potential to function as an independent profit-center in the long term.

## Organizational Role & Regulatory Compliance

- Bafna’s FR&D team helps prepare regulatory dossiers compliant with stringent international standards, supporting the Company’s export-oriented model
- This aligns with Bafna’s broader export strategy, where over 80 % of manufacturing output is exported to countries like the UK, Australia, Sri Lanka, the Philippines and Africa

## R&D Differentiators:



**Proven record of first-to-market generics** – Prednisolone GR: We were the first to launch generic Prednisolone GR tablets in UK. Then IVAB, SITAG, RECLAP in the Sri Lanka and Philippines markets.



**In-house Quality Control Laboratory** with all latest upgraded instrument and equipment.

At present, our R&D efforts have translated into some encouraging real product successes




38 products site-transferred to regulated markets



50 advanced dossiers ready for new market launches



150 products already registered in emerging markets



## Pipeline Strategy:



8+ products in advanced development for UK, SEA, and Africa



Ongoing feasibility studies for bi-layered tablets & oncology products



Targeting dossiers aligned with WHO PQ and UKMHRA expectations

## Rigorous R&D - Focus on Make in India

### Core R&D Focus

- Dedicated Formulation Research & Development (FR&D) team
- Located at Chennai HQ with proximity to manufacturing units
- Core objective: develop complex generics & value-added dosage forms
- Target markets: Australia, UK, Africa, SEA, future EU filings, ROW
- Approved by DSIR- Government of India

### Innovation Priorities

- Modified-release formulations (MR tablets, bi-layered formats)
- Potent Formulations Oncology, hormonal therapies
- Pediatric-friendly formats: dispersible tablets, granules, sachets

### R&D Investment & Capability Building

- FY 24-25 CapEx: ₹14 Cr in lab equipment, software, and stability chambers
- Upgraded formulation lab: HPLCs, UV spectros, tablet press simulators
- Adoption of Quality by Design (QbD) principles in formulation design
- Digital batch documentation and IP tracking under rollout



## Product Pipeline Snapshot

Product Type	Stage	Target Region
Anti-Diabetic	Under Development	UK, EU & Australia
Cardiovascular	Under Development	UK, EU & Australia
Anti-Hypertensive	Under Development	UK, EU & Australia
Bi-Layer Antihypertensive	Filed	SEA



## R&D for Strategic Focus Area

We are currently working on strengthening our brand, upscaling product innovation and expand the therapeutic areas and dosage forms. These will be important aid towards our future growth initiatives.

## Initiative: Global Expansion & Brand Leadership Initiative in Lifestyle drugs



➤ Developing patented molecules for registration In Regulated Market.



➤ Development in our DSIR approved FRND



➤ Targeted Countries/Regions

- UK and EU countries
- CIS countries and SE countries
- MENA and African Regions




# Strategy for Sustainable Growth

Strategic focus, future strategy (market, product, marketing, corporate, finance), year’s Strategy HL

At Bafna, we are adopting a balance strategy among product expansion, market expansion, higher margins and aggressive revenue aspirations.

## Strategic Growth Targets





## Future Roadmap for Strategic Growth Agenda

### ⇒ Upcoming Global Expansion Strategies

We are focusing on strengthening market presence in UK, Europe and Australia, MENA, Sri Lanka Philippines, and CIS regions as part of the next 18-month growth roadmap.

We are aiming to expand branded generics and potent molecule portfolios in regulated markets to capture new therapeutic segments.

### ⇒ New Target Markets & Product Lines

We are working on our entry into North American market with flagship products in the core therapeutic areas of advanced diabetes and oncology formulations.

We are working towards developing new product lines including novel oral anti-diabetics, oncology therapeutics, and advanced cardiovascular generics. We are also focused on licensing our own products.

### ⇒ Planned Collaborations & Promotions

Strategic partnerships with regional distributors and local manufacturing alliances to accelerate market entry.

Participation in major global trade shows, e.g., CPHI Worldwide, Arab Health, to showcase capabilities and establish new partnerships.

Strengthening digital expansion through digital marketing, virtual B2B meetings, and enhanced CRM outreach.

### ⇒ Scaling Beyond the Current Initiative

To leverage the success of 'Global Expansion of Complex Generics Leadership' Initiative to introduce additional high-value future off-Patent Molecules, globally.

To invest in advanced R&D and tech transfer capabilities to stay ahead in complex generics and niche formulations.

Capacity expansion plans aimed at doubling revenue and manufacturing output by 2027.

# Governance-driven, sustainably inclusive

## ESG

At Bafna, being a global supplier of life healing product, we take our environmental, social and governance responsibility with highest level of sincerity, compliance and priority. We believe in giving back to the society, caring for environment and staying sustainable for our shareholders, through growth and profitability.

At Bafna, the Environmental, Social and Governance (ESG) practices have been deeply ingrained in our business philosophy, our policies, our operations and our business strategies.

Some of our key initiatives under good ESG practices are given below:

### Environmental Sustainability

Our focus areas in environmental sustainability practices include water, energy, carbon impact, waste generation and sustainable manufacturing. Following are our key initiatives under environmental sustainability practices:



- **Water recycling:** Water recycling systems are fully operational at our manufacturing unit.
- **Energy optimization:** We have installed high-efficiency HVAC, LED lighting systems at our premises to conserve our energy
- **Reducing Carbon Impact: We reduced carbon impact through following key initiatives:**
  - Effluent treatment compliance (TNPCB-certified)
  - Minimal hazardous waste generation



**Environment Friendly Product Packaging:** We invested in green packaging trial for export products.



## Social Responsibility

Being responsible to our societies and the communities around our areas of operations, has been our priority. This approach of ours has stood true to the essence of social care and has helped us grow inclusively.

Our focus areas in social care include women empowerment, education, elementary healthcare and sanitation. Following are some of the major social care initiatives:

- **Employment of local talent:** Today >65% of our total workforce belongs to Tamil Nadu only. This brings employment for the locals, brings cultural synergies within manufacturing facilities premises.
- Major CSR programs in our areas of operations included the following:
  - **Women’s health awareness** camps were conducted at various Chennai clinics for periodic health-checks and awareness about likely key health issues
  - Aiding Elementary Healthcare through **school medication donation** drives in Red Hills & Madhavaram in Tamil Nadu



## Governance Practices

Good governance practices have been stringently followed at Bafna in order to safeguard all the stakeholders' interests and sustainably grow the stakeholder value in the Company. From fair corporate practices to adopting in-depth policies for major corporate challenges, fair and independent Board of Directors and stringent compliances with laws of the land.

Some of the governance practices at Bafna are as under:

- **Board composition:**
  - Three (3) Independent Directors
  - Separate Chief Executive Officer, Whole-Time Director(s), and Chief Financial Officer (CFO)
- **Board Committees:**
  - Audit Committee, Nomination & Remuneration Committee, Stakeholder Relationship Committee, Corporate Social Responsibility Committee
- **Statutory compliance:**
  - Quarterly audits, SEBI disclosures, insider trading controls

# FY25 in Snapshot


## Operational Highlights:

- **Established a New Quality Control (QC) Laboratory:** A testament to Bafna's our commitment to excellence, featuring sophisticated and cutting-edge technology designed to elevate our quality control processes to new heights.
- **Machinery Upgradation and Temperature Control Systems:** Comprehensive upgrades across various production lines, including the installation of high-precision equipment and advanced HVAC systems with dehumidifiers, facilitating superior temperature and humidity control.
- **Capacity Expansion:** Increased capacities of key equipment such as capsule-filling machines, blenders, and other process equipment, to significantly boost production output, reduce process downtime, and improve delivery timelines to customers.
- **Construction of a New Warehouse (20,000 sq. ft.):** A dedicated warehousing facility admeasuring 20,000 square feet, constructed at the Grantlyon Factory to streamline storage, logistics, and dispatch. This will support higher inventory volumes and improve supply chain efficiency in line with growing business needs




# Financial Highlights – FY25 & Historical Performance:


### Revenue (₹ Cr.)




### EBITDA (₹ Cr.)




### Networth (₹ Cr.)



### Fixed Assets (₹ Cr.)



### PAT (₹ Cr.)



# Vision that leads Message from the CEO



**We remain deeply committed to our governance and ESG goals. Our ongoing efforts include a focus on reducing our environmental footprint, ensuring ethical practices across our supply chain, and fostering a safe, welcoming, and inclusive workplace. Our adherence to stringent quality control measures, including our MHRA audit renewal, ensures that every product meets the highest standards.**

Dear Esteemed Stakeholders,

As we close another successful chapter and look ahead, I want to express my sincere gratitude for your continued trust and support in our mission of Health for All. The past year has been a period of consolidation and strategic advancement, solidifying our position as a resilient and forward-looking force in the pharmaceutical industry.

## Achievements and Progress

The financial year 2024-25 was marked by strong growth momentum in our business, which is a testament to our dedicated teams and strategic initiatives. Our total revenue from operations reached ₹145.86 Crores, a marginal decrease from the previous year's ₹152.47 Crores. Our EBITDA margin remained almost constant and hence, in line with the decline in revenue, the EBITDA dropped to ₹13.92 Crores from ₹14.63 Crores in the previous year. Our Profit After Tax (PAT) for the period stood at ₹4.15 Crores, a significant decline from ₹7.35 Crores in FY2023-24, mainly because of the Exceptional Item of ₹2.15 Crores on account of derecognition of intangible asset under development. Our net worth has grown to ₹84.81 Crores, demonstrating our strengthening financial foundation. These figures reflect our prudent financial management and a focused product strategy.



We have continued to leverage our 30+ years of pharma manufacturing experience to drive operational excellence. Our focus on quality has led to significant progress, including the successful set-up of our new, state-of-the-art in-house Quality Control lab. These investments enhance our ability to deliver innovative and accessible pharmaceutical solutions, ensuring our products not only meet but exceed global regulatory standards.

In line with our Vision 2027, we have made strides toward achieving 70%+ revenue growth in the next two financial years. This includes doubling down on our export-led business model by deepening our presence in current territories through more product registrations and entry into new, high-potential markets, including regulated ones.

## Commitment to Sustainability and Compliance

We remain deeply committed to our governance and ESG goals. Our ongoing efforts include a focus on reducing our environmental footprint, ensuring ethical practices across our supply chain, and fostering a safe, welcoming, and inclusive workplace. Regulatory compliance remains central to our operations, and our adherence to stringent quality control measures, including our MHRA audit renewal, ensures that every product meets the highest standards.

## Looking Ahead

The future holds immense potential for growth, and we are well-positioned to capitalize on emerging opportunities. Our strategic roadmap, Bafna Pharmaceuticals 2.0, focuses on continued growth through manufacturing expansion, including a brownfield expansion of Unit II to add 30% capacity by FY26. We are also actively developing our product & R&D pipeline, which includes launching oncology MR tablets and filing 4-6 new dossiers for the UK, Europe and Australia..

We are focused on expanding our geographic footprint, with ongoing groundwork in the LATAM and CIS regions and plans to appoint local distribution partners in several key countries. These initiatives, combined with our robust operational competencies, will drive the company toward a higher growth trajectory.

## Gratitude

Our success is a shared achievement, built on the dedication and expertise of our employees, the trust of our customers, and the continued support of our shareholders. Together, we will continue to drive innovation and deliver value to all our stakeholders.

In closing, on behalf of our Board of Directors, I extend my heartfelt gratitude to each of you. Your commitment and collaboration are the pillars of our progress. We remain confident in our ability to thrive in this ever-evolving industry, and we are excited about the journey ahead.

Thank you for your continued trust and partnership.

Best Regards,

**Bafna Mahaveer Chand**  
Chief Executive Officer



# Rewards & Recognitions FY25



# Board of Directors



**MS. SHANMUGAM HEMALATHA**  
(Whole Time Director)

Ms. S Hemalatha, a Commerce graduate with C.S. (Inter) and ICWA (Inter) qualifications, has over two decades of experience in the pharmaceutical industry. As a Whole-Time Director, she oversees commercial operations and plays a key role in strategic planning and financial oversight. She has been instrumental in driving the Company's growth and success.



**MR. VINAYAK DINESH DENDUKURI**  
(Whole Time Director – Quality)

Mr. Vinayak is the Co-founder & Director of NOVICK Biosciences. Under his guidance and leadership, NOVICK has established a system that delivers high-quality pharmaceutical product development services, assuring sound fiscal operations. Mr. Vinayak is also a Director at Brane Enterprises, a company emphasizing Natural Language (no coding) and Machine Learning. Prior to this role, Mr. Vinayak was Drug Safety Scientist at Quintiles, leading Phase II and Phase III clinical trials across the globe for major Pharmaceutical companies. Mr. Vinayak also served as a Scientist in several positions at Sanofi Pasteur and GlaxoSmithKline, USA. He completed his Bachelor's degree in Biotechnology from Rochester Institute of Technology, USA, and his Master's degree in Microbiology, Immunology, and Biochemistry from the University of Rochester, USA.



**MR. UPENDAR MEKALA REDDY**  
(Non-Executive Director)

Mr. Upendar holds MBA Degree with specialisation in finance from Indian Institute of Management Kozhikode (IIMK), Bachelor of Technology in Computer Science Engineering from JNTU - Hyderabad and FRM Certification from Global Association of Risk Professionals (GARP). Mr. Upendar Mekala Reddy has over 15 years of experience spanning across Project and Structured Finance, Fund Raising, Mergers and Acquisitions and Investment Banking. He has executed transactions across sectors including Power (Renewable & Non-renewable), Pharmaceuticals, Roads, Manufacturing, Cement, Real Estate, Ports, etc. Prior to iLabs Group, Upendar was working as Vice President with Edelweiss Financial Services, handling the wholesale and structured lending business. He also worked as Assistant Vice President with IL&FS Financial Services and Senior Manager with L&T Infrastructure Finance in the Project Finance Team.



**MRS. AKILA CHINTALAPATI RAJU**  
(Non-Executive Director)

Mrs. Akila Chintalapati Raju holds Master's degree in Law from NYU School of Law, New York. She has over a decade of diverse legal experience spanning Corporate Law, Private Equity, Real Estate transactions, Civil Litigation, and In-house Legal Advisory. Mrs. Akila C Raju worked as the in-house Legal Counsel of Bangalore based Pharmaceutical company, Strides Shasun Ltd, where she led the legal team in setting up the company's Australia business. Post her move to Hyderabad, she focused representing clients in civil litigation matters. Ms. Akila C Raju is passionate about utilizing her legal skills to further Social Causes. While in New York, she Volunteered at an immigration clinic where she worked 'pro bono' on several asylum petitions as well as fighting deportation and removal notices.



**MR. PALAMADAI KRISHNAN SUNDARESAN**  
(Independent Director)

Mr. Palamadai Krishnan Sundaresan, is a qualified Cost & Management Accountant (CMA) and Company Secretary (CS) with over 40 years' multi-industry experience spanning across Corporate Finance, Secretarial Practice, Foreign-exchange Management, Consolidation of Financial Statements, Cost and Value-chain Management, MIS, Pricing, Budgeting, Production Planning, Strategic and Turnaround Management, Strategic Sourcing, Mergers & Acquisitions, Business Valuation, Joint Venture formation and scale-up, complex Debt and Capital Restructuring, and Corporate Governance.



**MRS. RAVICHANDRAN CHITRA**  
(Chairperson & Independent Director)

Mrs. Ravichandran Chitra holds a Bachelor's degree in Commerce and a PGDPMIR from the Madras School of Social Work, Chennai. She brings over three decades of rich and diverse experience in Human Resource Management, Performance Management, Training & Development, Corporate and Legal Affairs, Labour Law Compliance, Compensation and Benefits Administration, and General Administration. Her core strengths include Talent Acquisition, Succession Planning, Employee Retention, Change Management, and designing effective training and development programs.



**MR. NAVIN KUMAR**  
(Independent Director)

Mr. Navin Kumar is a qualified Chartered Accountant from the Institute of Chartered Accountants of India (ICAI), and is currently in practice. He has over 13 years of professional experience in the fields of Corporate Finance, Taxation, Auditing, and Regulatory Compliance. His areas of expertise include Corporate Accounting, Statutory and Internal Audits, Income Tax, Goods and Services Tax (GST), and business advisory services.



# Corporate Information

**Name of Company:** Bafna Pharmaceuticals Limited

**CIN:** L24294TN1995PLC030698

**Incorporation:** 1995

**Initial Public Offering:** 2008

**Listing:** (i) BSE & (ii) NSE

## BOARD OF DIRECTORS

**Ms. S. Hemalatha**

Whole-Time Director

**Mr. Vinayak Dinesh Dendukuri**

Whole-Time Director (Quality)

**Ms. Akila C Raju**

Non-Executive Non-Independent Director

**Mr. Upendar Mekala Reddy**

Non-Executive Non-Independent Director

**Mr. P K Sundaresan**

Non-Executive Independent Director  
(Retired on June 24, 2025)

**Ms. R. Chitra**

Non-Executive Independent Director

**Mr. Navin Kumar**

Non-Executive Independent Director  
(Appointed on June 23, 2025)

**Mr. Krishna Yeachuri**

Non-Executive Independent Director  
(Resigned on March 31, 2025)

## KEY MANAGERIAL PERSONNEL:

**Mr. Bafna Mahaveer Chand**

Chief Executive Officer

**Mr. Melagiri Sridhar**

Chief Financial Officer

**Mr. Mohanachandran A**

Company Secretary

## REGISTERED OFFICE

Bafna Towers  
New No. 68, Old No.299,  
Thambu Chetty Street  
Chennai – 600001

## MANUFACTURING FACILITY

147, Madhavaram Redhills High Road  
Grantlyon, Redhills, Chennai – 600052

## BOARD COMMITTEES:

### Audit Committee

Mr. P K Sundaresan (Upto June 24, 2025)

Ms. R. Chitra

Mr. Upendar Mekala Reddy

Mr. Navin Kumar (From June 25, 2025)

### Nomination and Remuneration Committee

Mr. Krishna Yeachuri (Upto March 31, 2025)

Mr. P K Sundaresan (Upto June 24, 2025)

Ms. R Chitra (From May 20, 2025)

Ms. Akila C Raju

Mr. Navin Kumar (From June 25, 2025)

### Stakeholders Relationship Committee



Ms. R. Chitra

Ms. S. Hemalatha

Ms. Akila C Raju

### Corporate Social Responsibility Committee

Ms. R. Chitra

Ms. S. Hemalatha

Ms. Akila C Raju

## Statutory Auditors

**Brahmayya & Co.,**

Chartered Accountants, Chennai

## Internal Auditors

**K.S. Rao & Co.,**

Chartered Accountants, Chennai

## SHARE TRANSFER AGENTS

**Cameo Corporate Services Limited**

No.1, Club House Road

Chennai – 600002



**Statutory  
Reports**



# NOTICE

NOTICE IS HEREBY GIVEN THAT THE 30TH ANNUAL GENERAL MEETING OF THE MEMBERS OF BAFNA PHARMACEUTICALS LIMITED WILL BE HELD ON FRIDAY, THE 19TH DAY OF SEPTEMBER 2025, AT 10.00 AM (IST) THROUGH VIDEO CONFERENCING ("VC")/ OTHER AUDIO-VISUAL MEANS ("OAVM") TO TRANSACT THE FOLLOWING BUSINESS:

## ORDINARY BUSINESS:

### Item No. 1- Adoption of Audited Financial Statements:

To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2025, together with the Reports of the Board of Directors' and Auditor's thereon.

### Item No. 2- Re-appointment of a Director:

To appoint a Director in the place of Ms. Akila Chintalapati Raju (DIN: 07590312), who retires by rotation in terms of Section 152 of the Companies Act, 2013 and, being eligible, seeks re-appointment.

## SPECIAL BUSINESS:

### Item No. 3- Appointment of Mr. Navin Kumar (DIN: 08778662), as an Independent Director of the Company

To consider and if though fit, to pass the following Resolutions, as a Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152, 161, Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (the Act) read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and Regulation 17 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (the Listing Regulations) (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the Articles of Association of the Company and based on recommendation of the Nomination and Remuneration Committee and as approved by the Board of Directors, Mr. Navin Kumar (DIN: 08778662) who was appointed as an Additional Director (Category: Non- Executive, Independent Director) by the Board of Directors of the Company with effect from June 23, 2025, who meets the criteria for independence under Section 149(6) of the Act and the Rules framed thereunder and Regulation 16(1)(b) of the Listing Regulations and in respect of whom the Company has received a notice in writing from a Member under Section 160 of the Act proposing his candidature for the office of Independent Director, be and is hereby appointed as a Non- Executive, Independent Director of the Company, to hold the office for a term of One (1) year with effect from June 23, 2025 upto June 22, 2026 (both days inclusive) and that he shall not be liable to retire by rotation.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorised to do all acts, deeds, matters and things as may be deemed necessary, proper or desirable and to settle any question, difficulty or doubt that may arise in this regard and to sign and execute all necessary documents, applications, returns and writings as may be necessary, in order to give effect to the above resolution."

### Item No. 4- Re-Appointment of Mr. Palamadai Krishnan Sundaresan (DIN: 06954189), as an Independent Director of the Company:

To consider and if though fit, to pass the following Resolutions, as a Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 149, 152, Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (the Act) read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and Regulation 17 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (the Listing Regulations) (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the Articles of Association of the Company and based on recommendation of the Nomination and Remuneration Committee and the Board of Directors, Mr. Palamadai Krishnan Sundaresan (DIN: 06954189) being eligible for re-appointment, who meets the criteria for independence under Section 149(6) of the Act and the rules framed thereunder and Regulation 16(1)(b) of the Listing Regulations and in respect of whom the Company has received a notice in writing from a Member under Section 160 of the Act proposing his candidature for the office of Independent Director, be and is hereby re-appointed as a Non- Executive, Independent Director of the Company, to hold office for the second term of Five (5) consecutive years with effect from September 19, 2025 upto September 18, 2030 (both days inclusive) and that he shall not be liable to retire by rotation.

RESOLVED FURTHER THAT the Board of Directors be and is hereby authorised to do all acts, deeds, matters and things as may be deemed necessary, proper or desirable and to settle any question, difficulty or doubt that may arise in this regard and to sign and execute all necessary documents, applications, returns and writings as may be necessary, in order to give effect to the above resolution."

**Item No. 5- Re-Appointment of Mrs. Ravichandran Chitra (DIN: 07749125), as an Independent Director of the Company:**

*To consider and if though fit, to pass the following Resolutions, as a Special Resolution:*

“**RESOLVED THAT** pursuant to the provisions of Sections 149, 152, Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (the Act) read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and Regulation 17 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (the Listing Regulations) (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the Articles of Association of the Company and based on recommendation of the Nomination and Remuneration Committee and as approved by the Board of Directors, Mrs. Ravichandran Chitra (DIN: 07749125) who was appointed as an Independent Director of the Company and who holds office upto November 11, 2025 and being eligible for re-appointment, who meets the criteria for independence under Section 149(6) of the Act and the rules framed thereunder and Regulation 16(1)(b) of the Listing Regulations and in respect of whom the Company has received a notice in writing from a Member under Section 160 of the Act proposing her candidature for the office of Independent Director, be and is hereby re-appointed as a Non-Executive, Independent Director of the Company, to hold office for the second term of Five (5) consecutive years with effect from November 12, 2025 upto November 11, 2030 (both days inclusive) and that she shall not be liable to retire by rotation.

**RESOLVED FURTHER THAT** the Board of Directors be and is hereby authorised to do all acts, deeds, matters and things as may be deemed necessary, proper or desirable and to settle any question, difficulty or doubt that may arise in this regard and to sign and execute all necessary documents, applications, returns and writings as may be necessary, in order to give effect to the above resolution.”

**Item No. 6- Appointment of M/s. A.K. Jain & Associates as the Secretarial Auditors of the Company for a term of five (5) years:**

*To consider and if though fit, to pass the following Resolutions, as a Ordinary Resolution:*

“**RESOLVED THAT** pursuant to the provisions of Section 204 and other applicable provisions, if any, of the Companies Act, 2013, and the Rules framed thereunder, read with Regulation 24A and other applicable Regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s), re-enactment thereof for time being

in force), and based on the recommendation of the Audit Committee and the Board of Directors of the Company, the consent of the members be and is accorded for appointment of M/s. A.K. Jain & Associates, Company Secretaries (Firm Registration No. P2000TN000100), as the Secretarial Auditors of the Company, for a term of five (5) consecutive years commencing from financial year 2025-2026 to 2029-2030, on such remuneration as recommended by the Audit Committee and as may be mutually agreed between the Board of Directors and the Secretarial Auditors.

**RESOLVED FURTHER THAT** the Board of Directors of the Company be and is hereby authorised to do all acts, deeds, matters and things as may be deemed necessary and/or expedient in connection therewith or incidental thereto, to give effect to the above resolution.”

**Item No. 7- Ratification of Remuneration of Cost Auditors:**

*To consider and if though fit, to pass the following Resolution, as an Ordinary Resolution:*

“**RESOLVED THAT** pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the remuneration of ₹75,000/- (Rupees Seventy Five Thousand Only) excluding applicable taxes, reimbursement of out- of-pocket expenses payable to M/s. M/s N Sivashankaran & Co., Cost Accountants (ICMAI FRN. 100662), who, based on the recommendation of Audit Committee, have been appointed as the Cost Auditors of the Company by the Board of Directors, to conduct audit of the cost records of the Company for the financial year ended 2025-26, be and is hereby ratified.

**RESOLVED FURTHER THAT** the Board of Directors of the Company be and is hereby authorised to do all acts, deeds, matters and things as may be deemed necessary and/or expedient in connection therewith or incidental thereto, to give effect to the above resolution.”

**By Order of the Board of Directors  
For Bafna Pharmaceuticals Limited**

Place: Chennai  
Date: August 12, 2025

SD/-  
**A Mohanachandran**  
Company Secretary



**NOTES:**

1. In accordance with the General Circular No. 14/2020 dated April 08, 2020, General Circular No. 17/2020 dated April 13, 2020, General Circular No. 20/2020 dated May 05, 2020 and subsequent circulars issued in this regard, the latest being General Circular No. 09/2024 dated September 19, 2024, by the Ministry of Corporate Affairs (MCA) (hereinafter collectively referred to as "MCA circulars") and the Securities and Exchange Board of India ("SEBI"), vide its Circular(s) dated May 12, 2020, January 15, 2021, May 13, 2022, January 05, 2023, October 06, 2023, October 07, 2023 and October 03, 2024 ("SEBI Circulars"), and other applicable circulars issued in this regard from time to time, Companies are allowed to hold Annual General Meeting (AGM) through Video Conference (VC)/Other Audio Visual Means (OAVM) ("VC"), without the physical presence of Members at a common venue till September 30, 2025. In compliance with the applicable provisions of the Companies Act, 2013, SEBI Listing Regulations, MCA Circulars and SEBI Circulars, the 30<sup>th</sup> AGM of the Company will be held through VC/OAVM on Friday, September, 19, 2025 at 10:00 a.m. (IST). The proceedings of the AGM will be deemed to be conducted at the Registered Office of the Company situated at Bafna Towers, No.299, Thambu Chetty Street, Chennai - 600001, Tamil Nadu, India. The Company has engaged Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means i.e., remote e-voting and voting at the AGM.
2. In terms of Section 102 of the Companies Act, 2013 and Secretarial Standard on General Meetings (SS-2), the explanatory statements setting out the material facts in respect of special business to be transacted at the AGM is annexed and forms part of this Notice.
3. The register of members and share transfer books of the Company will remain closed from Saturday, September 13, 2025 to Friday, September 19, 2025 (both days inclusive).
4. Pursuant to the provisions of the Act, a member entitled to attend and vote at the AGM is entitled to appoint a proxy, to attend and vote on his/her behalf, and such proxy need not be a member of the Company. Since the AGM is being held in accordance with the Circulars through VC, the facility for appointment of proxies by the Members will not be available and hence the Route map, Proxy Form and Attendance Slip are not annexed to this Notice. In case of joint holders attending/participating in the Meeting, only such joint holder who is higher in the order of names will be entitled to vote, provided the votes are not already cast by remote e-Voting by the first holder.
5. The attendance of the Members attending the AGM through VC will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
6. The Members can join the AGM in the VC/ OAVM mode 15 minutes before the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/ OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
7. Corporate members intending to send their authorized representatives to attend the AGM through VC / OAVM on its behalf and to vote through remote e-voting are requested to send to the Company a certified copy of the board resolution authorizing their representative to the email address of the Company i.e., cs@bafnapharma.com.
8. Members holding shares in physical form are requested to notify immediately any change in their address or bank mandates to the Company/ Registrar & Share Transfer Agents quoting their Folio Number and Bank Account details along with self-attested documentary proofs. Members holding shares in the electronic form may update such details with their respective Depository Participants.
9. The cut-off date for the purpose of determining eligibility of members for voting in connection with the 30<sup>th</sup> AGM has been fixed as Friday, September 12, 2025.
10. In accordance with the aforementioned MCA & SEBI Circulars, Notice of the AGM along with the Annual Report 2024-25 are being sent only through electronic mode to those Members whose email address are registered with the Company/ RTA/Depositories. Members may note that the Notice and Annual Report 2024-25 will also be available on the Company's website www.bafnapharma.com website of the Stock Exchanges i.e., BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively and on the website of CDSL www.evotingindia.com.
11. Shareholders may claim their unclaimed dividend by applying in the prescribed Form No. IEPF-5. This Form can be downloaded from the website of the IEPF Authority at <http://www.iepf.gov.in/IEPF/corporates.html>.
12. Pursuant to Regulation 36 of the SEBI (LODR) and Secretarial Standard on General Meeting (SS-2), additional information/particulars, in respect of the directors seeking appointment/ re-appointment, as the case may be, at the AGM are furnished in the explanatory statement and annexure forming part of this Notice. The directors have furnished requisite consents / declarations for their

appointment / re-appointment as required under the Companies Act, 2013.

13. All documents referred to in this Notice, the Register of Directors and Key Managerial Personnel and their shareholdings maintained under Section 170 of the Companies Act, 2013 and the Register of Contracts or Arrangements in which the Directors are interested maintained under Section 189 of the Act, will be available in electronic form for inspection by the Members during the AGM. Members seeking to inspect such documents can send an email to [cs@bafnapharma.com](mailto:cs@bafnapharma.com).
14. The Members desirous of obtaining information, if any, with regard to the audited annual accounts of the Company for the financial year 2024-25 or on any other matters relating to this AGM are requested to write to the Company at e-mail IDs; [profit@bafnapharma.com](mailto:profit@bafnapharma.com) or [cs@bafnapharma.com](mailto:cs@bafnapharma.com) at least 7 days before the date fixed for the AGM, so that the information required could be kept ready.
15. The Board has appointed Mr. Balu Sridhar (CP No.3550), Partner, M/s. A.K Jain & Associates, Company Secretaries, Chennai, as the Scrutinizer for ensuring e-Voting in a fair and transparent manner. The Scrutinizer will submit his report to the Chairperson of the Company ('the Chairman') or to any other person authorized by the Chairperson (who shall countersign the same) after the completion of the scrutiny of the e-Voting (votes cast during the AGM and votes cast through remote e-Voting), within 2 working days from the conclusion of the AGM. The result declared along with the Scrutinizer's report shall be communicated to the stock exchanges, CDSL and RTA. The same will also be displayed on the Company's website [www.bafnapharma.com](http://www.bafnapharma.com) and on the website of CDSL [www.evotingindia.com](http://www.evotingindia.com). The Company has availed the services of CDSL for arrangement of the AGM on VC to enable the Members to participate in the meeting in terms of the MCA Circulars cited above. Also, the Company has provided a facility to the members to exercise their rights to vote electronically through electronic voting service facility provided by CDSL.
16. **Voting through electronic means (e-Voting):** Pursuant to provisions of Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014 substituted by the Companies (Management and Administration) Amendment Rules, 2015 read with Regulation 44 of the SEBI (LODR) Regulations, 2015, the Company has provided a facility to the Members to exercise their right to vote electronically through electronic voting (e-Voting) service facility provided/made available by the Central Depository Services Limited (CDSL). The facility for voting through electronic voting system will also be made available during the Annual General Meeting (AGM) and the Members who have not already cast their votes by remote e-Voting shall be able to exercise their right to

vote during said AGM through e-Voting. Members who have cast their votes by remote e-Voting prior to the AGM may attend the AGM on VC but shall not be allowed to vote again. The instructions for e-Voting are annexed to the Notice.

Since the AGM is being conducted through VC the said resolutions will not be voted on show of hands during the AGM in terms of Section 107 of the Companies Act, 2013. The manner of voting remotely, by Members holding shares in dematerialized mode, physical mode and for Members who have not registered their email addresses, is provided in the instructions for e-Voting as below: The instructions for remote e-Voting and joining AGM areas under:

The remote e-Voting period commences on Tuesday, September 16, 2025 (9:00 a.m. IST) and ends on Thursday, September 18, 2025 (5:00 p.m. IST). During this period, Members holding shares either in physical form or in dematerialized form, as on Friday, September 12, 2025 i.e. cut-off date, may cast their vote electronically. The remote e-Voting module shall be disabled by CDSL for voting thereafter. The voting rights of Members shall be in proportion to their shares in the paid-up equity share capital of the Company as on the cut-off date. ii. Process and manner for remote e-Voting are explained herein below: **Step 1:** Access to CDSL e-Voting system **Step 2:** Cast your vote electronically and join virtual meeting on CDSL e-Voting system. **Step 3:** Access to CDSL e-Voting system are mentioned below:

Pursuant to SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 09, 2020 on e-Voting facility provided by Listed Companies, individual shareholders holding securities in DEMAT mode are allowed to vote through their DEMAT account maintained with depositories and depository participants. Shareholders are advised to update their mobile number and e-mail ID with their DPs in order to access e-Voting facility.

**THE INSTRUCTIONS OF SHAREHOLDERS FOR E-VOTING AND JOINING VIRTUAL MEETINGS ARE AS UNDER:**

- Step 1:** Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.
  - Step 2:** Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.
- i). The voting period begins on Tuesday, September 16, 2025 (9:00 a.m. IST) and ends on Thursday, September 18, 2025 (5:00 p.m. IST). During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of Friday, September 12, 2025 may cast their vote electronically.



The e-voting module shall be disabled by CDSL for voting thereafter.

- ii). Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- iii). Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders’ resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to

enable e-voting to **all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants.** Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

**Step 1:** Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

- iv). In terms of **SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242** dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for e-Voting and joining virtual meetings for **Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with <b>CDSL Depository</b>	<ol style="list-style-type: none"> <li>1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsi website www.cdslindia.com and click on login icon &amp; My Easi New (Token) Tab.</li> <li>2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers’ website directly.</li> <li>3) If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login &amp; My Easi New (Token) Tab and then click on registration option.</li> <li>4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</li> </ol>



Type of shareholders	Login Method
<p>Individual Shareholders holding securities in demat mode with <b>NSDL Depository</b></p>	<ol style="list-style-type: none"> <li>1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <a href="https://eservices.nsd.com">https://eservices.nsd.com</a> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> <li>2) If the user is not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsd.com">https://eservices.nsd.com</a>. Select "Register Online for IDeAS "Portal or click at <a href="https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp</a>.</li> <li>3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsd.com/">https://www.evoting.nsd.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> <li>4) For OTP based login you can click on <a href="https://eservices.nsd.com/SecureWeb/evoting/evotinglogin.jsp">https://eservices.nsd.com/SecureWeb/evoting/evotinglogin.jsp</a> You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> </ol>
<p>Individual Shareholders (holding securities in demat mode) login through their <b>Depository Participants (DP)</b></p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p>



**Important note:** Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

**Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL**

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with <b>CDSL</b>	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with <b>NSDL</b>	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at : 022 - 4886 7000 and 022 - 2499 7000

**Step 2:** Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

v). Login method for e-Voting and joining virtual meetings for **Physical shareholders and shareholders other than individual holding in Demat form.**

- 1) The shareholders should log on to the e-voting website [www.evotingindia.com](http://www.evotingindia.com).
- 2) Click on "Shareholders" module.
- 3) Now enter your User ID
  - a) For CDSL: 16 digits beneficiary ID,
  - b) For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
  - c) Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to [www.evotingindia.com](http://www.evotingindia.com) and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first-time user follow the steps given below:

<b>For Physical shareholders and other than individual shareholders holding shares in Demat.</b>	
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> <li>• Shareholders who have not updated their PAN with the Company/ Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.</li> </ul>
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ul style="list-style-type: none"> <li>• If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.</li> </ul>

- vi). After entering these details appropriately, click on "SUBMIT" tab.
- vii). Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

- viii). For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- ix). Click on the EVSN for the relevant **"Bafna Pharmaceuticals Limited"** on which you choose to vote.
- x). On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/ NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- xi). Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- xii). After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- xiii). Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- xiv). You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.
- xv). If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- xvi). There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- xvii). **Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.**
  - a) Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to [www.evotingindia.com](http://www.evotingindia.com) and register themselves in the "Corporates" module.
  - b) A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com).
  - c) After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
  - d) The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.

- e) It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- f) Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; [cs@bafnapharma.com](mailto:cs@bafnapharma.com), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

**INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:**

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least **7 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number to [cs@bafnapharma.com](mailto:cs@bafnapharma.com). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance **7 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at (company email id).



These queries will be replied to by the company suitably by email.

8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders may be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

**PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/ MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/ DEPOSITORIES.**

1. **For Physical shareholders-** please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to Company/RTA email id.
2. **For Demat shareholders -**, Please update your email id & mobile no. with your respective Depository Participant (DP)
3. **For Individual Demat shareholders –** Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25<sup>th</sup> Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call toll free no. 1800 21 09911.

**Explanatory Statement Pursuant to Section 102(1) of the Companies Act, 2013:**

*The following Statements sets out all material facts relating to Item Nos. 3 to 7 as mentioned in the accompanying Notice.*

**Item No.3:-**

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, appointed Mr. Navin Kumar (DIN: 08778662) as an Additional Director (Category: Non-Executive Independent Director) of the Company, not liable to retire by rotation, for a term of one (1) year with effect from June 23, 2025, pursuant to the provisions of Section 161 of the Companies Act, 2013 (the "Act"). Accordingly, he holds office up to the date of this Annual General Meeting ("AGM").

Mr. Navin Kumar is a qualified Chartered Accountant from the Institute of Chartered Accountants of India (ICAI), and is currently in practice. He has over 13 years of professional experience in the fields of corporate finance, taxation, auditing, and regulatory compliance. His areas of expertise include corporate accounting, statutory and internal audits, income tax, Goods and Services Tax (GST), and business advisory services.

In terms of Regulations 17 and 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the appointment or reappointment of an Independent Director is required to be approved by the Members at the next General Meeting or within a period of three months from the date of appointment, whichever is earlier, by way of a Special Resolution.

Mr. Navin Kumar has provided his consent to act as a Director in terms of Section 152 of the Companies Act, 2013 and Companies (Appointment and Qualifications of Directors) Rules, 2014 and declaration confirming his non-disqualification under Section 164(2) of the Act. The Company has also received a declaration from Mr. Navin Kumar that he meets the criteria of independence as provided in Section 149 of the Act, read with the Rules framed thereunder and Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. He has confirmed that he is not debarred from holding the office of director by virtue of any order from SEBI or any such authority.

The Company has also received a notice under Section 160(1) of the Act proposing his candidature for the office of Independent Director. Mr. Navin Kumar holds no equity shares in the Company and is not related to any other Director or Key Managerial Personnel of the Company.

In accordance with the provisions of Sections 149, 150, 152, and Schedule IV to the Act, and the applicable rules made thereunder, as well as the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is proposed to appoint Mr. Navin Kumar as an Independent Director of the Company for a term of one (1) year, with effect from June 23, 2025 to June 22, 2026 (both days inclusive).

The Board of Directors is of the opinion that Mr. Navin Kumar is a person of integrity, possesses relevant expertise and experience, and fulfills the conditions for appointment as an Independent Director as prescribed under the Act and SEBI

Listing Regulations. Further, the Board believes that, his association would be of immense benefit to the Company and it is desirable to avail his services as an Independent Director.

Accordingly, the Board of Directors recommends the appointment of Mr. Navin Kumar as an Independent Director of the Company as set out in Item No. 3 of the accompanying Notice, for approval of the Members, by way of special resolution.

Additional information in respect of Mr. Navin Kumar, pursuant to Regulation 36 of the SEBI Listing Regulations and the Secretarial Standard on General Meetings (SS-2) and his brief profile, is given at Annexure to this Notice.

Except Mr. Navin Kumar being an appointee, none of the Directors, Key Managerial Personnel of the Company and/ or their relatives are concerned or interested, in any way, in the proposed resolutions except to the extent of their shareholding, if any, in the Company.

**Item No.4:-**

The Members of the Company, at the 25<sup>th</sup> Annual General Meeting held on July 31, 2020, approved the appointment of Mr. Palamadai Krishnan Sundaresan (DIN 06954189) as an Independent Director for a first term of five (5) consecutive years commencing June 25, 2020 and ending June 24, 2025. Accordingly, his first term concluded on June 24, 2025.

Based on the performance evaluation of Mr. Palamadai Krishnan Sundaresan and considering his skills, experience, expertise and knowledge, the Nomination and Remuneration Committee and the Board of Directors of the Company at their meeting held on August 12, 2025 have recommended his re-appointment as an Independent Director, for a second term of Five (5) consecutive years w.e.f September 19, 2025 pursuant to the provisions of Sections 149, 152 and Schedule IV of the Companies Act, 2013.

Mr. Palamadai Krishnan Sundaresan, is a qualified Cost & Management Accountant (CMA) and Company Secretary (CS) with over 40 years' multi-industry experience spanning: corporate finance, secretarial practice, foreign-exchange management, consolidation of financial statements, cost and value-chain management, MIS, pricing, budgeting, production planning, strategic and turnaround management, strategic sourcing, mergers & acquisitions, business valuation, joint-venture formation and scale-up, complex debt and capital restructuring, and corporate governance.

Mr. Palamadai Krishnan Sundaresan has given his consent to act as a Director in terms of Section 152 of the Companies Act, 2013 and Companies (Appointment and Qualifications of Directors) Rules, 2014 and declaration confirming his non-disqualification under Section 164 of the Act. The Company has also received a declaration from Mr. Palamadai Krishnan Sundaresan that he meets the criteria of independence as provided in Section 149 of the Act, read with the Rules framed

thereunder and Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The Company has also received a notice under Section 160(1) of the Act proposing his candidature for the office of Independent Director. Mr. Palamadai Krishnan Sundaresan does not hold any equity shares in the Company and is not related to any other Director or Key Managerial Personnel of the Company.

The Board is of the opinion that Mr. Palamadai Krishnan Sundaresan is a person of integrity and possesses the necessary qualifications, expertise, and experience to continue as an Independent Director of the Company. Given his contributions during the first term and his professional background, the Board considers that his continued association would be beneficial to the Company and it is desirable to continue to avail his services as an Independent Director. Accordingly, it is proposed to re-appoint Mr. Palamadai Krishnan Sundaresan as an Independent Director, not liable to retire by rotation, for a second term of five (5) consecutive years from September 19, 2025 to September 18, 2030 (both days inclusive). He is independent of the management.

Pursuant to Section 149(10) of the Companies Act, 2013 and Regulation 25(2A) of the SEBI Listing Regulations, the re-appointment of an Independent Director is subject to approval of Members by way of a special resolution. Since the Company could not obtain the approval of Members before the expiry of Mr. Palamadai Krishnan Sundaresan's first term, such approval is now being sought.

The Board of Directors recommends the re-appointment of Mr. Palamadai Krishnan Sundaresan as an Independent Director of the Company as set out in Item No. 4 of the accompanying Notice, for approval of the Members by way of special resolution.

Additional information in respect of Mr. Palamadai Krishnan Sundaresan, pursuant to Regulation 36 of the SEBI Listing Regulations and the Secretarial Standard on General Meetings (SS-2) and his brief profile, is given at Annexure to this Notice.

Except Mr. Palamadai Krishnan Sundaresan being an appointee, none of the Directors, Key Managerial Personnel of the Company and/ or their relatives are concerned or interested, in any way, in the proposed resolutions except to the extent of their shareholding, if any, in the Company.

**Item No.5:-**

The Members of the Company, at the 26<sup>th</sup> Annual General Meeting held on August 14, 2021, approved the appointment of Mrs. Ravichandran Chitra (DIN: 07749125) as an Independent Director of the Company for a term of five (5) consecutive years, commencing from November 12, 2020 and ending on November 11, 2025. Accordingly, her first term as an Independent Director will conclude on November 11, 2025.



Based on the performance evaluation of Mrs. Ravichandran Chitra and considering her skills, experience, expertise, and knowledge, the Nomination and Remuneration Committee has recommended to the Board of Directors her re-appointment as an Independent Director for a second term of five (5) consecutive years, with effect from November 12, 2025, pursuant to the provisions of Sections 149, 152, and Schedule IV of the Companies Act, 2013.

Mrs. Ravichandran Chitra holds a Bachelor's degree in Commerce and a PGDPMIR from the Madras School of Social Work, Chennai. She brings over three decades of rich and diverse experience in Human Resource Management, Performance Management, Training & Development, Corporate and Legal Affairs, Labour Law Compliance, Compensation and Benefits Administration, and General Administration. Her core strengths include talent acquisition, succession planning, employee retention, change management, and designing effective training and development programs.

Mrs. Ravichandran Chitra has given her consent to act as a Director in terms of Section 152 of the Companies Act, 2013 and Companies (Appointment and Qualifications of Directors) Rules, 2014 and declaration confirming her non-disqualification under Section 164 of the Act. The Company has also received a declaration from Mrs. Ravichandran Chitra that she meets the criteria of independence as provided in Section 149 of the Act, read with the Rules framed thereunder and Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The Company has also received a notice under Section 160(1) of the Act proposing her candidature for the office of Independent Director. Mrs. Ravichandran Chitra does not hold any equity shares in the Company and is not related to any other Director or Key Managerial Personnel of the Company.

The Board is of the opinion that Mrs. Ravichandran Chitra is a person of integrity and possesses the necessary qualifications, expertise, and experience to continue as an Independent Director of the Company. Given her contributions during the first term and her professional background, the Board considers that her continued association would be beneficial to the Company and it is desirable to continue to avail her services as an Independent Director. Accordingly, it is proposed to re-appoint Mrs. Ravichandran Chitra as an Independent Director, not liable to retire by rotation, for a second term of five (5) consecutive years commencing from November 12, 2025 to November 11, 2030 (both days inclusive). She is independent of the management.

Pursuant to Section 149(10) of the Companies Act, 2013 and Regulation 25(2A) of the SEBI Listing Regulations, the re-appointment of an Independent Director is subject to approval of the Members by way of a special resolution.

The Board of Directors recommends the re-appointment of Mrs. Ravichandran Chitra as an Independent Director of the Company as set out in Item No. 5 of the accompanying Notice, for approval of the Members by way of special resolution.

Additional information in respect of Mrs. Ravichandran Chitra, pursuant to Regulation 36 of the SEBI Listing Regulations and the Secretarial Standard on General Meetings (SS-2) and his brief profile, is given at Annexure to this Notice.

Except Mrs. Ravichandran Chitra being an appointee, none of the Directors, Key Managerial Personnel of the Company and/or their relatives are concerned or interested, in any way, in the proposed resolutions except to the extent of their shareholding, if any, in the Company.

**Item No.6:-**

In accordance with the provisions of Section 204 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act'), read with Rule 9 of the Companies (Appointment & Remuneration of Managerial Personnel) Rules, 2014 and Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), every listed entity shall undertake Secretarial Audit by a Secretarial Auditor who shall be a Peer Reviewed Company Secretary. The Company may appoint an individual as Secretarial Auditor for not more than one term of five consecutive years or a Secretarial Audit firm as Secretarial Auditor for not more than two terms of five consecutive years, with the approval of its Members in its Annual General Meeting.

Accordingly, the Board of Directors, at its meeting held on May 26, 2025, based on the recommendation of the Audit Committee, approved the appointment of M/s A K Jain & Associates, Practicing Company Secretaries [Firm Regn. No.P2000TN000100] [Peer Review Certificate No.1201/2021] as the Secretarial Auditors of the Company, for a term of 5 (five) consecutive years, commencing from financial year 2025-2026 to 2029-2030, subject to approval of the Members at this Annual General Meeting. The remuneration for the Secretarial Audit for the financial year 2025-26 is fixed at ₹ 1,00,000/- (Rupees One Lakh Only), and the remuneration for the remaining term shall be decided mutually between the Board of Directors and the Secretarial Auditors, from time to time.

M/s. A K Jain & Associates, established in the year 2000, has extensive corporate experience of over two decades in providing professional services in areas including Corporate Laws, SEBI Regulations, and FEMA Regulations. The firm is registered with the Institute of Company Secretaries of India (ICSI) and holds a valid Peer Review Certificate issued by the ICSI.

M/s. A K Jain & Associates, Practicing Company Secretaries, has confirmed its eligibility for appointment as Secretarial Auditors under the applicable provisions of the Companies Act, 2013, and has further confirmed that it is free from any disqualifications and has no conflict of interest in respect of their proposed appointment.

Therefore, the approval of the Members is sought by way of an Ordinary Resolution, as set out in Item No. 6 of the Notice of the Annual General Meeting. The Board recommends the resolution set forth in Item No. 6 for the approval of the Members.

None of the Directors, Key Managerial Personnel of the Company and/ or their relatives are concerned or interested, in any way, in the proposed resolutions except to the extent of their shareholding, if any, in the Company.

**Item No.7:-**

In terms of Section 148 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (the Rules), the Company is required to appoint a Cost Auditor to audit the cost records of the Company. The Board at its meeting held on May 26, 2025, based on the recommendation of the

Audit Committee, has approved the appointment of M/s. N Sivashankaran & Co., Cost Accountants (ICMAI FRN. 100662), as the Cost Auditor of the Company for the F.Y 2025-2026 at a remuneration of ₹ 75,000/- (Rupees Seventy-Five Thousand only) plus applicable taxes.

In accordance with the provisions of Section 148(3) of the Act read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors, as recommended by the Audit Committee and approved by the Board, is required to be ratified by the Members of the Company.

Therefore, the consent of the Members is sought for passing an Ordinary Resolution as set out at Item No.7 of the Notice for ratification of the remuneration payable to the Cost Auditor of the Company for the F.Y 2025-2026. The Board recommends the Resolution set forth in Item No.7 for the approval of the Members.

None of the Directors, Key Managerial Personnel of the Company and/ or their relatives are concerned or interested, in any way, in the proposed resolutions, except to the extent of their shareholding, if any, in the Company.





ANNEXURE TO NOTICE

Details of Directors seeking appointment / re-appointment at the 30th Annual General Meeting Pursuant to Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard-2 on General Meetings

<b>Name of the Director</b>	Mrs. Akila Chintalapati Raju	Mr. Navin Kumar
<b>Director Identification Number (DIN)</b>	07590312	08778662
<b>Date of Birth &amp; Age</b>	October 10, 1987 37 Years	October 02, 1980 44 Years
<b>Nationality</b>	Indian	Indian
<b>Date of first appointment on the Board</b>	September 10, 2020.	June 23, 2025
<b>Brief Resume, Qualification &amp; nature of expertise in specific functional areas</b>	Mrs. Akila Chintalapati Raju holds Master’s in Law from NYU School of Law, New York. She has over a decade of diverse legal experience spanning corporate law, private equity, real estate transactions, civil litigation, and in-house legal advisory.	Mr. Navin Kumar is a Graduate in Commerce and a qualified Chartered Accountant. He is a practicing Chartered Accountant with over 13 years of experience in corporate finance, taxation, auditing, regulatory compliance, income tax, GST, and business advisory.
<b>Terms and conditions of appointment &amp; Remuneration sought to be paid.</b>	Mrs. Akila Chintalapati Raju is re-appointed as Non-Executive, Non-Independent Director, liable to retire by rotation. She is entitled to receive sitting fees for attending meetings of the Board and committees thereof.	Mr. Navin Kumar is appointed as Independent Director for a term of 1 year w.e.f. June 23, 2025, not liable to retire by rotation. He is entitled to receive sitting fees for attending meetings of the Board and committees thereof.
<b>No. of meetings of the Board attended during the year</b>	Three (3) Board Meetings during F.Y 2024-2025.	Not Applicable.
<b>Directorship / Membership of the Committees in other listed companies as on March 31, 2025</b>	Nil	Starlite Global Enterprises (India) Limited.  He is Chairman of the Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee and Corporate Social Responsibility Committee of Starlite Global Enterprises (India) Limited.
<b>Membership / Chairmanship of Committees of the Board of the Company</b>	Member of the Nomination and Remuneration Committee, Stakeholders Relationship Committee and Corporate Social Responsibility Committee of the Company.	Chairman of the Audit Committee and the Nomination & Remuneration Committee of the Company.
<b>Last drawn remuneration</b>	Sitting fee paid during FY 2024-2025: ₹ 1.11 Lakhs	Not Applicable
<b>Skills and Capabilities for the role of Independent Director</b>	Not Applicable	Finance, Corporate Laws, Legal, Taxation, Governance, Business advisory and Financial strategy.
<b>Relationship with other Directors / Manager / other KMP</b>	Nil	Nil
<b>Number of Equity Shares held in the Company as on March 31, 2025</b>	Nil	Nil



**Details of Directors seeking appointment / re-appointment at the 30th Annual General Meeting Pursuant to Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard-2 on General Meetings**

<b>Name of the Director</b>	Mr. Palamadai Krishnan Sundaresan	Mrs. Ravichandran Chitra
<b>Director Identification Number (DIN)</b>	06954189	07749125
<b>Date of Birth &amp; Age</b>	May 20, 1956 69 Years	April 25, 1961 64 Years
<b>Nationality</b>	Indian	Indian
<b>Date of first appointment on the Board</b>	June 25, 2020.	November 12, 2020
<b>Brief Resume, Qualification &amp; nature of expertise in specific functional areas</b>	Mr. Palamadai Krishnan Sundaresan is a qualified Cost & Management Accountant (CMA), Company Secretary (CS). He has over 40 years' experience in corporate finance, secretarial, foreign exchange management, cost and value-chain management, turnaround strategies, strategic sourcing, mergers and acquisitions, corporate governance, and debt restructuring.	Mrs. Ravichandran Chitra is a Commerce graduate and has PGDPMIR from Madras School of Social Work, Chennai. She has more than 30 years of experience in Human Resources, performance management, training & development, labour laws, compensation, administration, talent acquisition, succession planning, and employee retention.
<b>Terms and conditions of appointment &amp; Remuneration sought to be paid.</b>	Mr. Palamadai Krishnan Sundaresan is re-appointed for second term of 5 consecutive years from September 19, 2025 to September 18, 2030, not liable to retire by rotation. He is entitled to receive sitting fees for attending meetings of the Board and committees thereof.	Mrs. Ravichandran Chitra is re-appointed for second term of 5 years from November 12, 2025 to November 11, 2030, not liable to retire by rotation. She is entitled to receive sitting fees for attending meetings of the Board and committees thereof.
<b>No. of meetings of the Board attended during the year</b>	Five (5) Board Meetings during F.Y 2024-2025.	Four (4) Board Meetings during F.Y 2024-2025.
<b>Directorship / Membership of the Committees in other listed companies as on March 31, 2025</b>	Nil	Nil
<b>Membership / Chairmanship of Committees of the Board of the Company</b>	Not Applicable.	Chairperson of the Stake Holders Relationship Committee and Corporate Social Responsibility Committee and Member of the Audit Committee and the Nomination & Remuneration Committee of the Company.
<b>Last drawn remuneration</b>	Sitting fee paid during FY 2024-2025: ₹ 1.67 Lakhs	Sitting fee paid during FY 2024-2025: ₹ 1.56 Lakhs
<b>Skills and Capabilities for the role of Independent Director</b>	Finance, Corporate Laws, Legal, Corporate Governance, Cost Management	Finance, Human resource, Corporate Governance, Succession Planning, Training and Development.
<b>Relationship with other Directors / Manager / other KMP</b>	Nil	Nil
<b>Number of Equity Shares held in the Company as on March 31, 2025</b>	Nil	Nil



# BOARD'S REPORT

To  
**The Shareholders,**  
 Your directors' have pleasure in presenting the Thirtieth (30<sup>th</sup>) Annual Report of your Company together with Audited Accounts for the Financial Year ended 31<sup>st</sup> March, 2025.

## 1. FINANCIAL PERFORMANCE

The summarized Audited Financial Results for the year ended 31<sup>st</sup> March, 2025 along with comparative figures for the Previous year is as under:

Particulars	Financial Highlights	
	31 <sup>st</sup> March 2025	31 <sup>st</sup> March 2024
Revenue from operations	14,585.70	15,246.57
Other Income	274.22	352.24
<b>Total Income</b>	<b>14,859.92</b>	<b>15,598.81</b>
<b>Expenses</b>		
Operating Expenditure	13,468.01	14,135.45
<b>EBITDA</b>	<b>1,391.91</b>	<b>1,463.36</b>
Depreciation and Amortization Expenses	488.97	499.54
Earnings before interest and taxes	902.94	963.82
Interest expenses	273.13	229.03
<b>Profit before taxes</b>	<b>629.81</b>	<b>734.79</b>
Less: Exceptional Items	214.56	-
Less: OCI	18.50	-3.65
<b>Net profit before taxes</b>	<b>396.75</b>	<b>738.44</b>
Tax expenses (Current and Deferred Tax)	-	-
<b>Net profit for the year</b>	<b>396.75</b>	<b>738.44</b>

## 2. OPERATING RESULTS

Your Company's Total Income during the financial year under review i.e., year 2024-25 is ₹ 14,859.92 Lakhs as compared to the previous year 2023-24, ₹ 15,598.81 Lakhs. Profit before Tax after other comprehensive income for the year 2024-25 is ₹ 396.75 Lakhs as against ₹ 738.44 Lakhs in the previous year. Profit after Tax for the year 2024-25 stands at ₹ 396.75 Lakhs as against ₹ 738.44 Lakhs in the previous year.

## 3. DIVIDEND

The Board has not declared any dividend for the Financial Year 2024-2025.

## 4. RESERVES

The Company has not transferred any amount to the general reserves during the year under review.

## 5. CAPITAL STRUCTURE

The Paid-up Equity Share Capital as on March 31, 2025 was ₹ 2,365.63 Lakhs. During the year under review the Issued, Subscribed and Paid-up capital has remained

the same. The Company has not issued any shares with differential voting rights nor granted stock options nor sweat equity.

## 6. FIXED DEPOSITS

The Company has not accepted / invited any deposits from the public in terms of Section 73 of the Companies Act, 2013.

## 7. CHANGE IN THE NATURE OF BUSINESS

The Company is engaged in the manufacture of pharmaceutical products. There is no change in the nature of business during the year under review.

## 8. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY

There have been no material changes and commitments between the end of the financial year 2024-25 and the date of this report, adversely affecting the financial position of the Company.

## 9. SUBSIDIARIES, ASSOCIATE AND JOINT VENTURE COMPANIES

The Company does not have any subsidiary, associate or joint venture.

## 10. LOANS, GUARANTEE AND INVESTMENT UNDER SECTION 186 OF COMPANIES ACT, 2013

During the year under review, your Company has neither advanced any loan nor given any guarantee under Section 186 of the Companies Act, 2013. The Company has invested an amount of ₹ 4,900/- subscribing 49 equity shares of ₹ 100/- each of M/s. Jimi Solar Private Limited, under the Group Captive Scheme for the purchase of solar power. The aforesaid amount is within the limits laid down under Section 186 of the Companies Act, 2013.

## 11. BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

### I. Composition

The composition of the Board of Directors and its Committees, viz., Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee and Corporate Social Responsibility Committee are constituted in accordance with Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR). The details of Composition of the Board, its Committees, meetings and an overview of the role, terms of reference are provided in the Corporate Governance Report annexed to this Report.

The following changes took place in the composition of Board of Directors:

#### a) Appointment of Directors:

Pursuant to recommendation of the Nomination and Remuneration Committee, the Board on June 23, 2025 approved the appointment of Mr. Navin Kumar (DIN: 08778662) as an Additional Director (Category: Non-Executive, Independent Director) of the Company, for a period of One (1) year, with effect from June 23, 2025, subject to approval of the shareholders of the Company.

#### b) Resignation & Retirement of Directors:

Mr. Krishna Yeachuri (DIN: 00066898), resigned as Independent Director of the Company with effect from March 31, 2025. The Board places on record its appreciation for the guidance rendered by him during his tenure as Director of the Company.

Mr. Palamadai Krishnan Sundaresan (DIN: 06954189), retired as an Independent Director of the Company, upon completion of first term of five years, with effect from June 24, 2025.

There were no other changes in the composition of the Board of Directors.

### II. Retirement by Rotation

Pursuant to the provisions of Section 152 of the Companies Act, 2013 and the Articles of Association of the Company, Mrs. Akila Chintalapati Raju (DIN: 07590312), Director retires by rotation at the ensuing 30<sup>th</sup> Annual General Meeting (AGM) of the Company and being eligible, offers herself for re-appointment. Your Board recommends her re-appointment as Director of the Company.

### III. Re-appointment of Director:

The Board of Directors, based on recommendation of the Nomination and Remuneration Committee, in its meeting held on June 23, 2025, appointed Mr. Navin Kumar (DIN: 08778662) as an Additional Director (Category: Non-Executive, Independent Director) of the Company, for a period of One (1) year, with effect from June 23, 2025. He shall hold office as an Additional Director up to the date of the ensuing Annual General Meeting (AGM) and is eligible for appointment as an Independent Director. The appointment of Mr. Navin Kumar as an Independent Director of the Company for a period of one (1) year, commencing from June 23, 2025 to June 22, 2026, is subject to the approval of the Members at the ensuing AGM. He shall not be liable to retire by rotation.

Further, pursuant to the recommendation of the Nomination and Remuneration Committee, the Board of Directors, at its meeting held on August 12, 2025, considered and recommended the re-appointment of Mr. Palamadai Krishnan Sundaresan (DIN: 06954189) and Mrs. Ravichandran Chitra (DIN: 07749125) as Non-Executive, Independent Directors for a second term, commencing from September 19, 2025, and November 12, 2025, respectively, subject to the approval of the Members at the ensuing AGM.

Accordingly, the proposals for the appointment of Mr. Navin Kumar and the re-appointment of Mr. Palamadai Krishnan Sundaresan and Mrs. Ravichandran Chitra as Non-Executive, Independent Directors of the Company are included in the Notice convening the 30<sup>th</sup> Annual General Meeting. Your Board recommends their appointment and re-appointment as Independent Directors of the Company.

The brief resumes of the Directors seeking appointment/re-appointment and other relevant details, as required under the Companies Act, 2013 and SEBI (LODR) Regulations, 2015, are provided in the Notice convening the 30<sup>th</sup> AGM.

The Board of Directors is of the opinion that the Directors proposed for appointment/re-appointment at the ensuing AGM possess integrity, relevant expertise, and the necessary experience for their respective roles. The Corporate Governance Report, annexed to this Report,



also contains the requisite disclosures relating to the Directors.

**IV. Number of Board Meetings:**

The Board of Directors met Five (5) times during the year under review and the gap between 2 meetings did not exceed 120 days. The details of the Board & Committee Meetings and the attendance of the Directors are provided in the Report on Corporate Governance.

**V. Declaration by Independent Directors & Adherence to Company's Code of Conduct:**

The Company has received necessary declaration from each independent director under Section 149(7) of the Companies Act, 2013, that he/ she meets the criteria of independence laid down in Section 149(6) of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All Independent Directors have affirmed compliance to the code of conduct for independent directors as prescribed in Schedule IV to the Companies Act, 2013 and the Company's Code of Conduct for Directors and Senior Management Personnel.

In the opinion of the Board, the Independent Directors, fulfill the conditions of independence specified in Section 149(6) of the Act and Regulation 16(1) (b) of the Listing Regulations. The terms and conditions of appointment of Independent Directors have been disclosed in the website of the company at [www.bafnapharma.com](http://www.bafnapharma.com).

**VI. Board Evaluation:**

The annual evaluation of the performance of the Board, functioning of its committees, and individual Directors was carried out based on the evaluation criteria prescribed by the Nomination and Remuneration Committee and the SEBI (LODR) Regulations, 2015. The performance review of Non-Independent Directors were carried out by the Independent Directors in their separate meeting held during the year.

**VII. Committees Of the Board:**

The Board has constituted following committees:

- i). Audit Committee;
- ii). Nomination and Remuneration Committee;
- iii). Stakeholders' Relationship Committee;
- iv). Corporate Social Responsibility Committee.

**i). Audit Committee**

In terms of Section 177 of the Companies Act, 2013, and other applicable provisions if any, and as per the Regulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has constituted Qualified and Independent Audit Committee. The Audit Committee comprises of the following Members as on March 31, 2025:

- a) Mr. P K Sundaresan – Chairman
- b) Ms. R Chitra – Member
- c) Mr. Upendar Mekala Reddy – Member

The terms of reference of the Audit Committee includes matters specified in section 177 of the Companies Act 2013, and Regulation 18 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015. All the recommendations made by the Audit Committee during the year were accepted by the Board of Directors of the Company.

The details of the Audit Committee along with its composition, number of meetings, attendance and terms of reference are provided in the Corporate Governance Report, which forms part of this report.

**ii). Nomination & Remuneration Committee**

In terms of Section 178 of the Companies Act, 2013 & other applicable provisions, if any, and as per the Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has constituted Nomination & Remuneration Committee. The Nomination & Remuneration Committee comprises of the following Members as on March 31, 2025:

- a) Mr. Krishna Yeachuri\* – Chairman
- b) Mr. P K Sundaresan – Member
- c) Mrs. Akila C Raju – Member

\* Ceased w.e.f March 31, 2025

The Committee consists of only Non-Executive Directors as its members. The details of the Nomination & Remuneration Committee along with its composition, number of meetings, attendance and terms of reference are provided in the Corporate Governance Report, which forms part of this report.

**iii). Stakeholders Relationship Committee**

In terms of Section 178 of the Companies Act, 2013 & other applicable provisions, if any, and as per the Regulation 20 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has constituted Stakeholders Relationship Committee. The Stakeholders Relationship Committee comprises of the following Members as on March 31, 2025:

- a) Mrs. R Chitra – Chairperson
- b) Ms. S Hemalatha – Member
- c) Mrs. Akila C Raju – Member

The details of the Stakeholders Relationship Committee along with its composition, number of meetings, attendance and terms of reference are

provided in the Corporate Governance Report, which forms part of this report.

Also there has been no instance of fraud reported by the statutory auditors for the financial year under review.

**VIII. Details of KMP:**

The following are the Key Managerial Personnel of the Company in accordance with the provisions of Section 2(51) read with Section 203 of the Act:

- a) Mr. Mahaveer Chand Bafna – Chief Executive Officer
- b) Mr. Melagiri Sridhar – Chief Financial Officer
- c) Mr. A. Mohanachandran – Company Secretary

Mr. A. Mohanachandran was appointed as the Company Secretary & Compliance Officer of the Company w.e.f May 29, 2024.

**b) Internal Auditor**

Pursuant to the provisions of Section 138 of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014, the Board, on recommendation of the Audit Committee, has appointed M/s. K S Rao & Co, Chartered Accountants (ICAI FRN. 003109S) as internal auditors of the Company for the financial year 2025-2026.

**c) Cost Auditor & Maintenance of Cost Records**

Pursuant to section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, the Board of Directors, on recommendation of Audit Committee, appointed M/s. N. Sivashankaran & Co, Cost Accountants (ICMAI Registration No: 100662) as the Cost Auditor of the Company, to conduct audit of cost records maintained by the Company for financial year 2025 – 2026 at a remuneration of ₹ 75,000/- (Rupees Seventy Five Thousand Only) excluding applicable taxes, reimbursement of out- of-pocket expenses. In terms of Section 148(3) of the Companies Act, 2013 the remuneration payable to the Cost Auditors, as fixed by the Board, is required to be ratified by the members and the resolution for the ratification of Cost Auditors Remuneration is provided under Item No.7 of the Notice convening the 30<sup>th</sup> Annual General Meeting.

The Company maintains all such accounts and records as specified by the Central Government under section 148 (1) of the Companies Act, 2013.

**13. AUDITORS**

**a) Statutory Auditor**

As per the provisions of Section 139 of the Companies Act, 2013, M/s. Brahmayya & Co, Chartered Accountants, Chennai (ICAI FRN:000511S), were appointed as Statutory Auditors of the Company, for a period of five (5) years from the conclusion of the 27<sup>th</sup> Annual General Meeting till the conclusion of 32<sup>nd</sup> Annual General Meeting of the Company.

**Auditors' Report:**

The Auditors' Report on the financial statements of the Company for the financial year ended 31<sup>st</sup> March, 2025 is enclosed with the financial statements, which forms part of this Annual Report.

The report is unmodified i.e. it does not contain any qualification, reservation, adverse remark or disclaimer. The remarks in the Auditors Report and Notes on financial statement referred to in the Auditor's Report are self-explanatory and do not call for any further comments.

**d) Secretarial Auditor & Secretarial Audit Report**

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors had appointed M/s. A.K. Jain & Associates, Company Secretaries in Practice, Chennai, as the Secretarial Auditors of the Company for the FY 2024-2025.

The Secretarial Audit Report in Form MR-3 is annexed as **Annexure-C** to this Report.

**Reply to the Qualifications made in the Secretarial Audit Report:**

The Board's reply for the qualifications, observations made by the Secretarial Auditor in Secretarial Audit Report for F.Y 2024-2025 is provided hereunder:

Sl. No.	Secretarial Auditor Qualifications / Observations	Board's Reply
01	The Company did not comply with the Minimum Public Shareholding requirements as prescribed under Regulation 38 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Rule 19(2) and Rule 19A of the Securities Contracts (Regulation) Rules, 1957.	During the year under review, M/s. SRJR Life Sciences LLP, Promoter of the Company has made an Offer for Sale (OFS) of 31,45,296 Equity Shares representing 13.30% of total Paid-up capital of the Company, on March 27, 2025 & March 28, 2025, through the stock exchange mechanism to comply with Minimum Public Shareholding requirements. The aforesaid OFS was fully subscribed by the Public Shareholders. Accordingly, the Company has complied with the Minimum Public Shareholding (MPS) requirement of 25% with effect from April 02, 2025.



Sl. No.	Secretarial Auditor Qualifications / Observations	Board's Reply
02	The Company has belatedly submitted the disclosure required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, relating to the temporary disruption of operations at its factory situated at Grantlyon, Chennai, due to a breakdown of temperature control equipment, with a delay of three days from the prescribed timeline.	The delay of three days in making the said disclosure was inadvertent and occurred due to a delay in the outcome of the initial assessment. The Board has since initiated internal corrective measures and has improvised the reporting mechanism and compliance framework to ensure timely adherence to regulatory requirements going forward.

**14. ANNUAL RETURN:**

The copy of the Annual Return (Form MGT-7) for F.Y 2024-2025 is made available in the website of the Company at the weblink [www.bafnapharma.com](http://www.bafnapharma.com)

**15. RELATED PARTY TRANSACTIONS**

All Related Party Transactions that were entered into during the Financial Year under review were on an arm's length basis, and in the ordinary course of business and were in accordance with the Company's Policy on RPT. There are no materially significant related party transactions made by the Company with Related parties which requires approval of the shareholders / which may have potential conflict with the interest of the Company at large.

All related party transactions are placed before the Audit Committee as also the Board for approval. Prior omnibus approval of the Audit Committee is obtained on a yearly basis for the transactions which are repetitive in nature. A statement giving details of the transactions entered into with the related parties, pursuant to the omnibus approval so granted, is placed before the Audit Committee and the Board of Directors for their approval, ratification on a quarterly basis.

During the year, the Company had not entered into any material related party transactions which are not in ordinary course of business or which are not on arm's length basis and hence there is no information to be provided as required under Section 134(3) (h) of the Act read with Rule 8(2) of the Companies (Accounts) Rules, 2014. Necessary disclosure as required by the Indian Accounting Standards (IND AS 24) has been made in the notes to the Financial Statements.

The Company has adopted a Policy for dealing with Related Party Transactions which has been uploaded on the Company's website under the web-link [www.bafnapharma.com](http://www.bafnapharma.com).

**16. ENERGY CONSERVATION, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO**

The Company is conscious of its responsibility to conserve the energy and has taken measures in relation to conservation of energy and technology absorption. The prescribed particulars on conservation of energy, technology absorption and foreign exchange earnings and outgo as required under Section 134(3) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014 are furnished in **Annexure-A** to this Report.

**17. CORPORATE SOCIAL RESPONSIBILITY**

The Company satisfies the criteria as prescribed in section 135 of the Companies Act, 2013 for applicability of Corporate Social Responsibility (CSR) provisions. The Company has adopted a Corporate Social Responsibility (CSR) Policy outlining various CSR activities to be undertaken by the Company, in accordance with Schedule VII to the Companies Act, 2013. The said policy is made available on the Company's website at the following link [www.bafnapharma.com](http://www.bafnapharma.com). The Report on CSR Activities is annexed as **Annexure-B** to this Report.

**18. PARTICULARS OF DIRECTORS, KEY MANAGERIAL PERSONNEL AND EMPLOYEES**

The Company is continuously focusing on retaining the appropriate talent and increasingly systematizing the HR processes. We have excellent industrial relations across all facilities including the corporate office and strongly believe that the workers will continue to work towards achieving a profitable and productive Company.

The information as per Section 197 (12) of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is provided in **Annexure-D** to this Report. Further, the information pertaining to Rule 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, pertaining to the

names and other particulars of employees is available for inspection at the Registered office of the Company during business hours and pursuant to provisions of Section 136(1) of the Act, the Report and the accounts are being sent to the members excluding this. Any shareholder interested in obtaining a copy of the same may write to the Company Secretary/ Compliance Officer either at the Registered/Corporate Office address or by email to cs@bafnapharma.com.

**19. CORPORATE GOVERNANCE**

The detailed report on Corporate Governance and Certificate from a Practicing Company Secretary regarding compliance with requirements of Corporate Governance are annexed as **Annexure-E** to this Report.

**20. MANAGEMENT DISCUSSION AND ANALYSIS REPORT**

Pursuant to Regulation 34 read with Schedule V of the SEBI (LODR) Regulations, 2015, a detailed review of the business operations, performance, future outlook, major events occurred during the year as well as state of company's affairs is given in the Management Discussion and Analysis Report, which is annexed as **Annexure-F** to this Report. Certain Statements in the report may be forward-looking. Many factors may affect the actual results, which could be different from what the Directors envisage in terms of future performance & outlook.

**21. RISK MANAGEMENT:**

Your Company recognizes that risk is an integral part of business and is committed to managing the risks in a proactive and efficient manner. Your Company periodically assesses risks in the internal and external environment, along with the cost of treating risks and incorporates risk treatment plans in the strategy, business and operational plans.

**22. ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS:**

The Company has an Internal Control System, commensurate with the size, scale and complexity of its operations. The Internal Auditors monitor and evaluate the efficacy and adequacy of internal control system in the Company, its compliance with operating systems, accounting procedures and policies of the Company. The internal audit reports were reviewed periodically by the Audit Committee & the Board. Further, the Board annually reviews the effectiveness of the Company's internal control system.

**23. DIRECTORS RESPONSIBILITY STATEMENT**

In terms of Section 134(3)(c) read with section 134(5) of the Companies Act, 2013, the Directors, to the best of their knowledge and belief, based on the information and explanations obtained by them, confirm that:

- a) In the preparation of the annual accounts, the applicable accounting standards had been followed and there were no material departures;
- b) Appropriate accounting policies had been selected and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the Profit of the Company for the year under review;
- c) Proper and sufficient care had been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company, preventing and detecting fraud and other irregularities;
- d) The financial statements for the financial year had been prepared on a 'going concern basis';
- e) The internal financial controls had been laid down, to be followed by the Company and such internal financial controls were adequate and were operating effectively; and
- f) In order to ensure compliance with the provisions of all applicable laws, proper systems had been devised and that such systems were adequate and operating effectively.

**24. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS/ COURTS:**

There are no significant and material orders passed by the Regulators / Courts which would impact the going concern status of your Company and its future operations.

**25. SECRETARIAL STANDARDS**

The Company has complied with the applicable Secretarial Standards issued by Institute of Company Secretaries of India (ICSI) as per section 118(10) of the Companies Act, 2013.

**26. INSIDER TRADING REGULATIONS**

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the code of conduct for prevention of insider trading and the code for corporate disclosures are in force. The Company has adopted a Code of Conduct




for Prevention of Insider Trading with a view to regulate trading in securities by the Directors and designated persons of the Company, as per SEBI (Prohibition of Insider Trading) Regulations, 2015.

**27. DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT THE WORK PLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013**

The Company has a zero tolerance towards sexual harassment. The Company has adopted a policy on prevention of sexual harassment of women at work place and put in place proper dissemination mechanism across the Company. The Company has conducted awareness programs for its employees under the said Act.

The Company has complied with the provisions relating to the constitution of Internal Complaints Committee (ICC) under The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. During the financial year 2024-25, the Company has not received any complaint.

**28. VIGIL MECHANISM / WHISTLE BLOWER POLICY**

The Board of Directors adopted the Whistle-Blower Policy in accordance with Section 177(9) of the Act, and Regulation 22 of the SEBI (LODR) Regulations, 2015. The policy provides adequate safeguard against victimization and for direct access to the Chairman of the Audit 

Committee for the employees and state their complaints / grievances. The Whistle Blower Policy is uploaded on the Company's website www.bafnapharma.com.

**29. DISCLOSURE UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:**

During the year under review, no application was made or any proceeding is pending under the Insolvency and Bankruptcy Code, 2016.

**30. DISCLOSURE REGARDING VALUATION UNDER ONE TIME SETTLEMENT:**

Not Applicable.

**31. ACKNOWLEDGEMENT AND APPRECIATION**

The Board takes this opportunity to thank all shareholders, business partners, financial institutions, banks, distributors, suppliers, customers, government and regulatory authorities, etc., for their co-operation and support extended to the Company. The Directors also wish to express their gratitude to the Shareholders for the confidence and faith that they continued to repose in the Company. The Directors place on record their appreciation of the consistent and dedicated services of the employees at all levels who have immensely contributed to the performance of the Company during the year under review.

On behalf of the Board of Directors  
For **BAFNA PHARMACEUTICALS LIMITED**

SD/-  
**S. Hemalatha**  
Whole-Time Director  
DIN:02714329  
Place: Chennai

SD/-  
**Vinayak Dinesh Dendukuri**  
Whole-Time Director  
DIN: 07601309  
Place: Hyderabad

Date: August 12, 2025



# ANNEXURE TO THE BOARDS' REPORT

"Annexure-A"

## CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO FOR THE FINANCIAL YEAR 2024-2025

(Pursuant to Section 134 of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014)

### A. CONSERVATION OF ENERGY

#### i). Steps taken or impact on conservation of energy

The Company is making continuous efforts on an ongoing basis to conserve energy. Efforts to conserve energy continued during the year through timely preventive maintenance and inspection of Plant and Machinery, minimizing leakages and energy waste.

#### ii). Steps taken for Utilising alternate source of energy

The Company has entered into a Solar Power Purchase Agreement (PPA) to source Solar Power for the manufacturing operations. Nearly 60% of our power consumption is from renewable energy thereby making the factory a carbon neutral facility.

#### iii). Capital investment in energy conservation equipment

The Company has not made any capital investment in energy conservation equipment.

### B. TECHNOLOGY ABSORPTION

#### i). Efforts made towards technology absorption:

With latest technology, its development & up-gradation enable us to provide technically superior, process efficient and international standards product. The Company has full-fledged R&D Center, which are continuously engaged in R&D activities with respect to new product development and process improvement/excellence.

a) The R&D center has been upgraded and adopted various methods of drug particle coating with a gastro-resistant polymers of various genre to improve drug safety and efficacy and technology is absorbed into process scale up of branded generics with innovative methodologies involving combination with taste masking technology (with Ion-Exchange resins)-for producing efficacious generics with highly taste masked bitter drugs.

b) The R&D center also absorbed and adopted innovative techniques of Multi-layer Coating technology which is subjected scale-up levels to produce stable and effective dosage forms-especially applicable for drug products that are pH sensitive and for intestinal release and gastric resistance.

#### ii). Benefits derived like product improvement, cost reduction, product development or import substitution

- a) Control of drug therapy is achieved
- b) Drug administration can be made convenient

- c) The safety margin of high potency drug can be increased
- d) Drugs with shorter half-life can be given in less frequent dose with better compliance
- e) Less fluctuating blood plasma concentrations
- f) Bioavailability enhancement of poorly soluble drugs
- g) Targeting drug delivery at most absorbing sites to improve bioavailability
- h) Reduction of adverse effects due to avoidance of dose dumping
- i) Rapid onset of action can be achieved
- j) Taste masking of bitter oral liquid drug formulations

#### iii). Details of Imported Technology (during the last 3 years reckoned from the beginning of the FY 2024-25) - Nil

#### iv). Research and Development expenditure incurred

Particulars	₹ In Lakhs	
	2024-2025	2023-2024
Capital Expenditure	--	--
Recurring Expenditure	219.43	153.62

### C. FOREIGN EXCHANGE EARNINGS AND OUTGO

Particulars	₹ In Lakhs	
	2024-2025	2023-2024
Foreign Exchange Earnings	7,292.87	10,307.23
Foreign Exchange Outgo	332.54	1,207.84

On behalf of the Board of Directors  
For BAFNA PHARMACEUTICALS LIMITED

SD/-  
**S. Hemalatha**  
Whole-Time Director  
DIN:02714329  
Place: Chennai

SD/-  
**Vinayak Dinesh Dendukuri**  
Whole-Time Director  
DIN: 07601309  
Place: Hyderabad

Date: August 12, 2025



# ANNEXURE TO THE BOARDS' REPORT

"Annexure-B"

## ANNUAL REPORT ON CSR ACTIVITIES FOR THE FINANCIAL YEAR 2024-25

(Pursuant to Section 134(3) of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility) Rules, 2014)

### 1. BRIEF OUTLINE ON CSR POLICY OF THE COMPANY:

The CSR policy of the Company focuses on implementing impactful and sustainable CSR initiatives in the areas of healthcare, education, reducing inequalities, promotion of sports, environmental sustainability and community development and other areas prescribed under schedule VII of the Companies Act, 2013. As a part of its CSR initiatives, the Company's vision is to be a socially responsible organization committed to sustainable development and improving the quality of life in the communities where we operate.

### 2. COMPOSITION OF CSR COMMITTEE:

The CSR Committee of the Company comprises of the following Directors:

Sl. No	Name of Director	Designation / Nature of Directorship	Number of Meetings of CSR Committee held during the year (On 05.02.2025)	Number of Meetings of CSR Committee attended during the year
1	Mrs. R Chitra	Chairperson –Independent Director	1	1
2	Mrs. Akila C Raju	Member – Non-Executive Director	1	1
3	Ms. S Hemalatha	Member – Whole-Time Director	1	1

### 3. PROVIDE THE WEB-LINK WHERE COMPOSITION OF CSR COMMITTEE, CSR POLICY AND CSR PROJECTS APPROVED BY THE BOARD ARE DISCLOSED ON THE WEBSITE OF THE COMPANY. – [www.bafnapharma.com](http://www.bafnapharma.com)

### 4. PROVIDE THE DETAILS OF IMPACT ASSESSMENT OF CSR PROJECTS CARRIED OUT IN PURSUANCE OF SUB-RULE (3) OF RULE 8 OF THE COMPANIES (CORPORATE SOCIAL RESPONSIBILITY POLICY) RULES, 2014, IF APPLICABLE. – Not Applicable

5. DETAILS OF PRESCRIBED CSR EXPENSES	AMOUNT (IN ₹)
(a) Average Net Profit of the Company as per Section 135(5)	₹ 8,54,79,153/-
(b) Two percent of average Net Profit of the Company as per Section 135(5)	₹ 17,09,583/-
(c) Surplus arising out of the CSR projects or programmes or activities of the previous financial years	--
(d) Amount required to be set off for the financial year, if any	--
(e) Total CSR Obligation for the financial year [(b)+(c)-(d)]	₹ 17,09,583/-

6. DETAILS OF CSR EXPENSES INCURRED	AMOUNT (IN ₹)
(a) Amount spent on CSR Project (both Ongoing project and other than Ongoing project)	₹ 17,10,580/-
(b) Amount spent in Administrative Overheads	--
(c) Amount spent on Impact Assessment, if applicable	--
(d) Total amount spent for the Financial Year [(a)+(b)+(c)]	₹ 17,10,580/-

### 7. CSR AMOUNT SPENT OR UNSPENT FOR THE FINANCIAL YEAR:

Total Amount Spent for the Financial year (in ₹)	Amount unspent (in ₹)				
	Total Amount transferred to Unspent CSR account as per section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5)		
	Amount	Date of Transfer	Name of the fund	Amount	Date of Transfer
17,10,580	--	--	--	--	--



**8. EXCESS AMOUNT FOR SET OFF, IF ANY:** Nil

**9. DETAILS OF UNSPENT CSR AMOUNT FOR THE PRECEDING THREE FINANCIAL YEARS:**

Sl. No	Preceding Financial Year	Amount Transferred to Unspent CSR Account Under Section 135 (6) (in ₹)	Balance Amount in Unspent CSR Account under sub Section 135(6) (in ₹)	Amount Spent in the Financial Year (in ₹)	Amount transferred to Fund as specified under Schedule VII as per second previous to Section 135(5), if any		Amount remaining to be spent in succeeding Financial Years (in ₹)	Deficiency, If any
					Amount (in ₹)	Date of Transfer		
1	2023-24	--	--	--	6,70,553	05.08.2024	--	--
					6,00,000	05.08.2024		

**10. WHETHER ANY CAPITAL ASSETS HAVE BEEN CREATED OR ACQUIRED THROUGH CORPORATE SOCIAL RESPONSIBILITY AMOUNT SPENT IN THE FINANCIAL YEAR:** Nil

**11. SPECIFY THE REASON(S), IF THE COMPANY HAS FAILED TO SPEND TWO PER CENT OF THE AVERAGE NET PROFIT AS PER SECTION 135(5). – Not Applicable.**

On behalf of the Board of Directors  
For **BAFNA PHARMACEUTICALS LIMITED**

SD/-  
**S. Hemalatha**  
Whole-Time Director  
DIN:02714329  
Place: Chennai

SD/-  
**Vinayak Dinesh Dendukuri**  
Whole-Time Director  
DIN: 07601309  
Place: Hyderabad

Date: August 12, 2025



# ANNEXURE TO THE BOARDS' REPORT

"Annexure-C"

## FORM NO. MR-3

### SECRETARIAL AUDIT REPORT

For The Financial Year Ended 31.03.2025

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To  
The Members,  
**BAFNA PHARMACEUTICALS LIMITED**  
299, THAMBU CHETTY STREET,  
Chennai – 600001

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **M/s. BAFNA PHARMACEUTICALS LIMITED (CIN: L24294TN1995PLC030698)** (hereinafter called as "**The Company**"). The Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31.03.2025, complied with the statutory provisions listed here under and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minutes books, forms and returns filed and other records maintained by the Company for the financial year ended on 31.03.2025 according to the provisions of:

- i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- ii) The Securities Contracts (Regulation) Act, 1956 ("SCRA") and the rules made thereunder;
- iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign

Direct Investment. The Company has no Overseas Direct Investment and External Commercial Borrowings.

- v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ("SEBI Act"):-

- a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- c) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act, 2013 and dealing with client;
- d) The Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018;
- e) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We report that, the following Regulations and Guidelines were not applicable to the Company during the audit period:-

- a) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- b) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;
- c) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021;
- d) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; and
- e) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018.

We have also examined compliance with the applicable clauses of the following:

- i). Secretarial Standards issued by The Institute of Company Secretaries of India.
- ii). The Listing Agreement entered into by the Company with BSE Limited (BSE) and National Stock Exchange Limited (NSE) as per SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.

During the period under review the Company has complied with the above provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. except for the following:

- a) *The Company did not comply with the Minimum Public Shareholding requirements as prescribed under Regulation 38 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Rule 19(2) and Rule 19A of the Securities Contracts (Regulation) Rules, 1957.*
- b) *The Company has belatedly submitted the disclosure required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, relating to the temporary disruption of operations at its factory situated at Grantlyon, Chennai, due to a breakdown of temperature control equipment, with a delay of three days from the prescribed timeline.*

We further report that, having regard to the compliance system prevailing in the Company and based on the written representations received from the officials/executives of the Company, we state that there are adequate systems and processes commensurate with the size and operations of the company to monitor and ensure compliance of the following laws applicable specifically to the Company:

- (a) The Factories Act, 1962 as amended from time to time.
- (b) Drug and Cosmetics Act, 1940 and Rules made thereunder.
- (c) Drugs Price Control Order, 2013 and notifications made thereunder.
- (d) The Water (Prevention and Control of Pollution) Act, 1974.
- (e) The Air (Prevention and Control of Pollution) Act, 1981.


We further report that:

- a) The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive

Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

- b) Adequate notice is given to all the directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance or as the case may be, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.
- c) All the decisions at Board meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.
- d) There are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that the applicable financial laws, such as the Direct and Indirect Tax Laws, have not been reviewed under our audit as the same falls under the review of statutory audit by other designated professionals.

 We further report that during the audit period, there were no instances of:

- i) Public / Right / Preferential Issue of Shares / Sweat Equity Shares.
- ii) Redemption / Buy-back of Securities.
- iii) Foreign technical collaborations.
- iv) Merger / Amalgamation / Reconstruction.

We further report that during the year under review, M/s. SRJR LIFESCIENCES LLP, the Promoter has made an Offer for Sale (OFS) of 31,45,296 Equity Shares representing 13.30% of total Paid-up capital of the Company, on March 27, 2025 ("T Day") (For Non-Retail Investors) and on March 28, 2025 ("T+1 Day") (For Retail Investors and for Non-Retail Investors who choose to carry forward their un-allotted bids from T Day). The Offer for Sale was carried out through the stock exchange mechanism in accordance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, regarding the "Manner of Achieving Minimum Public Shareholding," read with the revised operational guidelines for Offer for Sale issued by BSE and NSE dated July 01, 2024, and July 12, 2024, respectively, in order to comply with Minimum Public Shareholding requirements as mandated under Rule 19(2) (b) and 19A of the Securities Contracts (Regulation) Rules,



1957 read with Regulation 38 of SEBI (LODR) Regulations, 2015. Accordingly, M/s. SRJR LIFESCIENCES LLP disposed of 31,45,296 Equity Shares, representing 13.30% of total Paid-up capital of the Company, on March 27, 2025 and on March 28, 2025. As a result of the aforesaid OFS, the Company has complied with the Minimum Public Shareholding (MPS) requirement of 25% with effect from April 02, 2025.

Company has not yet completed the sale/disposal of the Undertaking to the identified buyer, due to the pending receipt of license approval from the Government.

This report is to be read with our letter of even dated which is annexed as 'Annexure-A' and form an integral part of this report.

We further report that during the year under review, the Company passed a Board Resolution dated August 13, 2024, and a Special Resolution at the Annual General Meeting held on September 25, 2024, approving the sale, transfer, or other disposal of its manufacturing unit located at No. 13, S.V. Koil Street, Madhavaram, Chennai – 600 060, Tamil Nadu, India ("Undertaking"), together with all its assets including the building, plant and machinery, employees, contracts, licences, permits, rights, consents, and all other assets related to the Undertaking, on an "as is where is" basis. However, the

For **A.K.JAIN & ASSOCIATES**  
Company Secretaries

SD/-

**BALU SRIDHAR**

Partner

M.No. F5869

C.P. No. 3550

Place: Chennai

Date: 26-05-2025

UDIN: F005869G000441194

PR No.1201/2021

**ANNEXURE- A**

To,  
The Members,  
**BAFNA PHARMACEUTICALS LIMITED**  
299, Thambu Chetty Street,  
Chennai – 600 001

**OUR REPORT OF EVEN DATE IS TO BE READ ALONG WITH THIS LETTER.**

1. Maintenance of Secretarial Records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial Records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events, etc.
5. The compliances of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For **A.K.JAIN & ASSOCIATES**  
Company Secretaries

SD/-

**BALU SRIDHAR**

Partner

M.No. F5869

C.P. No. 3550

Place: Chennai

Date: 26-05-2025

UDIN: F005869G000441194

PR No.1201/2021

# ANNEXURE TO THE BOARDS' REPORT

"Annexure-D"

## PARTICULARS OF DIRECTORS, KEY MANAGERIAL PERSONNEL AND EMPLOYEES

(Disclosure as per Section 197 of the Companies Act, 2013 and Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014)

Date: 26-05-2025

PR No.1201/2021

### 1. RATIO OF REMUNERATION PAID TO DIRECTORS AND KEY MANAGERIAL PERSONNEL:

Name of Director, Key Managerial Personnel	Designation	% of Increase / (Decrease) in Remuneration during F.Y 2024-25	Ratio of remuneration to median remuneration during F.Y 2024-25
Ms. S Hemalatha	Whole-Time Director	12.61%	7.00:1
Mr. Vinayak Dinesh Dendukuri	Whole-Time Director	Nil	12.13:1
Mr. Bafna Mahaveer Chand	Chief Executive Officer	Nil	26.38:1
Mr. Melagiri Sridhar	Chief Financial Officer	8.86%	5.36:1
Mr. Mohanachandran A	Company Secretary	Nil	3.84:1

#### Notes:

- None of the Non-Executive Directors (including Independent Directors) receive any remuneration from the Company except sitting fees for attending meeting of the Board & Committee(s) thereof. Hence, the ratio of remuneration and percentage increase for Non-Executive Directors have not been considered.
  - Mr. Mohanachandran A, was appointed as Company Secretary of the Company with effect from May 29, 2024.
- PERCENTAGE INCREASE IN THE MEDIAN REMUNERATION OF EMPLOYEES IN THE FINANCIAL YEAR:** Approx 4.50%.
  - NUMBER OF PERMANENT EMPLOYEES ON THE ROLLS OF THE COMPANY AS ON MARCH 31, 2025:** 406 Employees.
  - AVERAGE PERCENTILE INCREASE ALREADY MADE IN THE SALARIES OF EMPLOYEES OTHER THAN THE MANAGERIAL PERSONNEL IN THE LAST FINANCIAL YEAR (FY 2024-2025) AND ITS COMPARISON WITH THE PERCENTILE INCREASE IN THE MANAGERIAL REMUNERATION AND JUSTIFICATION THEREOF:** The average percentile increase was 8% in 2024-2025 for employees other than the managerial personnel.
  - It is hereby affirmed that the remuneration paid is in accordance with the remuneration policy of the Company

On behalf of the Board of Directors  
For **BAFNA PHARMACEUTICALS LIMITED**

SD/-  
**S. Hemalatha**  
Whole-Time Director  
DIN:02714329  
Place: Chennai

SD/-  
**Vinayak Dinesh Dendukuri**  
Whole-Time Director  
DIN: 07601309  
Place: Hyderabad

Date: August 12, 2025



# ANNEXURE TO THE BOARDS' REPORT

"Annexure-E"

## REPORT ON CORPORATE GOVERNANCE

(Pursuant to Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015)

### 1. COMPANY'S PHILOSOPHY

Your Company believes in professionalism of management, transparency and sound business ethics. It emphasizes the need for full transparency and accountability and conducting its business in a highly professional and ethical manner, thereby enhancing trust and confidence of all its stakeholders and encouraging their wide participation.

Effective corporate governance practices constitute the strong foundation on which successful commercial enterprises are built to last. The Company has always been committed to the principles of good Corporate Governance. The Company's philosophy on corporate governance oversees business strategies and ensures fiscal accountability, ethical corporate behavior and fairness to all stakeholders.

The Company is generally in compliance with the applicable provisions of Corporate Governance as stipulated under Regulation 17 to 27 read with Schedule V and Regulation 46 of SEBI (LODR) Regulations, 2015 ("SEBI Listing Regulations"), as applicable, with regard to corporate governance.

A report on compliance with Corporate Governance principles as prescribed under the SEBI Listing Regulations is given below:

iii). During the FY 2024-25, the Board met Five (5) times on May 29, 2024; August 13, 2024; November 11, 2024; February 06, 2025 and March 28, 2025. The requisite quorum was present throughout the meetings.

iv). The composition, nature of directorship, number of meetings attended and their directorship in other public companies of the Board of Directors as on March 31, 2025 are as under:

Name of Director	Category	Number of board meeting attended	Attendance at the last AGM held on September 25, 2024	Number of Directorship in other public companies		Number of Committee positions held in other public companies		Directorship in other listed entity
				Chairman	Member	Chairman	Member	
Ms. S Hemalatha (DIN:02714329)	Whole-Time Director	5	Yes	--	--	--	--	--
Mr. Vinayak Dinesh Dendukuri (DIN: 07601309)	Whole-Time Director	5	Yes	--	--	--	--	--

### 2. BOARD OF DIRECTORS

#### Composition, Attendance and Meetings

i). The Company has an optimum combination of Executive and Non-Executive Directors on its Board. As on March 31, 2025, the Board comprises of Six (6) Directors, including Two (2) Whole Time Directors, Two (2) Non-Executive Directors and Two (2) Independent Directors. The composition of the Board, as at the end of F.Y 2024-25, is in conformity with Regulation 17 of the SEBI Listing Regulations read with Section 149 of the Act. The profiles of Directors are available at Company's website.

ii). To the best of our knowledge and information furnished to the Board, total Directorships held by the Directors are within the limits prescribed under Section 165 of the Companies Act, 2013 (Act) read with Regulation 17A of SEBI LODR. None of the Independent Directors serves as an Independent Director in more than seven (7) listed companies and not more than three (3) listed companies, in case he is a whole-time-Director in a listed company. Similarly, none of the Directors on the Board is a member of more than ten (10) Committees or Chairperson of more than five (5) Committees across all listed and unlisted public companies in which he / she is a Director in terms of Regulation 26 of SEBI LODR. The Directors notify the Company about change in their Directorship(s) / Committee position(s) as and when they take place.



Name of Director	Category	Number of board meeting attended	Attendance at the last AGM held on September 25, 2024	Number of Directorship in other public companies		Number of Committee positions held in other public companies		Directorship in other listed entity
				Chairman	Member	Chairman	Member	
Mrs. Akila C Raju (DIN: 07590312)	Non-Executive Director	3	Yes	--	--	--	--	--
Mr. Upendar Mekala Reddy (DIN: 08898174)	Non-Executive Director	5	Yes	--	1	--	--	--
Mrs. R. Chitra (DIN:07749125)	Chairperson & Independent Director	4	Yes	--	--	--	--	--
Mr. P K Sundaresan (DIN: 06954189)	Independent Director	5	Yes	--	--	--	--	--
Mr. Krishna Yeachuri* (DIN: 00066898)	Independent Director	4	Yes	--	1	--	1	1

**Notes:**

- a. Excludes Directorships held on the Boards of Private Companies, Section 8 Companies, Debt-Listed Companies and Companies incorporated outside India.
- b. Membership in Audit Committee and Stakeholder Relationship Committee of other public companies are only considered as per Regulation 26 of SEBI LODR and membership includes the positions held as chairperson of the Committee.
- c. \*Mr. Krishna Yeachuri, Independent Director, resigned with effect from March 31, 2025.
- v). During the financial year under review, Mr. Krishna Yeachuri (DIN: 00066898) resigned from the Directorship of the Company w.e.f March 31, 2025. He has confirmed in the resignation letter that there are no other material reasons other than those provided therein i.e due to pre-occupation.
- vi). None of the Directors is related to any other Directors of the Company as on March 31, 2025.
- vii). The Company placed before the Board the Annual Plans and Budget, Capital Budget, Performance of the Company, Unaudited Quarterly Financial Results, Audited Annual Financial Results and various other information/ details, as specified under Part A of Schedule II of the SEBI (LODR) Regulations, 2015, from time to time. The Board also periodically reviews the compliance reports of all laws applicable to the Company.

- viii). As on March 31, 2025, none of the Non-Executive Directors hold any Shares in the Company.
- ix). **Independent Directors:** In accordance with Schedule IV of the Companies Act, 2013 and Regulation 25(3) of the SEBI (LODR) Regulations, 2015, a separate meeting of Independent Directors of the Company, was held on March 28, 2025 for reviewing the performance of Non-Independent Directors, the Board as a whole, the Chairperson of the Company as well as for assessing the quality, quantity and timeliness of flow of information between the Company management and the Board.
- x). In the opinion of the Board, the Independent Directors, fulfill the conditions of independence specified in Section 149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations.
- xi). The familiarization program on the nature of the industry, the business model of the Company, roles, rights and responsibilities of Independent Directors, etc., are conducted to the Independent Directors of the Company, at the time of induction. The details of the familiarization program are disclosed in the website of the Company at the weblink www.bafnapharma.com. Further, at the time of appointment of an Independent Director, the Company issues a formal letter of appointment outlining his/her role, functions, duties and responsibilities as a Director. The terms and conditions of the appointment of Independent Director are also available on Company's website www.bafnapharma.com.



xii). **Chart/ Matrix setting out the skills/expertise/competence of the board of directors:** The Board comprises of qualified members who bring in the required skills, competence and expertise that allow them to make effective contributions to the Board and Committees. The Board has identified the following skills / expertise with the individual Board Members with reference to the Company’s business and Industry.

Name of the Director	Skills / Expertise / Competencies
Ms. S Hemalatha	Industry & Technology, Business Administration & Strategy, Sales, Marketing, Regulatory Compliance, Finance, Legal
Mr. Vinayak Dinesh Dendukuri	Industry & Technology, Business Administration & Strategy, Sales, Marketing.
Mrs. Akila C Raju	Business Administration & Strategy, Finance, Legal, Corporate Governance.
Mr. Upendar Mekala Reddy	Industry & Technology, Business Administration & Strategy, Corporate Governance.
Mr. P K Sundaresan	Finance, Corporate Laws / Legal, Corporate Governance.
Mrs. R Chitra	Finance, Human resource Corporate Governance.
Mr. Krishna Yeachuri	Industry & Technology, Business Administration & Strategy, Finance, Legal, Corporate Governance.

**3. COMMITTEES OF THE BOARD**

**i). Audit Committee**

**a) Composition, Attendance and Meetings:**

The Audit Committee of the Company is constituted in accordance with the Section 177 of the Companies Act, 2013 and Regulation 18 of the SEBI (LODR) Regulations, 2015. The Committee comprises of Three (3) Directors consisting of Two (2) Independent Director and One (1) Non-Executive Director.

During the year under review, the Committee met Four (4) times on May 29, 2024; August 13, 2024; November 11, 2024 and February 06, 2025 and the requisite quorum was present throughout the meetings. The Composition of the Audit Committee and details of its members attendance as on March 31, 2025 are as below:

Name of the Director	Category	No. Of Meetings Attended
Mr. P K Sundaresan	Chairman, Independent Director	4
Mrs. R Chitra	Member, Independent Director	4
Mr. Upendar Mekala Reddy	Member, Non-Executive Director	4

All the members of the Audit Committee are financially literate and possess accounting and related financial management expertise. The Statutory Auditors, Internal Auditors and Chief Financial Officer attended the meetings, by invitation, whenever necessary. The Company Secretary of the Company acts as the Secretary to the Committee. The Chairman of the Audit Committee was present at the last AGM of the Company held on September 25, 2024.

All the recommendations of the Audit Committee during the year, were considered and accepted by the Board.

**b) Terms of Reference:**

The terms of reference and powers of the Audit Committee are those prescribed under Section 177 of the Companies Act, 2013 and Regulation 18 read with Part C of Schedule II of the SEBI (LODR) Regulations, 2015. The brief terms of reference

of the Audit Committee of the Company, inter alia include:

- i. Recommendation for appointment, remuneration and terms of appointment of auditors of the Company.
- ii. Review and monitor the Auditor’s independence and performance and effectiveness of audit process.
- iii. Review with the Management the quarterly Financial Statements and the annual Financial Statements and the Auditor’s Report thereon, before submission to the Board for approval, with particular reference to:
  - a) matters required to be included in the Director’s responsibility statement to be included in the board’s report in terms of Clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013.
  - b) disclosure of any related party transactions.

- c) modified opinion(s) in the draft audit report.
- iv. Approval or any subsequent modification of transactions of the Company with related parties.
- v. Scrutiny of inter-corporate loans and investments.
- vi. Valuation of undertakings or assets of the Company, wherever it is necessary.
- vii. Evaluation of internal financial controls and risk management systems.
- viii. Monitoring the end use of funds raised through public offers and related matters.

- ix. To review the functioning of the whistle blower mechanism.

ii). **Nomination & Remuneration Committee:**

a) **Composition, Attendance and Meetings:**

The Nomination & Remuneration Committee of the Company is constituted in accordance with the Section 178 of the Companies Act, 2013 and Regulation 19 of the SEBI (LODR) Regulations, 2015. As on March 31, 2025, the Committee comprised of Three (3) Directors consisting of Two (2) Independent Director and One (1) Non-Executive Director.

During the year under review, the Committee met One (1) time on May 28, 2024 and the requisite quorum was present throughout the meetings. The Composition of the Nomination & Remuneration Committee and details of its members attendance as on March 31, 2025 are as below:

Name of the Director	Category	No. Of Meetings Attended
Mr. Krishna Yeachuri*	Chairman, Independent Director	1
Mr. P K Sundaresan	Member, Independent Director	1
Mrs. Akila C Raju	Member, Non-Executive Director	--

\*\* Ceased as Chairman w.e.f March 31, 2025.

b) **Terms of Reference:**

The terms of reference and powers of the Nomination & Remuneration Committee are those prescribed under Section 178 of the Companies Act, 2013 and Regulation 19 read with Part D of Schedule II of the SEBI (LODR) Regulations, 2015. The brief terms of reference of the Nomination & Remuneration Committee of the Company, inter alia include:

- i). Formulation of the criteria for determining qualifications, positive attributes and independence of a Director and recommend to the Board a policy, relating to the remuneration of the Directors, Key Managerial Personnel and other employees;
- ii). For every appointment of an independent Director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an Independent Director. The person recommended to the Board for appointment as an Independent Director shall have the capabilities identified in such description.
- iii). Formulation of criteria for evaluation of Independent Directors and the Board;
- iv). Devising a policy on Board diversity;

- v). Identifying persons who are qualified to become Directors and who may be appointed in Senior Management in accordance with the criteria laid down and recommend to the Board their appointment and removal.
- vi). Whether to extend or continue the term of appointment of the Independent Director, on the basis of the report of performance evaluation of Independent Directors.
- vii). Recommend to the Board all remuneration, in whatever form, payable to Senior Management.

c) **Remuneration Policy**

The policy on appointment and remuneration of Directors, Key Managerial Personnel (KMP) and Senior Management Personnel (SMP) is available on the website of the Company [www.bafnapharma.com](http://www.bafnapharma.com).

d) **Remuneration to Non-Executive Directors:**

The Non-Executive Directors are paid sitting fees for attending meetings of the Board and Committee(s) thereof. Apart from receiving the sitting fees, the Non-Executive Directors did not have any pecuniary relationship or transactions with the Company during the year.



The details of remuneration including sitting fees paid to the Non-Executive Directors for the year ended March 31, 2025 are as follows:

Name of the Director	Category
Mr. P K Sundaresan	₹ 1.67 Lakhs
Mrs. R. Chitra	₹ 1.56 Lakhs
Mrs. Akila C Raju	₹ 1.11 Lakh
Mr. Upendar Mekala Reddy	₹ 1.56 Lakhs
Mr. Krishna Yeachuri (Ceased w.e.f March 31, 2025)	₹ 0.89 Lakh

**e) Remuneration Paid to Executive Directors**

The Remuneration paid to Executive Directors for the year ended 31<sup>st</sup> March 2025 is as follows:

Name of Director	Remuneration
Ms. S Hemalatha	₹ 19.70 Lakhs
Mr. Vinayak Dinesh Dendukuri	₹ 33.12 Lakhs

**f) Performance Evaluation Criteria for Independent Directors:**

The performance evaluation criteria for independent directors is determined by the Nomination and

The Composition of the Stakeholders Relationship Committee and details of its members attendance as on March 31, 2025 are as below:

Name of the Director	Category	No. Of Meetings Attended
Mrs. R Chitra	Chairperson, Independent Director	--
Mrs. Akila C Raju	Member, Non-Executive Director	1
Ms. S Hemalatha	Member, Executive Director	1

**b) Terms of Reference:**

The functioning and terms of reference of the Committee are as prescribed and in due compliance with the Regulation 20 of SEBI (LODR) Regulations, 2015 as well as Section 178 of the Companies Act, 2013. The Stakeholders Relationship Committee looks into the redressal of shareholder and investor grievances, issue of duplicate/consolidated share certificates, remat / demat of shares and review of cases for refusal of transfer/transmission and reference to statutory and regulatory authorities.

**c) Name & Designation of Compliance Officer:**

Name	Mr. A. Mohanachandran
Designation	Company Secretary & Compliance Officer
Address	Bafna Pharmaceuticals Limited No.299, Thambu Chetty Street, Chennai-600001
Contact	044-42677555
E-Mail	cs@bafnapharma.com

**d) Details of investor complaints received and redressed during financial year 2024 - 2025 are as follows:**

No. of Complaints pending as on April 01, 2024	No. of complaints received during the year 2024-25	No. of complaints resolved to the satisfaction of Shareholders during the year 2024-25	No. of complaints pending as on March 31, 2025
0	0	0	0

Remuneration Committee. An indicative list of factors on which evaluation was carried out includes participation and contribution by a director, commitment, effective deployment of knowledge and expertise, integrity and maintenance of confidentiality and independence of behavior and judgement.

**iii). Stakeholders Relationship Committee:**

**a) Composition, Attendance and Meetings:**

The Stakeholders Relationship Committee of the Company is constituted in accordance with the Section 178 of the Companies Act, 2013 and Regulation 20 of the SEBI (LODR) Regulations, 2015. The Committee comprises of Three (3) Directors consisting of One (1) Independent Director, One (1) Non-Executive Director and One (1) Whole-Time Director.

During the year under review, the Committee met One (1) time on February 05, 2025 and the requisite quorum was present throughout the meetings. The Company Secretary is the compliance officer of the Company and acts as the Secretary to the Committee.

**iv). Corporate Social Responsibility Committee:**

The Corporate Social Responsibility Committee of the Company is constituted in accordance with the Section 135 of the Companies Act, 2013. The Committee comprises of Three (3) Directors consisting of One (1) Independent Director, One (1) Non-Executive Director and One (1) Whole-Time Director

During the year under review, the Committee met One (1) time on February 05, 2025 and the requisite quorum was present throughout the meetings. The Composition of the Corporate Social Responsibility Committee and details of its members attendance as on March 31, 2025 are as below:

Name of the Director	Category	No. Of Meetings Attended
Mrs. R Chitra	Chairperson, Independent Director	1
Mrs. Akila C Raju	Member, Non-Executive Director	1
Ms. S Hemalatha	Member, Executive Director	1

The CSR policy of the Company focuses on implementing impactful and sustainable CSR initiatives in the areas of healthcare, education, reducing inequalities, promotion of sports, environmental sustainability and community development and other areas prescribed under schedule VII of the Companies Act, 2013. The CSR projects and activities undertaken by the Company are in line with the CSR Policy and recommendations of the Board / CSR Committee which are in accordance with the areas or subjects specified under the Companies Act, 2013, as amended from time to time.

**4. GENERAL BODY MEETINGS**

**i). Annual General Meeting**

The Details of last three Annual General Meetings (AGMs) are as under:

Financial Year	Date	Time	Venue	Any special resolution was passed
2021-2022	July 28, 2022	11:00 am	Video Conferencing and other Audio Visual Means (VC/ OAVM)	No
2022-2023	September 22, 2023	10.25 am	Video Conferencing and other Audio Visual Means (VC/ OAVM)	Yes *
2023-2024	September 25, 2024	10.30 am	Video Conferencing and other Audio Visual Means (VC/ OAVM)	Yes **

\* Appointment of Mr. Krishna Yeachuri (DIN: 00066898) as a Non-executive Independent Director of the Company.

\*\* Sale / Disposal of Manufacturing Unit located at Madhavaram, Chennai

**ii). Postal Ballot & Extra-Ordinary General Meeting**

No resolution was passed either through Postal Ballot or Extra-Ordinary General Meeting during the Financial Year 2024-25. There are no special resolution proposed to be passed through Postal Ballot.

communications to Stock Exchanges, in which the Company's shares are listed.

The Quarterly Unaudited Financial Results and the Annual Audited Financial Results of the Company, in the prescribed format, are taken on record by the Board and are submitted to the Stock Exchanges. The financial results of the Company are generally published in "Business Standard" (English) & "Makkal Kural" (Tamil).

**5. MEANS OF COMMUNICATION**

The Board believes that effective communication of information is an essential component of corporate governance. The Company regularly interacts with shareholders through multiple channels of communication such as results announcement, annual report, media releases, Company's website and specific

The Quarterly & Annual Financial Results are posted in the website of the Company at [www.bafnapharma.com](http://www.bafnapharma.com) and also on the website of the BSE Limited and National Stock Exchange of India Limited.



**6. GENERAL SHAREHOLDERS' INFORMATION**

**i). Annual General Meeting**

Date	September 19, 2025
Day	Friday
Time	10.00 A.M (IST)
Mode	Through Video Conferencing (VC) and Other Audio Visual Means (OAVM)
E-Mail	cs@bafnapharma.com

**ii). Financial Calendar**

Financial Year	April 01, 2025 – March 31, 2026
Un-audited financial results for the 1 <sup>st</sup> quarter	By August, 14 2025
Un-audited financial results for the 2 <sup>nd</sup> quarter	By November, 14 2025
Un-audited financial results for the 3 <sup>rd</sup> quarter	By February, 14 2026
Audited Financial Results	By May 30, 2026

The above schedule is only tentative in nature and may undergo changes due to change in circumstances

**iii). Dividend Payment Date :** The Board of Directors of the Company has not recommended any dividend for the financial year 2024-25.

**iv). Date of book closure/ Record date:** Saturday, September 13, 2025 to Friday, September 19, 2025 (both days inclusive)

**viii). Distribution of equity shareholding as on March 31, 2025:**

Share holding Shares	Shareholders		Shareholding	
	Number	% of Total	Shares	% of Total
Upto 500	6756	93.08	3,93,534	1.66
501 – 1000	200	2.75	1,52,949	0.65
1001 – 2000	130	1.79	1,91,017	0.81
2001 – 3000	52	0.72	1,30,165	0.55
3001 – 4000	36	0.50	1,24,460	0.53
4001 – 5000	14	0.19	64,739	0.27
5001 – 10000	23	0.32	1,61,024	0.68
10001 & above	47	0.65	2,24,38,447	94.85
<b>Total</b>	<b>7,258</b>	<b>100.00</b>	<b>2,36,56,335</b>	<b>100.00</b>

**ix). Dematerialization of shares and Liquidity:**

The Company has entered into the necessary agreements with National Securities Depository Limited and Central Depositories Services (India) Limited for dematerialisation of the shares held by the Shareholders. As of March 31, 2025, about 99.97% of the shareholdings have been dematerialised.

**v). Listing on stock exchanges:**

Stock Exchanges	Stock Code
National Stock Exchange of India Limited (NSE) Exchange Plaza, C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai 400 051	BAFNAPH
BSE Limited (BSE) Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001	532989

Your Company has paid the Listing Fees for the financial year 2025-26.

**vi). Registrars and Transfer Agents**

Cameo Corporate Services Ltd  
Subramanian Building,  
No.1, Club House Road, Chennai -600 002  
Telephone: 044-4002 0700  
Online Investor Portal – <https://wisdom.cameoindia.com>  
Website: [www.cameoindia.com](http://www.cameoindia.com)

**vii). Share transfer system**

Pursuant to the amendment to the Listing Regulations effective from April 1, 2019, except in case of transmission or transposition of securities, requests for effecting transfer of securities shall not be processed unless the securities are held in dematerialized form with a depository. Members holding shares in physical form are therefore requested to convert their holdings to dematerialized mode. Transfers of Share in Demat form are affected through the depositories with no involvement of the Company.

Under the Depository System, the International Securities Identification Number (ISIN) allotted to the Company's shares is INE878I01022. A comparative table of physical and demat holdings as on March 31, 2025 is given below:

Particulars	No. Of Shares	No. of Shareholders	% of Shares
Electronic Form	2,36,49,295	7,241	99.97
Physical Form	7,040	17	0.03
<b>Total</b>	<b>2,36,56,335</b>	<b>7,258</b>	<b>100.00</b>

A reconciliation of share capital, audited by Practicing Company Secretary (PCS) is submitted to the Stock Exchanges on a quarterly basis in terms of regulation 76 of SEBI (Depositories and Participants) Regulations, 2018.

**x). Outstanding GDRs / ADRs / Warrants or any convertible instruments, conversion date and likely impact on equity:**

The Company has not issued any GDRs/ADRs. As of March 31, 2025, the Company does not have any outstanding convertible instruments, which are likely to have an impact on the equity of the Company.

**xi). Transfer of unclaimed / unpaid amounts to the Investor Education and Protection Fund:**

During the year under review, the Company has not transferred any unclaimed/unpaid amounts to the Investor Education and Protection Fund.

**xii). Credit Rating obtained by the Company**

The Company obtained credit rating for the Working Capital Facilities availed from banks, by ICRA, as detailed below

Facilities	Amount	Rating
Long Term (Fund Based)	₹ 40.00 Crores	[ICRA] BB+
Short Term (Non-Fund Based)	₹ 5.00 Crores	[ICRA] A4+

**xiii). Plant Location**

The Company has manufacturing facility situated at:

- a) No.147, Madhavaram, Redhills, High Road, Grantlyon village, Redhills, Chennai-600052 and

**xiv). Address for Correspondence:**

Bafna Pharmaceuticals Limited  
 Old No. 299, New No.68, Thambu Chetty Street,  
 Chennai-600001  
 Email ID: cs@bafnapharma.com  
 Website: www.bafnapharma.com

**7. OTHER DISCLOSURES**

- i). There are no material related party transactions during the year under review that have conflict with the interest of the Company. Transactions entered into with related parties during FY 2024 - 2025 were in the ordinary course of business and at arms' length basis. All routine and periodic transactions with related parties were covered in the omnibus approval of the Audit Committee. The policy on dealing with Related Party Transactions is posted on the Company's website www.bafnapharma.com.
- ii). During the year under review, the Company did not comply with Minimum Public shareholding as per the provisions of Regulation 38 of SEBI (LODR) Regulations, 2015. The BSE Limited and National Stock Exchange of India Ltd have imposed penalties for non-compliance of aforesaid Regulation, however, the Company has applied for waiver of penalty application before the designated stock exchange and the Order is awaited. Whereas, the Company has complied with the Minimum Public shareholding as on April 02, 2025.
- iii). The Board of Directors adopted the Whistle-Blower Policy in accordance with Section 177(9) of the Act, and Regulation 22 of the SEBI (LODR) Regulations, 2015. We hereby confirm that no person has been denied access to the Chairman of the Audit Committee.
- iv). The Board of Directors has laid down a code of conduct for all Board members & Senior Management of the Company. All the Directors & Senior Management have affirmed their compliance with the code of conduct. A declaration to this effect signed by Ms. S Hemalatha, Whole Time Director, to this effect is annexed to this report on Corporate Governance.
- v). The Company is generally in compliance with the mandatory requirements of Regulation 17 to 27 and Regulation 46 of SEBI (LODR) Regulations, 2015.
- vi). The Company does not have any material listed / unlisted subsidiary as defined in Regulation 24 of the SEBI LODR. Hence, the Company is not required to frame a policy for determining material subsidiary.



- vii). The Company does not have any significant exposure in commodities directly and does not carry out any commodity hedging activities.
- viii). During the year under review, the Company has not raised any funds through preferential allotment or qualified institutions placement and hence, the disclosure on utilization of funds is not applicable. There are no convertible instruments issued or outstanding.
- ix). In terms of Section 178 of the Companies Act, 2013, rules made there under & other applicable provisions, if any, the Board of Directors has approved Succession Plan for Board & Senior Management.
- x). The Company has obtained a certificate from M/s. A.K Jain & Associates, Company Secretaries, Chennai, stating that none of the Directors on the Board of the Company, as on March 31, 2025, have been debarred or disqualified from being appointed or continuing as Director of the companies by the Board / Ministry of Corporate Affairs or any such statutory authority. The Certificate obtained is annexed to this Report on Corporate Governance.
- xi). Pursuant to Regulation 17(8) of the SEBI (LODR) Regulations, 2015, the CEO and CFO of the Company have certified to the Board on the integrity of the financial results / statements, effectiveness of internal controls and significant changes in internal control / accounting policies, for the year under review. The Certificate issued by the CEO and CFO is annexed to this Report.
- xii). The Board of Directors of the Company has considered and accepted all the recommendation(s) made by Committee(s) to the Board.

- xiii). The total fees for all services paid by the listed entity, to M/s. Brahmayya & Co, Chartered Accountants, Chennai, the Statutory Auditor of the Company is provided hereunder:

Particulars of Service	Amount (₹ In Lakhs)
Services as statutory auditors (including quarterly audits)	12.00

- xiv). The disclosure in relation to Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 is provided in the Board's Report.
- xv). During the year under review, the Company has not provided any loans and advances in the nature of loans to firms/companies in which directors are interested.
- xvi). The Company has not entered into any agreement which are to be disclosed under clause 5A of paragraph A of Part A of Schedule III of SEBI (LODR) Regulations, 2015, which have an impact on the management or control of the listed entity or create any liability on the listed entity during the FY 2024-25.

On behalf of the Board of Directors  
For **BAFNA PHARMACEUTICALS LIMITED**

SD/-  
**S. Hemalatha**  
Whole-Time Director  
DIN:02714329  
Place: Chennai  
Date: August 12, 2025

SD/-  
**Vinayak Dinesh Dendukuri**  
Whole-Time Director  
DIN: 07601309  
Place: Hyderabad

## CERTIFICATE OF COMPLIANCE WITH CODE OF CONDUCT

I, S Hemalatha, Whole Time Director (DIN: 02714329), do hereby certify and confirm that the Company has obtained affirmation from all the members of the Board and Senior Management, their compliance with Code of Conduct for Directors and Senior Management in respect of financial year 2024-2025.

For **BAFNA PHARMACEUTICALS LIMITED**

Place: Chennai  
Date: May 26, 2025

SD/-  
**S. Hemalatha**  
Whole-Time Director  
DIN:02714329

**CEO AND CFO CERTIFICATION****(Pursuant to Regulation 17(8) of SEBI (LODR) Regulations, 2015)**

We, (1) Bafna Mahaveer Chand, Chief Executive Officer and (2) Melagiri Sridhar, Chief Financial Officer, of the Company, to the best of our knowledge and belief hereby certify that:

- a) We have reviewed standalone financial statements and cash flow statement for the year ended March 31, 2025, that to the best of our knowledge and belief:
  - i) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading; and
  - ii) These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- b) There are to the best of our knowledge and belief, no transactions entered into by the Company during the year, which are fraudulent, illegal or violative of the Company's code of conduct.
- c) We accept responsibility for establishing and maintaining internal controls for financials reporting and that we have evaluated the effectiveness of the internal control systems of the Company pertaining to financial reporting, deficiencies in the design or operation of such internal controls, if any, of which we are aware, have been disclosed to the auditors and the Audit Committee and steps have been taken or propose to be taken to rectify these deficiencies.
- d) We have indicated to the Auditors and Audit Committee:
  - i) significant changes in internal control over financial reporting during the year;
  - ii) significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
  - iii) instances of significant fraud of which they have become aware and the involvement therein, if any, of the management or an employee having a significant role in the listed entity's internal control system over financial reporting.

For **BAFNA PHARMACEUTICALS LIMITED**

Place: Chennai.  
Date: May 26, 2025

SD/-  
**Bafna Mahaveer Chand**  
Chief Executive Officer

SD/-  
**Melagiri Sridhar**  
Chief Financial Officer

**CERTIFICATE**

[Pursuant to Regulation 34(3) of Securities Exchange Board of India  
(Listing Obligations and Disclosure Requirements) Regulations, 2015]

To,  
The Members of  
**BAFNA PHARMACEUTICALS LIMITED**  
No. 299, Thambu Chetty Street,  
Chennai – 600001

In pursuance of Regulation 34 (3) read with sub-clause (i) of Clause 10 of Part C of Schedule V of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR) in respect of **M/s. BAFNA PHARMACEUTICALS LIMITED (CIN: L24294TN1995PLC030698)**, having registered office at No.299, Thambu Chetty Street, Chennai – 600001, We hereby certify that :

On the basis of the written Representations and Declarations received from the Directors of the Company and taken on record by the Board of Directors of the Company, as on March 31, 2025, none of the directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as Director of companies by the Securities Exchange Board Of India, Ministry of Corporate Affairs or any such statutory authorities.

For **A.K.JAIN & ASSOCIATES**  
Company Secretaries

SD/-

**BALU SRIDHAR**

Partner

M.No. F5869

C.P. No. 3550

UDIN: F005869G000441251

PR No.1201/2021



Place: Chennai  
Date: May 26, 2025

**CERTIFICATE ON CORPORATE GOVERNANCE**

To  
The Members of  
**BAFNA PHARMACEUTICALS LIMITED**  
No.299, Thambu Chetty Street,  
Chennai – 600001

We have examined the compliance of conditions of Corporate Governance by M/s. Bafna Pharmaceuticals Limited (“The Company”), for the financial year ended March 31, 2025, as stipulated under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”).

**MANAGEMENT RESPONSIBILITY:**

The Management is responsible for ensuring that the Company complies with the conditions of Corporate Governance. This responsibility also includes the design, implementation and maintenance of internal controls and procedures to ensure compliance with the conditions of the Corporate Governance stipulated in the Listing Regulations.

**AUDITORS RESPONSIBILITY:**

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our responsibility is limited to examining the procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company. We have examined the relevant records and documents maintained by the Company for the purpose of providing reasonable assurance on the compliance with Corporate Governance requirements by the Company.

**OPINION:**

In our opinion and to the best of our information and according to the explanations given to us and the representation made by the Directors and the Management, we certify that the Company has complied with the all the provisions of Corporate Governance as stipulated in Regulations 17 to 27 and Regulation 46 (2) and Paragraphs C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, during the financial year ended March 31, 2025.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For **A.K.JAIN & ASSOCIATES**  
Company Secretaries

SD/-  
**BALU SRIDHAR**  
Partner  
M.No. F5869  
C.P. No. 3550  
UDIN: F005869G000441326  
PR No.1201/2021

Place: Chennai  
Date: May 26, 2025



# ANNEXURE TO THE BOARDS' REPORT

"Annexure-F"

## MANAGEMENT DISCUSSION AND ANALYSIS

### GLOBAL ECONOMY OVERVIEW & OUTLOOK:

According to the International Monetary Fund's (IMF) World Economic Outlook April 2025 report, global growth is projected to moderate to 2.8% in 2025 and 3.0% in 2026, a downward revision from the earlier forecast of 3.3% for both years in the January 2025 update. These projections remain well below the historical average of 3.7% (2000–2019) and the 3.3% growth in 2024, reflecting the persistence of structural and cyclical challenges across major economies.

While inflationary pressures have broadly eased, supported by stabilizing commodity prices and balanced monetary policy responses, geopolitical tensions and shifting trade dynamics continue to cloud the global economic landscape, putting a pause on the likely relaxation of monetary policies by most central banks. The recent imposition of new tariffs by the United States and retaliatory measures by its key trading partners are already exerting a dampening effect on global trade, business confidence, and investment flows. The world trade volumes are therefore expected to remain subdued in 2025 and 2026.

Among major economies, growth in advanced economies is forecast to remain modest, with the United States projected to grow at 1.8% and the Eurozone at just 0.8% in 2025, falling from 2.8% and 0.9% growth in 2024, respectively. While the Emerging Markets and Developing Economies (EMDE) are expected to grow at a relatively higher rate of 3.7%, the momentum has slowed significantly from 4.3% growth in 2024. Some EMDEs, such as China, may experience greater loss of momentum due to their greater exposure to trade tensions and policy unpredictability. Overall, while global inflation is gradually receding, the lingering uncertainty around trade policies, currency volatility, and geopolitical developments continues to challenge the global economic recovery.

### 2025 GDP Growth Projections by the IMF for a few of the Company's Key Markets:


<b>Nigeria</b> 3% (2024: 3.4%)	<b>Philippines</b> 5.5% (2024: 5.7%)	<b>Honduras</b> 3.3% (2024: 3.6%)
<b>Tanzania</b> 6% (2024: 5.4%)	<b>Sri Lanka</b> N.A. (2024: 5%)	<b>Australia</b> 1.6% (2024: 1%)
<b>Kenya</b> 4.8% (2024: 4.5%)	<b>Nepal</b> 4% (2024: 3.1%)	<b>United Kingdom</b> 1.1% (2024: 1.1%)
<b>Ethiopia</b> 6.6% (2024: 8.1%)	<b>Ukraine</b> 2% (2024: 3.5%)	<b>Europe</b> 1.1% (2024: 1.2%)

### INDIAN ECONOMIC OVERVIEW:

Amid global uncertainties and geopolitical tensions, India's Real GDP growth for FY 2024–25 was provisionally estimated at approximately 6.5% by the National Statistics Office (NSO), moderating from 9.2% in the previous fiscal year. This

deceleration reflects the impact of external headwinds from a global slump in manufacturing and geopolitical tensions, which led to weaker trade, lower government spending due to elections, and uneven monsoon coverage.

Broad Sector-wise Growth Rates	Primary Sector	Secondary Sector	Tertiary Sector
FY2023-24	2.7%	11.4%	9.0%
FY2024-25	4.4%	6.1%	7.2%



Retail inflation eased significantly to 4.6% in FY2024-25, the lowest level in several years, aided by stable food prices and effective policy interventions. This decline enabled the Reserve Bank of India (RBI) to initiate a supportive monetary environment through repo rate cuts from February 2025 onwards, thereby creating favourable conditions for credit growth, investment, and consumer spending.

India is expected to demonstrate continued economic resilience in FY 2025–26, despite further exacerbation of geopolitical tensions, ongoing global trade frictions, and commodity price volatility. Underpinned by strong domestic consumption, a sustained infrastructure push, and proactive fiscal and monetary policies. India's structural growth story remains intact, with investment-led recovery, rising FDI inflows, expansion of the digital economy, and rural income growth driving capacity enhancement and inclusivity. These factors continue to reinforce macroeconomic stability and long-term growth potential. Looking ahead to FY 2025–26, the Indian economy is projected to grow in the range of 6.3% to 6.8%, supported by sustained momentum in the manufacturing and services sectors, alongside easing inflationary pressures. The Reserve Bank of India (RBI) has projected a growth of 6.5% in India's real GDP during FY2025-26. It also expects the inflation to further moderate to 3.7%, well within the target range of the RBI. However, downside risks to growth from ongoing global trade disruptions and geopolitical developments remain.



**GLOBAL PHARMA INDUSTRY OVERVIEW**

The global pharmaceutical market is estimated at US\$1,737 billion in 2024 and is expected to grow at a compounded annual growth rate ('CAGR') of between 5 - 8% in the forecast period of 2025 – 2029 to touch US\$2,376 billion, as per 'The Global Use of Medicines Outlook through 2029: Increasing Access, Use, and Spending' report by IQVIA. Similarly, BMI expects global pharmaceutical sales to reach US\$1.7 trillion by 2025, representing a 5.3% growth from 2024. The sector's expansion is driven by sustained demand for chronic disease therapies, rising healthcare investments, and a growing focus on innovative treatments such as biologics, biosimilars, and specialty drugs, particularly in oncology and metabolic disorders. However, the industry is navigating a complex environment that includes the most severe patent cliff estimated to impact drugs with over US\$180 billion in annual revenues from 2027 to 2028, along with increasing pricing pressure due to regulatory reforms. This figure is estimated by IQVIA to be US\$220 billion in annual revenues over the 5 years from 2025 to 2029, of which nearly US\$43 billion is from biologics and the rest from small molecules. Other key downside risks to the industry's growth include supply chain protectionism, persistent reimbursement challenges across public health systems, and drug pricing scrutiny from regulators. Amidst evolving global health demands and economic pressures, the industry strengthened its foundation for long-term growth while adapting to structural changes across regions and therapeutic segments.

Emerging markets, especially in Asia-Pacific and Latin America, are expected to outpace developed economies in pharmaceutical sales growth, as per BMI. These regions are witnessing accelerated adoption of pharmaceuticals owing to expanding healthcare infrastructure and increasing access to medications. Emerging economies are projected to grow at 6.3% YoY in 2025, compared to developed market growth of 4.4%. The global top 20 ranking by size of the pharmaceutical market is expected to see India displace Spain as the ninth largest market and South Korea overtake Russia as the twelfth largest. The United States is expected to continue to be the largest market with nearly 30% share of the global sales, with China and Japan being the distant second and third largest markets.

Pharmaceutical companies are adapting to global supply chain realignments and geopolitical shifts by localizing manufacturing and investing in digital innovation. Advances in AI-enabled drug discovery, decentralized clinical trials, and personalized medicine are reshaping R&D models and time-to-market efficiencies. The five years from 2025 to 2029 are likely to see between 325 to 375 new drug launches or Novel Active Substance (NAS) launches, which will contribute US\$181 billion in annual revenue by 2029 as per IQVIA. While macroeconomic uncertainty and regulatory risks persist, the medium-term outlook for the pharmaceutical sector remains positive, underpinned by innovation, increased healthcare

spending, and robust demand in both developed and emerging markets.

Within this dynamic landscape, the CRAMS (Contract Research and Manufacturing Services) segment continues to gain strategic relevance, driven by cost optimization pressures, growing outsourcing by global innovators, and the need for agile, end-to-end development capabilities. India and China remain dominant players in this segment, offering competitive advantages in talent, infrastructure, and regulatory compliance. Demand remains strong for both discovery services and commercial-scale manufacturing, particularly in APIs, injectables, and high-potency formulations. Leading CROs (Contract Research Organizations) and CDMOs (Contract Development and Manufacturing Organizations) are reporting improved order inflows and expanded client relationships, indicating long-term visibility and a healthy pipeline of opportunities. Investments in technology platforms, regulatory readiness, and integrated services are expected to further strengthen CRAMS as a key growth driver for the global pharma value chain. The global CRAMS market size was valued at US\$143.71 billion in 2024 and is projected to reach US\$157.07 billion in 2025, as per a report from Research And Markets, a growth of 9.3%.

**INDIAN PHARMACEUTICAL SECTOR OVERVIEW**

The Indian pharmaceutical industry has established itself as a global leader in the production of generic medicines and low-cost vaccines, playing a pivotal role in improving global healthcare access. Over the years, the sector has transformed into a dynamic and innovation-driven industry, ranking third globally in pharmaceutical production by volume and fourteenth by value. Currently, the Indian pharmaceutical sector contributes approximately 1.72% to the country's GDP, backed by a robust ecosystem of over 3,000 drug companies and around 10,500 manufacturing units. India is the world's largest supplier of generic medicines, producing nearly 60,000 different generic brands across 60 therapeutic categories, and accounts for 20% of global generic drug exports.

In FY2024-25, the country's pharmaceuticals market had a total turnover of ₹2.25 trillion, which represents a jump of 8.4% over FY2023-24. Cardiac, Gastro-intestinal, and Anti-Diabetic segments contributed ~34% of this size. Indian drugs and pharmaceutical exports totaled US\$30.47 billion in FY2024-25, a growth of 9.39% over the previous fiscal. Key markets for Indian drugs and pharmaceutical exports are the United States, the United Kingdom, South Africa, the Netherlands, France, and Brazil.

**Key segments of the Indian Pharma industry are:**

- **Active Pharmaceutical Ingredients (APIs):** "An API is the biologically active component of a drug responsible for its intended medical effect." It represents 35% of the total industry size. India accounts for 8% share of the Global API Industry and is the 3<sup>rd</sup> largest market. About



500+ different APIs are manufactured in India, and it contributed 57% of APIs to the prequalified list of the World Health Organization (WHO).

- **Biosimilars & Biologics:** Biologics are drugs derived from living cells or organisms, used to treat severe and life-threatening diseases. Biosimilars, a class of drugs related to biologics, are designed to improve patient access to these treatments. The industry size for biosimilars and biologics in India was projected to be ~US\$12 billion in 2025.
- **Formulations:** Formulations consist of Branded and Generic Prescription Drugs and Over-The-Counter (OTC) medicines, which can be purchased without prescriptions. India is the largest supplier of generic medicines with a share of nearly 20% of the global volume.
- **Vaccines:** A Vaccine is a biological substance designed to strengthen the immune system and protect against bacterial and viral infections. Vaccines are a critical part of public health management across the world. India contributes to 60 % of global vaccine production.
- **Contract Research and Manufacturing Services (CRAMS):** The global pharmaceutical industry uses outsourcing services from CRAMS providers in the form of Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs).

India is also emerging as a vital player in the global pharmaceutical value chain, particularly through the expansion of its Contract Research, Development, and Manufacturing Organization (CRDMO) industry, which is projected to double to ₹1.21 lakh crore (US\$14 billion) by 2028. The sector is increasingly focused on quality enhancement, affordability, and innovation, positioning itself to capture a larger share of the global pharmaceutical market expected to reach 13% in the near future. The Indian pharmaceutical industry is projected to grow at a compound annual growth rate (CAGR) of 22.4%, driven by increased healthcare awareness, expansion in domestic and export markets, and strong policy support. The total market size of the Indian pharma industry is expected to reach US\$130 billion by 2030 and US\$450 billion by 2047.

Recognizing the Pharmaceutical sector’s strategic importance, the Union Budget 2025–26 has proposed an allocation of ₹5,268.72 crore (US\$602.90 million) to the Department of Pharmaceuticals, marking a 28.8% increase over the previous year’s budget estimate of ₹4,089.95 crore (US\$468.01 million). The Government also announced a Production Linked Incentive (PLI) scheme for pharmaceuticals with a total outlay of US\$1.8 billion (₹15,000 crore), to boost investment in India’s pharmaceutical manufacturing capacity. These measures reflect the government’s intent to enhance pharmaceutical research, manufacturing infrastructure, and drug accessibility. India also holds a competitive edge in human capital, being the second-largest contributor to the global biotech and pharmaceutical workforce, an asset that continues to strengthen its global footprint in the life sciences domain.

**OPPORTUNITIES & THREATS:**

The Indian pharmaceutical sector operates in a dynamic environment, influenced by global trends, domestic policies, and structural shifts in healthcare delivery. As one of the world’s largest suppliers of generic medicines, India is well-positioned to capitalize on emerging opportunities, while also facing significant headwinds that demand resilience, compliance, and innovation.



**Opportunities**

**a) Global Expansion & Demand for Affordable Drugs:**

- **Emerging Markets Growth:** Asia, Africa, Latin America, and select Eastern European regions offer substantial growth potential, driven by rising healthcare access and demand for cost-effective generics.
- **Patent Expirations:** With multiple high-value drugs approaching patent cliffs globally, Indian companies have strong prospects to expand their presence in the US, EU, and Japan through generic launches and biosimilars.

**b) Growing Domestic Healthcare Ecosystem:**

- **Population & Urbanization:** India’s large and increasingly urbanized population, with rising income and health awareness, continues to boost demand for both preventive and chronic disease therapies.
- **Digital Healthcare & Telemedicine:** The rise of digital health platforms and e-pharmacies is creating new channels for outreach, especially in Tier II & III cities and rural areas.

**c) Government & Policy Support:**

- **PLI & FDI Incentives:** The Production Linked Incentive (PLI) schemes for APIs, bulk drugs, and medical devices, along with 100% FDI in pharma under the automatic route, continue to attract domestic and foreign investments.
- **Public Health Spending:** The government’s commitment to increase healthcare spending to 2.5% of GDP by 2026, under schemes like Ayushman Bharat, supports growth in both demand and infrastructure.

**d) CRAMS & Biotech Growth:**

- **CRAMS Momentum:** India remains a preferred outsourcing destination for Contract Research and Manufacturing Services, driven by global pharma’s cost rationalization and a shift toward asset-light models. Integrated service offerings, high-quality infrastructure, and regulatory compliance are attracting long-term partnerships with innovators.
- **Biotech and Biosimilars:** The biosimilar market is expanding rapidly, and Indian firms are gaining ground through robust pipelines, R&D investments, and strategic alliances.

**e) Technological Integration:**

- **AI & Digital R&D:** AI-enabled drug discovery, automated manufacturing, and real-time clinical trial analytics are opening efficiency gains. Companies leveraging digital transformation stand to improve time-to-market and regulatory approvals.



**Threats**

**a) Regulatory & Compliance Risks:**

- **Stringent Oversight:** Increasing regulatory scrutiny in key markets (U.S. FDA, EU EMA) and evolving GxP norms may delay approvals and raise compliance costs.
- **Domestic Price Controls:** The expansion of the National List of Essential Medicines (NLEM) and ongoing pricing interventions by NPPA continue to impact margins in the domestic market.

**b) Supply Chain Vulnerabilities:**

- **Geopolitical Tensions & Raw Material Dependency:** India remains dependent on China and other countries for key APIs and intermediates. Global trade tensions, tariff hikes, and logistics disruptions raise costs and supply uncertainty.
- **Environmental & ESG Compliance:** Rising expectations on environmental standards and sustainable practices, especially from EU/US buyers, require additional investments in clean manufacturing.

**c) Intensified Competition & Margin Pressure:**

- **Generic Price Erosion:** High competition in generic markets, both globally and domestically, continues to compress margins.
- **Entry of Local Startups:** Low barriers to entry in segments like OTC, nutraceuticals, and branded generics have led to increasing competition from agile domestic players.

**d) Operational Risks & Talent Constraints:**

- **FDA Warning Letters & Import Alerts:** Manufacturing facilities face reputational and financial risks from lapses in quality compliance.
- **Skilled Workforce Gap:** As industry embraces AI, biopharma, and digital tech, a shortage of skilled professionals in these domains could limit growth.

While opportunities in CRAMS, biosimilars, digital health, and emerging markets are significant, Indian pharmaceutical companies must proactively address regulatory, supply chain, and margin-related risks. Long-term competitiveness will depend on innovation, operational excellence, digital integration, and strategic global partnerships.



Bafna Pharmaceuticals exports its products to the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. It is known for providing consistent and unmatched service, supplying high-end pharmaceutical formulations to regulated and emerging markets. Additionally, the company has established itself as a competent player in the Contract Research and Manufacturing Services (CRAMS) industry.

**COMPANY OVERVIEW**

Bafna Pharmaceuticals Limited has been engaged in the manufacturing of pharmaceutical formulations for more than 3 decades. Bafna Pharmaceuticals exports its products to the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. It is known for providing consistent and unmatched service, supplying high-end pharmaceutical formulations to regulated and emerging markets. Additionally, the company has established itself as a competent player in the Contract Research and Manufacturing Services (CRAMS) industry. It has a WHO-GMP certified manufacturing facility in Chennai, at Grantlyon. The Company's manufacturing facility is also accredited by EU GMP, UK MHRA, and TGA Australia for Non-Betalactum solid oral dosage forms. It has established an in-house state-of-the-art Quality Control Lab at the company's manufacturing facility. The lab features sophisticated and cutting-edge technology with advanced instruments to ensure rigorous quality control across all manufacturing processes. The facility has a dedicated containment area for manufacturing high potent drugs within the current manufacturing facility. This includes special features for ensuring protection of workers from

cytotoxic agents, specialized equipment for handling highly potent formulations, and protocols to achieve safety, quality control, and compliance with stringent regulations.

The Company's primary focus is to expand revenue from registered products globally while continuing to apply for registrations to generate new opportunities. It currently holds active product registrations in over 20 countries and has over 200 products pending registration across Africa, Asia, and the Rest of the World (RoW) markets. UK, Australia, and Africa continue to be the growth drivers for Bafna Pharmaceuticals as it has strong penetration in key markets. The Company also has a well-established footprint in South and Southeast Asia with expanding registrations. It currently has a limited presence in CIS/ Latin America and other parts of the world. However, it is exploring newer, high-potential markets through product filings to expand its global presence. With ongoing investments in regulatory compliance, R&D, and infrastructure, the Company is well-positioned to deepen its presence in existing geographies while expanding into new global markets over the next 3 to 5 years. Key geographies where the Company holds product registrations are:

African Region	Asian Region	European & CIS Region	Central America
<ul style="list-style-type: none"> <li>➤ Nigeria</li> <li>➤ Madagascar</li> <li>➤ Mauritius</li> <li>➤ Kenya</li> <li>➤ Rwanda</li> </ul>	<ul style="list-style-type: none"> <li>➤ Tanzania</li> <li>➤ Ethiopia</li> <li>➤ Uganda</li> <li>➤ DRC/Congo</li> </ul>	<ul style="list-style-type: none"> <li>➤ Philippines</li> <li>➤ Sri Lanka</li> <li>➤ Nepal</li> </ul>	<ul style="list-style-type: none"> <li>➤ Ukraine</li> <li>➤ UK</li> <li>➤ Australia</li> <li>➤ Honduras</li> <li>➤ Guatemala</li> <li>➤ Peru</li> <li>➤ Nicaragua</li> </ul>

The Company distributes to the export markets through a mix of:

- Local Distributors: with established networks in wholesale distributors and Government tenders, and
- Export Agents and Channel Partners: for regulated markets or regions with specific trade regulations.

In major geographies like Nigeria, Philippines, Sri Lanka, Tanzania, and Nepal, the Company operates through multiple registered product lines, each linked with dedicated local distributors who ensure regional compliance, marketing, and delivery.

The Company's product portfolio has brands catering to select therapeutic segments. The following table gives details of the therapeutic segments it focuses on:

Therapeutic Segment	Treatment/ Applications
Cardiovascular	Beta Blockers, ACE Inhibitors, Statins
Lifestyle & Potent Drugs	Oncology, Women's Health, Metabolic Disorders Diabetic and hypertension

In addition to the above, the Company also manufactures specialty and complex generics, develops differentiated



dosage forms (modified release tablets), and offers Contract Research and Manufacturing Services. It currently has partnerships with British and Southeast Asian pharmaceutical companies for Contract Manufacturing. The Company's product pipeline strategy is to build a high-value, low-volume specialty product pipeline. The current pipeline includes potent formulations (oncology, hormonal therapies), stability-challenging molecules, high-barrier generics for emerging and regulated markets, and feasibility studies for bi-layered tablets and oncology products.

The Company is deeply committed to upholding high standards of Environmental, Social, and Health (ESH) practices. To promote environmental sustainability, it has implemented water recycling systems at its manufacturing facility, invested in energy optimization through high-efficiency HVAC and LED lighting, and is taking efforts to procure ~60% of its power requirement from non-renewable sources (solar power). The dedication to a reduced carbon footprint is further demonstrated by the Company's compliance with effluent treatment norms and minimal generation of hazardous waste. It has also recently initiated a trial of green packaging for its export products. In addition, its commitment to social responsibility is reflected in the employment practices, with over 65% of the workforce being locals from Tamil Nadu. The Company also actively engages in community welfare through CSR programs focusing on women's health awareness in Chennai clinics and conducting school medication donation drives in the Red Hills and Madhavaram areas.

**OPERATIONAL AND FINANCIAL PERFORMANCE:**

During the financial year 2024-25, the total revenue from operations was ₹14,859.92 Lakhs as compared to ₹15,598.81

Lakhs during the previous financial year 2023-24, thereby registering a marginal decline of 4.74% over the previous year. During the said period, the Company saw a revenue decline of roughly ₹1,500 Lakhs due to operational disruption caused by an unexpected breakdown of the temperature control equipment in the Grantlyon factory, which necessitated a complete replacement, led to a temporary halt in production for about 2 months, thus impacting delivery schedules. The Company replaced the equipment with higher-capacity systems to improve future reliability. Excluding the impact of the above one-off factor, revenue from operations would have gone up by 4.88% over the previous financial year. The Export Turnover of the Company for the financial year 2024-25 was ₹7,297.80, which declined by 22.53%. Whereas the Domestic Turnover of the Company for the financial year was ₹7,203.41 Lakhs, which was an increase of 26.96%.

The EBITDA for the financial year 2024-25 was ₹1,391.91 Lakhs for the year ended, as against ₹1,463.36 Lakhs for the corresponding previous period, recording a decrease of 4.88%. However, despite a decline in revenue, the EBITDA margins were nearly constant at 9.54% in FY 2024-25 vs. 9.60% in the previous year. The Profit After Tax (PAT) for the period was ₹415.25 Lakhs for the year ended 31<sup>st</sup> March 2025, as against ₹734.79 Lakhs for the corresponding previous period, a decline of 43.48%. The sharper decline in PAT of ₹214.56 lakhs was primarily driven by the Company's prudent and pragmatic derecognition of an Intangible Asset under Development of ₹177 lakhs – expenditures incurred in earlier years for securing certain product registrations. The management believes that the conservative write-down is intended to be temporary and will be re-assessed in future.

**KEY FINANCIAL RATIOS**

Ratios	F.Y 2024-25	F.Y 2023-24	Variance	Explanation for Variance
<b>Profitability Ratio</b>				
Operating Profit Margin	6.19%	4.82%	28.42%	Reduction of Expenses helped the Company to improve Operating Profit Margin.
Net Profit Margin	2.72%	4.82%	-43.57%	Due to write off of Intangible Assets and increase in Borrowings.
Return on Net Worth	6.86%	9.14%	-24.96%	
EBITDA Margin	9.54%	9.60%	-0.63%	
<b>Efficiency Ratios</b>				
Debt Equity Ratio	0.33 Time	0.30 Time	10.21%	
Current Ratio	1.63 Time	1.73 Time	6.11%	
Inventory Turnover Ratio	5.05 Times	5.88 Times	-14.06%	
Debtors Turnover Ratio	3.41 Times	3.52 Times	-3.15%	
Interest Coverage Ratio	3.52 Times	4.97 Times	-29.16%	Interest cost on borrowing grew by 32.24% in FY 2024-25 over the previous year because of an increase in borrowings, whereas EBIT declined.



**OUTLOOK:**

The outlook for the Indian pharmaceutical sector remains resilient and promising, supported by increasing healthcare awareness, policy thrust on self-reliance, and consistent demand across both domestic and export markets. In this evolving landscape, the Company continues to strengthen its operational capabilities, focusing on product quality, regulatory compliance, and customer-centric solutions to enhance competitiveness. The Company has set a target to reach ₹250 crores in revenue by FY2026-27, a target of ~30% CAGR, with an EBITDA margin of 15%+. This will be driven by an export-led growth with a strategy to focus on complex generics, niche therapies, and a high-value product mix. With improved operational efficiencies, robust quality systems, and strategic sourcing, the Company is well-positioned to offer competitive pricing without compromising on product excellence. Its ability to leverage bulk procurement and economies of scale enhances both pricing flexibility and delivery reliability.

Barring unforeseen macroeconomic or regulatory disruptions, the Company remains confident of achieving improved performance in the current financial year. A diversified product mix, strengthening distribution network, and expected demand momentum further support a positive outlook. Its portfolio of promising R&D pipeline and growing market registrations of products in numerous markets is a key growth driver. The Company continues to prioritize sustainability by adhering to the highest standards of Environment, Health, and Safety (EHS), while driving cost optimization, operational excellence, and long-term business resilience.

**RISKS AND CONCERNS**

While growth prospects remain robust, the Company faces multiple external and internal risks. The risks may pose a threat to the supply chain, result in a high cost of capital, impact operating margins, increase the cost of operations, affect realizations and profitability. The Company remains vigilant in monitoring these risks and is actively enhancing its risk mitigation strategies. The key risks, their impact, and mitigation measures are given below. While mitigation measures have been put in place to the extent possible, residual risks cannot be wished away, and hence, the objective of the Risk Management approach is to minimize the adverse impact.

**A. Pricing and Market Pressures**

**Risk Description and Impact:** Increased competition, government-led price controls, and shifts in prescribing habits can erode product prices and demand. This can negatively affect profitability and the success of new product launches.

**Mitigation:** Implement cost reduction and efficiency programs. Invested in R&D with a focus on developing and launching innovative, high-value products that can command better pricing.

**B. Product Portfolio Risk**

**Risk Description and Impact:** The product development lifecycle is vulnerable to costly investments, patent

litigation, and clinical trial delays. Technical challenges and regulatory hurdles can impact commercial launch timelines and the company's future growth.

**Mitigation:** Prioritize resources for key launches and implement robust project management to identify and address delays. Use innovative development techniques to mitigate clinical and technical risks.

**C. Regulatory, Quality, and Compliance**

**Risk Description and Impact:** Failure to meet stringent pharmaceutical regulations of the global regulatory landscape can lead to regulatory warnings, manufacturing suspensions, product recalls, and reputational damage. This can hinder commercial launches and impact business operations. For CRAMS and export-oriented businesses, any adverse regulatory action in key markets like the US and EU could lead to delays in approvals and revenue recognition.

**Mitigation:** Maintain a robust Compliance Management and Quality Management System with digital support and keep them abreast of the latest regulatory developments. Conduct regular audits, improve training programs, and proactively identify and address non-conformities with corrective and preventive actions.

**D. Geopolitical & Economic Volatility**

**Risk Description and Impact:** Geopolitical instability, such as war, sanctions, and economic pressures, can disrupt supply chains, increase costs, and affect cash flow. This can negatively impact business growth and operations in affected regions. Volatility in foreign exchange markets, particularly in emerging economies, could adversely affect realizations and profitability, even if underlying business volumes remain strong.

**Mitigation:** Limit exposure to high-risk areas and monitor developments closely. Consider local manufacturing or partnerships and secure receivables through advance payments or bank guarantees. Judiciously use currency hedging to protect the Company's cash flows from currency volatility.

**E. Supply Chain Disruptions**

**Risk Description and Impact:** Interruptions in the supply of raw materials, particularly from single-source vendors, can disrupt manufacturing, lead to product shortages, and damage the company's reputation and revenue. Inflationary pressures can also increase procurement costs.

**Mitigation:** Continuously monitor the supply chain for potential disruptions and maintain sufficient inventory of key materials. Develop alternate vendors to optimize costs and de-risk single-source procurement.



**F. Talent & Skill Availability**

**Risk Description and Impact:** The inability to attract, retain, and engage skilled employees can hinder strategic execution and weaken succession plans. This can reduce productivity, cause workforce fatigue, and adversely impact business objectives.

**Mitigation:** Implement targeted recruitment and retention strategies for critical roles and functions. Promote internal transfer opportunities and conduct employee engagement surveys to foster a culture of high performance.

**G. Information Security**

**Risk Description and Impact:** The pharmaceutical sector is a prime target for cybercriminals. A significant cybersecurity breach or failure to comply with data privacy regulations can result in financial losses, regulatory penalties, and reputational damage.

**Mitigation:** Implement advanced information security controls and monitoring. Proactively identify vulnerabilities through threat intelligence and periodic reviews. Conduct cybersecurity incident simulations to improve response readiness.

**INTERNAL CONTROL SYSTEMS & ADEQUACY**

The Company has put in place a system of Internal Controls in line with the regulatory requirements that are appropriate for its size and nature of business. These controls are designed to achieve effective governance and compliance and ensure:

- orderly and efficient conduct of business,
- safeguarding of its assets,
- adherence to its policies and procedures,
- prevention and detection of fraud and errors,
- accuracy and completeness of the accounting records, and
- timely preparation of reliable financial information.

The key elements of the system put in place by the Company are:

- a well-defined organisational hierarchy with clearly outlined role definitions, responsibilities, and authority matrix.

- Financial planning and budgeting
- Policies and SOPs, including for financial transactions such as purchase, etc.
- IT systems to digitize the processes with in-built controls

In addition to these, the system incorporates continuous monitoring, reporting, checks and balances, and audit, etc. Internal controls are adequately supported by Internal Audit and periodic review by management.

The Internal Audit is undertaken by an Independent Auditor, M/s K S Rao & Co., Chartered Accountant firm, Chennai, The Audit Committee and the Board meets periodically to review with the internal auditor, statutory auditors and management the adequacy/scope of internal audit function, significant findings and follow up there on and findings of any abnormal nature. The system is improved and modified continuously to meet changes in business conditions, statutory, and accounting requirements.

**MATERIAL DEVELOPMENT IN HUMAN RESOURCES / INDUSTRIAL RELATIONS FRONT**

Human resources continue to be one of the critical assets of the organization. The Company firmly believes that its people are its most valued resource and that their efficiency plays a key role in achieving defined goals and building a competitive work environment. We continue to take proactive steps to hire, retain talent and ensure continuity of business through talent acquisition, talent management, and succession planning initiatives. The key approach implemented by the Company for talent retention is to focus on career development for chosen talent, focus on employee experience and their well-being, and maintain transparent communication practices.

Employee relations continued to be cordial and harmonious across all levels of the Company. The number of employees as of March 31, 2025, is 406. This translates to a net reduction of 212 as compared to the headcount of 618 as of March 31, 2024.

**CAUTIONARY STATEMENT**

The information and opinions expressed in this report may contain certain forward-looking statements, which the management believes are true to the best of its knowledge at the time of its preparation. Actual results may differ materially from those either expressed or implied in this report.

On behalf of the Board of Directors  
For **BAFNA PHARMACEUTICALS LIMITED**

SD/-  
**S. Hemalatha**  
Whole-Time Director  
DIN:02714329  
Place: Chennai

SD/-  
**Vinayak Dinesh Dendukuri**  
Whole-Time Director  
DIN: 07601309  
Place: Hyderabad

Date: August 12, 2025



**Financial**  
  
**Statement**

# Independent Auditor's Report

To  
The Members of  
**Bafna Pharmaceuticals Limited**

## REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

### Opinion

We have audited the accompanying Financial Statements of **Bafna Pharmaceuticals Limited ("the Company")**, which comprise the Balance Sheet as at 31<sup>st</sup> March 2025, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended, and notes to the Financial Statements, including a summary of material accounting policies and other explanatory information (hereinafter referred to as "the Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013, as amended ('the Act') in the manner so required and give a true and fair view in conformity with accounting principles generally accepted in India including the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), of the state of affairs of the Company as at 31<sup>st</sup> March 2025, its profit (including other comprehensive income), its changes in equity and its cash flows for the year ended on that date.

### Basis for Opinion

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report.

We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Financial Statements.

### Emphasis of Matters

#### Attention is invited to:

- a. the non-receipt of the foreign currency receivables as on 31<sup>st</sup> March 2025 aggregating to INR 120 Lakhs (as on 31<sup>st</sup> March 2024 - INR 174 Lakhs), which are outstanding beyond the stipulated time period permitted under the RBI Master Direction on Export of Goods and Services vide FED Master Direction No. 16/2015-16 dated 1<sup>st</sup> January, 2016 (as amended), issued by the Reserve Bank of India ("RBI"). The management of the Company is in the process of obtaining approval towards extension of time limits for realization or write off of the balances. Pending such confirmation, no adjustment is envisaged in the books of accounts as on 31<sup>st</sup> March 2025.
- b. the adjustment of Income Tax Refund pertaining to previous Assessment Years amounting to INR 45.17 Lakhs. The Income Tax Department has issued the refund order on various dates for respective assessment years; however, such refunds have been adjusted against the outstanding demands through Centralized Processing Centre ("CPC"). As represented by the management, the Company has filed a writ petition with Honourable Madras High Court against the adjustment of refund issued with the outstanding demand.
- c. Note No. 36 to the Financial Statement regarding the non-compliance with various statutory compliances under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Securities Contracts (Regulations) Rules, 1957, as amended with respect to the Minimum Public Shareholding, appointment of Compliance Officer and submission of certain prescribed information to the Stock Exchanges during the previous reporting periods. The Company has received the communication from BSE Limited and National Stock Exchange of India Limited in respect to such non-compliance and appropriate provision has been accounted in the books of accounts as on reporting date. However, the management is perusing with the Stock Exchanges for waiver of such penalties since the Company has complied with the Minimum Public Shareholding threshold.

Our opinion is not modified in respect of the above matters.



**KEY AUDIT MATTERS**

Key Audit Matters are those matters that, in our professional judgement, were of the most significance in our audit of the Financial Statements of the financial year ended 31<sup>st</sup> March 2025. These matters were addressed in the context of our audit of the Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the following matters as Key Audit Matters to be communicated in our report:

Key Audit Matters	Auditor's Response
<p>Litigations and claims-provisions and contingent liabilities</p> <p>As disclosed in Note 35 detailing contingent liability and provision for contingencies, the Company is involved in litigations concerning direct tax, indirect tax and other matters that are pending with various statutory authorities.</p> <p>Whether a liability is recognized or disclosed as a contingent liability in the Financial Statements is inherently judgmental and dependent on a number of significant assumptions and assessments.</p> <p>The amounts involved are potentially significant and determining the amount, if any, to be recognized or disclosed in the Financial Statements, is inherently subjective.</p>	<p>Our audit approach include:</p> <ul style="list-style-type: none"> <li>Assessed the appropriates of the Company's accounting policies, including those relating to provision and contingent liability by comparing with the applicable Indian Accounting Standards;</li> <li>Assessed the Company process for identification of the pending litigations and completeness for financial reporting and also for monitoring of significant developments in relation to such pending litigations;</li> <li>Engaged subject matter specialists to gain an understanding of the current status of litigations and monitored changes in the disputes, if any, through discussions with the management and by reading external advice received by the Company, where relevant, to establish that the provisions had been appropriately recognized or disclosed as required;</li> <li>Assessed the Company's assumptions and estimates in respect of litigations, including the liabilities or provisions recognized or contingent liabilities disclosed in the Financial Statements. This involved assessing the probability of an unfavorable outcome of a given proceeding and the reliability of estimates of related amounts;</li> <li>Obtained details of completed tax assessments and demands.</li> <li>We involved our internal experts to review the management's underlying assumptions in estimating the tax provision and the possible outcome of the disputes.</li> <li>Assessed the management's conclusions through understanding precedents set in similar cases; and considering the appropriateness of the Company's description of the disclosures related to litigations and whether these adequately presented in the Financial Statements.</li> </ul>
<p><b>Inventories</b></p> <p>Inventories are also the critical component of Financial Statement. Correctness, completeness and valuation are critical for reflecting true and fair financial results of operations.</p>	<p>Our audit approach include:</p> <ul style="list-style-type: none"> <li>We assessed the Company's process regarding Maintenance of records, Valuation and accounting of transactions relating to Inventory as per the IND AS - 2.</li> <li>We have evaluated the design of Internal Controls relating to recording and valuation of Inventory.</li> <li>We have carried out substantive audit procedures at financial and assertion level to verify the allocation of overheads to Inventory.</li> <li>We have verified the compliance with the standard norms relating to production as framed and timely updated by the management.</li> </ul>

**Other Information**

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Company's Annual Report, but does not include the Financial Statements, and our auditor's report thereon. The other information is expected to be made available to us after the date of auditor's report. Thus, our report does not deal with matters mentioned under other information in Annual Report.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

When we read the other information, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

**Management's Responsibilities for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Financial Statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Ind AS specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

**Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to Financial Statements in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the



underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the financial year ended 31<sup>st</sup> March 2025 and are therefore the Key Audit Matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

**Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order 2020 ("the Order"), issued by the Central Government of India in terms of sub section (11) of Section 143 of the Act, we give in the "Annexure A", a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Financial Statements.
  - b. In our opinion, proper books of account as required by law relating to preparation of the aforesaid Financial Statements have been kept by the Company so far as it appears from our examination of those books, except for the matters stated in the paragraph 3(f) below on reporting under Rule 11(g)

of the Companies (Audit and Auditors) Rules, 2014, as amended.

- c. The Balance Sheet, the Statement of Profit and Loss (including Other Comprehensive Income), Statement of Changes in Equity and the Statement of Cash Flows dealt with by this Report are in agreement with the books of account.
  - d. In our opinion, the aforesaid Financial Statements comply with the Ind AS specified under Section 133 of the Act read with Companies (Indian Accounting Standard) Rules, 2015 as amended.
  - e. On the basis of the written representations received from the directors as on 31<sup>st</sup> March 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March 2025 from being appointed as a director in terms of Section 164(2) of the Act.
  - f. The modifications relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2(b) above on reporting under Section 143(3)(b) of the Act and paragraph 3(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014, as amended.
  - g. With respect to the adequacy of the internal financial controls with reference to Financial Statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B" to this report.
3. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:
    - (a) The Company has disclosed the impact of pending litigations on its financial position in its Financial Statements. Refer Note: 35 to the Financial Statements.
    - (b) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
    - (c) There are no amounts which are required to be transferred to the Investor Education and Protection Fund by the Company.
    - (d) (i) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entity(ies) ("Intermediaries"), with the understanding,



whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- (ii) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person(s) or entity(ies), including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.
- (e) The Company has not declared, paid interim dividend during the year or proposed final dividend for the year.

- (f) Based on our examination which included test checks and information given to us, the Company has used accounting software for maintaining its books of account, which does not have a feature of recording audit trail (edit log) facility, and the same did not operate throughout the year for all relevant transactions recorded in the respective software.

Additionally, the preservation of audit trail is not applicable for the previous year as the accounting software did not have the feature of recording of audit trail.

- 4. With respect to the other matters to be included in the Auditor's Report in accordance with requirement of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its director during the year is in accordance with the provision of section 197 of the Act. The remuneration paid to directors is not in excess of the limit laid down under section 197(16) which are required to be commented upon by us.

For **Brahmayya & Co.**,  
Chartered Accountants  
Firm Registration No. 000511S

**Lokesh Vasudevan**  
Partner

Place : Chennai  
Date : 26<sup>th</sup> May 2025

Membership No. 222320  
UDIN: 25222320BBIKTW2187



## Annexure 'A' to the Independent Auditor's Report

The "Annexure A" referred to in clause 1 of "Report on Other Legal and Regulatory Requirements" Paragraph of the Independent Auditor's Report of even date to the members of **Bafna Pharmaceuticals Limited ("the Company")** on the Financial Statements as on and for the year ended 31<sup>st</sup> March 2025.

- i) a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property Plant and Equipment.
- (B) The Company has derecognised the intangible assets under development during the year. Further, the Company does not have any intangible assets. (Refer Note 5 and Note 32).
- b) We are informed that a test of physical verification of Property Plant and Equipment was carried out by the management at a reasonable interval and no material discrepancies were noticed. In our opinion, the frequency of verification of these assets is reasonable having regards to the size of the Company and nature of its assets.
- c) The title deeds of immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the Company) as disclosed in the Financial Statements are held in the name of the Company.
- d) According to the information and explanations given to us and on the basis of our examination of the

records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has not revalued its Property, Plant and Equipment during the year ended 31<sup>st</sup> March 2025.

- e) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, there are no proceedings initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended) and rules made thereunder.
- ii) (a) The management has conducted physical verification of inventory at reasonable interval during the year and no discrepancies were noticed on verification between the physical stocks and the book records that were 10% or more in the aggregate for each class of inventory.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets. In our opinion, the quarterly returns/statements filed by the Company with such banks were not in agreement with the books of account of the Company. The details are as follows:

Name of the Bank	Quarter Ended	Particulars of Security Provided	Amount as per books of accounts	Amount as reported in Quarterly return	Variance
ICICI Bank	June-24	Inventory	3,067.26	2,572.51	494.75
		Books Debts	3,089.89	3,188.40	(98.51)
		Sundry Creditors	2,361.15	2,025.82	335.33
	Sept-24	Inventory	2,747.12	2,126.02	621.10
		Books Debts	3,371.50	3,410.05	(38.55)
		Sundry Creditors	2,287.00	1,889.73	397.27
	Dec-24	Inventory	2,965.33	2,320.67	644.66
		Books Debts	3,157.95	3,287.46	(129.51)
		Sundry Creditors	2,411.63	2,035.98	375.65
	March-25	Inventory	2,808.61	2,183.34	625.27
		Books Debts	4,017.35	4,095.44	(78.09)
		Sundry Creditors	3,094.52	2,892.15	202.37



iii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has provided staff advances during the year as follows:

Particulars	Amount in Lakhs
Aggregate amount of loans provided during the year ended 31 <sup>st</sup> March 2025	
Loans and Advances to Employees	17.42
Balance outstanding as at balance sheet date 31 <sup>st</sup> March 2025	2.30

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, in our opinion the investment made and the terms and conditions of the grant of loans and advances to employees during the year are, prima facie, not prejudicial to the interest of the Company.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, in our opinion, the Company has given staff advances to its employees during the year as per the Company's policy and receipts are generally regular.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, there is no overdue amount.

e) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance

vii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, in our opinion, Company is generally regular in depositing the undisputed statutory dues including Provident Fund, Employee's State Insurance, Income Tax, Service Tax, Excise Duty, Value Added Tax, Goods and Service Tax, Duty of Customs, Cess, and Other Statutory Dues with the appropriate authorities. There are no outstanding undisputed statutory dues on the last day of financial year concerned for a period of more than 6 month from the date they become payable except as follows:

Name of the Statute	Nature of Dues	Amount (INR in Lakhs)	Period to which amount relates
SEBI Regulations	Penalties levied by BSE Limited*	3.01	Sept-20
SEBI Regulations	Penalties levied by BSE Limited*	1.30	Mar-22
SEBI Regulations	Penalties levied by BSE Limited*	5.37	June-22
SEBI Regulations	Penalties levied by BSE Limited*	4.78	Sept-22
SEBI Regulations	Penalties levied by BSE Limited*	5.43	Dec-22

with generally accepted auditing practices in India, there are no loan and advances to employees granted that has fallen due during the year, which has been renewed or extended or fresh loans granted to settle the overdue of existing loans given to same parties.

(f) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has not granted any loans or staff advances during the year which are either repayable on demand or without specifying any terms or period of repayment.

iv) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has complied with the provisions of Section 185 and 186 of the Act to the extent applicable to the Company in respect to the loans given and investments made. The Company has not provided any guarantee or security.

v) According to the information and explanations given to us, and based on our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has not accepted any deposits from the public and no order has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other tribunal. Therefore, the provisions of clause (v) of paragraph 3 of the Order are not applicable to the Company.

vi) We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under Section 148 of the Act and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. We have not, however made a detailed examination of the same.



Name of the Statute	Nature of Dues	Amount (INR in Lakhs)	Period to which amount relates
SEBI Regulations	Penalties levied by BSE Limited*	3.19	Mar-23
SEBI Regulations	Penalties levied by BSE Limited*	0.58	Mar-23
SEBI Regulations	Penalties levied by BSE Limited*	1.24	Sept-23
SEBI Regulations	Penalties levied by BSE Limited*	5.43	Dec-23
SEBI Regulations	Penalties levied by BSE Limited*	5.37	Mar-24
SEBI Regulations	Penalties levied by BSE Limited*	10.74	June-24
SEBI Regulations	Penalties levied by BSE Limited*	10.86	Sept-24
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	3.01	Sept-20
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	1.30	Mar-22
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	5.37	Jun-22
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	4.78	Sept-22
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	5.43	Dec-22
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	3.19	Mar-23
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	0.14	Jun-23
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	2.48	Sept-23
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	5.43	Dec-23
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	10.74	Mar-24
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	10.74	June-24
SEBI Regulations	Penalties levied by National Stock Exchange of India Limited.*	10.86	Sept-24
Income Tax Act, 1961	Tax Deducted at Source**	0.00***	FY 2007-08
Income Tax Act, 1961	Tax Deducted at Source**	1.00	FY 2008-09
Income Tax Act, 1961	Tax Deducted at Source**	0.35	FY 2009-10
Income Tax Act, 1961	Tax Deducted at Source**	2.37	FY 2010-11
Income Tax Act, 1961	Tax Deducted at Source**	0.19	FY 2011-12
Income Tax Act, 1961	Tax Deducted at Source**	0.96	FY 2012-13
Income Tax Act, 1961	Tax Deducted at Source**	2.76	FY 2013-14
Income Tax Act, 1961	Tax Deducted at Source**	3.49	FY 2014-15
Income Tax Act, 1961	Tax Deducted at Source**	8.26	FY 2015-16
Income Tax Act, 1961	Tax Deducted at Source**	6.31	FY 2016-17
Income Tax Act, 1961	Tax Deducted at Source**	7.08	FY 2017-18
Income Tax Act, 1961	Tax Deducted at Source**	5.18	FY 2018-19
Income Tax Act, 1961	Tax Deducted at Source**	2.63	FY 2019-20

\*According to the information and explanations given to us, the Company has made suitable representation seeking waiver of penalties imposed by BSE Limited and National Stock Exchange of India Limited. Refer Note No. 36 to the Financial Statements.

\*\*In respect of Tax Deducted at Source, the amounts were due during various reporting periods and are still outstanding.

\*\*\* Amount is less than INR 1,000.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, the particulars of dues of Income Tax or Sales Tax or Service Tax or Excise Duty or Value Added Tax or Goods and Services Tax or Cess or Stamp Duty as at 31<sup>st</sup> March 2025 which have not been deposited on account of any dispute are as under:

Nature of Statute	Nature of Dues	Amount (INR in Lakhs)	Period to which amounts relates	Forum where Dispute is Pending
Provident Fund Act, 1952	Provident Fund*	33.67	FY 2016-2018	Honourable Madras High Court
Goods and Service Tax Act, 2017	Sales Tax*	25.26	FY 2016-2017	Honourable Madras High Court
Finance Act, 1994	Service Tax*	22.32	Various Period from FY 2014-15 to June 2018	Honourable Madras High Court
Foreign (Development and Regulation) Act, 1992	Trade Penalty Under Foreign Trade (Development & Regulation) Act, 1992*	20.00	Various Period for Advance Authorization obtained in October, 2004	Honourable Madras High Court
Income Tax Act, 1961	Income Tax*	342.19	AY 2015-2016	Honourable Madras High Court
Goods and Service Tax Act, 2017	Goods and Service Tax	235.47	FY 2017-18 to FY 2020-21	Honourable Goods and Service Tax (Appeals)

\* In respect to the demands raised, amounts were due during the various reporting periods prior to the approval of the Resolution Plan by the Honourable National Company Law Tribunal. As represented by the management, the Company has filed the writ petitions with the Honourable Madras High Court for quashing all demands pursuant to the approval of the Resolution Plan. Refer Note No. 35 (c) to the Financial Statements.

viii) According to the information and explanations given to us, and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

ix) a) According to the information and explanations given to us and based on our examination of the records of the Company, carried out in accordance with the generally accepted auditing practices in India, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year. However, with respect to interest free loan availed from KMP in previous financial years, the terms and conditions for repayment of principal has not been stipulated and accordingly we are unable to comment on the default in repayment of such loans.

b) According to the information and explanations given to us, and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority or any lenders. Therefore, the provisions of clause (ix)(b) of paragraph 3 of the Order are not applicable to the Company.

c) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, term loans were applied for the purpose for which they were obtained during the year.

d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, carried out in accordance with the generally accepted auditing practices in India, in our opinion, funds raised on short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.

e) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in

(INR in Lakhs)

Particulars	Amount
Outstanding at the beginning of the year	150.07
Repaid during the year	-
Outstanding at the end of the year	150.07



India, the Company does not have subsidiaries, joint ventures, associate companies. Therefore, the provisions of clause (ix)(e) of paragraph 3 of the Order are not applicable to the Company.

- f) According to the information and explanations given to us and on the basis of our examination of records of the Company, carried out in accordance with the generally accepted auditing practices in India, in our opinion, the Company does not have subsidiaries, joint ventures, associate companies. Therefore, the provisions of clause (ix)(f) of paragraph 3 of the Order are not applicable to the Company.
- x) a) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, the Company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year.
- b) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with generally accepted auditing practices in India, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Therefore, the provisions of clause (x)(b) of paragraph 3 of the Order are not applicable to the Company.
- xi) a) According to the information and explanation given to us and on the basis of our examination of records of the Company, carried out in accordance with the generally accepted auditing practices in India, we have neither come across any instance of material fraud by the Company or on the Company, noticed or reported during the year, nor have we been informed of any such cases by the management during the course of our audit.
- b) No report under Section 143 (12) of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- c) According to the information and explanations given to us, the Company has not received any whistle blower complaints during the year. Therefore, the provisions of clause (xi)(c) of paragraph 3 of the Order are not applicable to the Company.
- xii) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company is not

a Nidhi Company. Therefore, the provisions of clause (xii) (a), (xii)(b) and (xii)(c) of paragraph 3 of the Order are not applicable to the Company.

- xiii) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, transactions with the related parties are in compliance with sections 177 and 188 of the Companies Act where applicable and details of such transactions have been disclosed in the Financial Statements as required by the applicable Ind AS.
- xiv) a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, carried out in accordance with the generally accepted auditing practices in India, the Company has an internal audit system that commensurate with the size and nature of its business.
- b) We have considered the internal audit reports of the Company for the period under audit, issued to the Company.
- xv) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, the Company has not entered into non-cash transactions with directors or persons connected with them. Therefore, the provisions of clause (xv) of the paragraph 3 of the Order are not applicable to the Company.
- xvi) a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Therefore, the provision of clause (xvi) (a) of the paragraph 3 of the Order are not applicable to the Company.
- b) The Company has not conducted non-banking financial/housing finance activities during the year. Therefore, the provisions of clause (xvi)(b) of the paragraph 3 of the Order are not applicable to the Company.
- c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Therefore, the provisions of clause (xvi)(c) of paragraph 3 of the Order are not applicable to the Company.
- d) According to the information and explanations provided to us during the course of audit, the Group does not have any CIC. Therefore, the provisions of clause (xvi)(d) of paragraph 3 of the Order are not applicable to the Company.

- xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.
- xviii) There has been no resignation of the statutory auditors during the year. Therefore, the provisions of clause (xviii) of the paragraph 3 of the Order are not applicable to the Company.
- xix) According to the information and explanations given to us and on the basis of the financial ratios (Refer Note 42) to the Financial Statements, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- xx) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, in our opinion, there is no unspent amount under sub-section (5) of Section 135 of the Act. Therefore, the provisions of clause (xx)(a) of the paragraph 3 of the order are not applicable to the Company.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company carried out in accordance with the generally accepted auditing practices in India, there are no ongoing projects as on balance sheet date, Therefore, the Company does not have any amount remaining unspent under Section 135 (6) of the Act. Therefore, the provision of clause (xx) (b) of the paragraph 3 of the Order are not applicable to the Company.

**For Brahmayya & Co.,**  
Chartered Accountants  
Firm Registration No. 000511S

**Lokesh Vasudevan**  
Partner

Membership No. 222320  
UDIN: 25222320BBIKTW2187

Place : Chennai  
Date : 26<sup>th</sup> May 2025



## Annexure "B" to the Independent Auditor's Report

The **Annexure B** referred to in Clause 2 (g) of "Report on Other Legal and Regulatory Requirements" Paragraph of Independent Auditor's Report of even date to the Members of **Bafna Pharmaceuticals Limited ("the Company")** on the Financial Statements as of and for the year ended 31<sup>st</sup> March 2025.

### Report on the Internal Financial Controls with reference to Financial Statements under Clause (i) of sub-section 3 of Section 143 of the Companies Act, 2013 (the "Act")

We have audited the internal financial controls with reference to Financial Statements of the Company as of 31<sup>st</sup> March 2025 in conjunction with our audit of the Financial Statements of the Company for the year ended on that date.

### Management's Responsibility for Internal Financial Controls

The Company's Board of Directors is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ("the Guidance Note") issued by the Institute of Chartered Accountants of India (the "ICAI"). These responsibilities include the design, implementation, and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

### Auditor's Responsibility for Internal Financial Controls

Our responsibility is to express an opinion on the Company's internal financial controls with reference to Financial Statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, issued by the ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to

obtain reasonable assurance about whether adequate internal financial controls with reference to Financial Statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to Financial Statements and their operating effectiveness. Our audit of internal financial controls with reference to Financial Statements included obtaining an understanding of internal financial controls with reference to Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to Financial Statements.

### Meaning of Internal Financial Controls With Reference to Financial Statements

A Company's internal financial control with reference to Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Financial Statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control with reference to Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Financial Statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with the authorisation of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the Financial Statements.

**Inherent Limitations of Internal Financial Controls with reference to Financial Statements**

Because of the inherent limitations of internal financial controls with reference to Financial Statements including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to Financial Statements to future periods are subject to the risk that the internal financial control with reference to Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

**Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls with

reference to Financial Statements and such internal financial controls with reference to Financial Statements were operating effectively as at 31<sup>st</sup> March 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

**For Brahmayya & Co.,**  
Chartered Accountants  
Firm Registration No. 000511S

**Lokesh Vasudevan**

Partner

Membership No. 222320

UDIN: 25222320BMITW2187

Place : Chennai

Date : 26<sup>th</sup> May 2025





# Balance Sheet

as at 31<sup>st</sup> March 2025

(Amount are in INR Lakhs unless specified)

Particulars	Note No.	As at 31 <sup>st</sup> March 2025	As at 31 <sup>st</sup> March 2024
<b>I ASSETS</b>			
<b>(1) Non Current Assets</b>			
(a) Property, Plant and Equipment	3	5,877.99	4,021.14
(b) Capital Work in Progress	4	731.32	1,049.58
(c) Intangible Assets Under Development	5	-	177.00
<b>(d) Financial Assets</b>			
(i) Investments	6	0.05	-
(ii) Other Financial Assets	7	80.66	143.38
<b>Total Non Current Assets</b>		<b>6,690.02</b>	<b>5,391.10</b>
<b>(2) Current assets</b>			
(a) Inventories	8	2,808.61	2,964.18
<b>(b) Financial Assets</b>			
(i) Trade Receivables	9	4,017.35	4,539.48
(ii) Loans	10	2.30	8.18
(iii) Cash and Cash Equivalents	11	343.27	139.60
(iv) Other Financial Assets	7	-	0.24
<b>Total Financial Asset</b>		<b>4,362.92</b>	<b>4,687.50</b>
(c) Current Tax Assets (Net)	12	29.79	64.81
(d) Other Current Assets	13	1,271.44	1,660.57
<b>Total Current Assets</b>		<b>8,472.76</b>	<b>9,377.06</b>
Non Current Assets Held For Sale		145.13	-
<b>Total Assets</b>		<b>15,307.91</b>	<b>14,768.16</b>
<b>II EQUITY AND LIABILITIES</b>			
<b>A EQUITY</b>			
(a) Equity Share Capital	14	2,365.63	2,365.63
(b) Other Equity		6,115.02	5,718.27
<b>Total Equity</b>		<b>8,480.65</b>	<b>8,083.90</b>
<b>B LIABILITIES</b>			
<b>(1) Non Current Liabilities</b>			
<b>(a) Financial Liabilities</b>			
(i) Borrowings	15	1,402.85	1,075.32
<b>Total Financial Liabilities</b>		<b>1,402.85</b>	<b>1,075.32</b>
(b) Government Grant	16	191.42	161.47
(c) Provisions	21	47.82	39.17
<b>Total Non Current Liabilities</b>		<b>1,642.09</b>	<b>1,275.96</b>
<b>(2) Current Liabilities</b>			
<b>(a) Financial Liabilities</b>			
(i) Borrowings	17	1,417.01	1,363.61
(ii) Trade payables	18		
a. total outstanding dues of Micro and Small Enterprises		930.21	1,304.46
b. total outstanding dues of Other than Micro and Small Enterprises		2,164.31	2,237.77
(iii) Other financial liabilities	19	258.40	183.37
<b>Total Financial Liabilities</b>		<b>4,769.93</b>	<b>5,089.21</b>
(b) Other current liabilities	20	260.39	182.72
(c) Provisions	21	138.30	126.49
(d) Government Grant	16	16.55	9.88
<b>Total Current Liabilities</b>		<b>5,185.17</b>	<b>5,408.30</b>
<b>Total Equity and Liabilities</b>		<b>15,307.91</b>	<b>14,768.16</b>
Summary of Material Accounting Policies	1-2		

The accompanying notes form an integral part of the Financial Statements  
In Terms of our Report of even date

**For Brahmayya & Co.**  
Chartered Accountants  
Firm Regn No. 000511S

For and on behalf of Board of  
**Bafna Pharmaceuticals Limited**

**S. Hemalatha**  
Whole Time Director  
DIN : 02714329

**Vinayak Dinesh Dendukuri**  
Whole Time Director  
DIN : 07601309

**Bafna Mahaveer Chand**  
Chief Executive Officer

**Lokesh Vasudevan**  
Partner  
M.No. 222320

**Melagiri Sridhar**  
Chief Financial Officer

**Mohanachandran A**  
Company Secretary  
M.No.65827

Place: Chennai  
Date: 26<sup>th</sup> May 2025

Place: Chennai  
Date: 26<sup>th</sup> May 2025



# Statement of Profit and Loss

for the Year Ended 31<sup>st</sup> March 2025

(Amount are in INR Lakhs unless specified)

Particulars	Note No.	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
I Revenue from Operations	22	14,585.70	15,246.57
II Other Income	23	274.22	352.24
<b>III Total Income (I + II)</b>		<b>14,859.92</b>	<b>15,598.81</b>
<b>IV EXPENSES</b>			
Cost of Material Consumed	24	7,448.56	7,901.24
Purchase of Traded Goods	25	-	1,256.91
Manufacturing Expenses	26	2,212.89	2,017.75
Change in Inventories of Work in Progress and Finished Goods	27	644.65	(485.18)
Employee benefits expenses	28	2,102.97	1,902.74
Finance cost	29	273.13	229.03
Depreciation and Amortization expense	30	488.97	499.54
Other expenses	31	1,058.94	1,541.99
<b>Total Expenses (IV)</b>		<b>14,230.11</b>	<b>14,864.02</b>
<b>V Profit / (Loss) before Exceptional Items and Tax (III - IV)</b>		<b>629.81</b>	<b>734.79</b>
VI Exceptional Items	32	214.56	-
<b>VII Profit / (Loss) before Tax (V - VI)</b>		<b>415.25</b>	<b>734.79</b>
<b>VIII Tax Expense</b>			
Relating to previous periods		-	-
<b>Total Tax Expense (VIII)</b>		<b>-</b>	<b>-</b>
<b>XIII Profit / (Loss) for the Period (IX + XII)</b>		<b>415.25</b>	<b>734.79</b>
<b>XIV Other Comprehensive Income</b>			
A (i) Items that will not be reclassified to profit and loss		(18.50)	3.65
<b>XV Total Comprehensive Income for the period (XIII + XIV)</b>		<b>396.75</b>	<b>738.44</b>
<b>Earnings Per Equity Share</b>			
Basic (₹)	33	1.76	3.11
Diluted (₹)		1.76	3.11
Summary of Material Accounting Policies	1-2		

The accompanying notes form an integral part of the Financial Statements

In Terms of our Report of even date

**For Brahmaya & Co.**  
Chartered Accountants  
Firm Regn No. 000511S

For and on behalf of Board of  
**Bafna Pharmaceuticals Limited**

**S. Hemalatha**  
Whole Time Director  
DIN : 02714329

**Vinayak Dinesh Dendukuri**  
Whole Time Director  
DIN : 07601309

**Bafna Mahaveer Chand**  
Chief Executive Officer

**Lokesh Vasudevan**  
Partner  
M.No. 222320

**Melagiri Sridhar**  
Chief Financial Officer

**Mohanachandran A**  
Company Secretary  
M.No.65827

Place: Chennai  
Date: 26<sup>th</sup> May 2025

Place: Chennai  
Date: 26<sup>th</sup> May 2025



# Statement of Cash Flows

for the Year Ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

Particulars	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
<b>A. Cash Flow From Operating Activities After Exceptional Item before OCI</b>		
Profit / (Loss) before Tax	415.25	734.79
<b>Adjustments for:</b>		
Exceptional Items	214.56	-
Depreciation and Amortization	488.97	499.54
(Profit) / Loss on Sale of Property, Plant and Equipment	7.44	(6.57)
Provision for Expected Credit Loss	(30.09)	52.51
Provision on Recoverability of Non Financial Assets (Net)	79.62	-
Bad Debts and Irrecoverable Balances Written Off	1.82	7.47
Interest Income	(13.64)	(12.53)
Government Grant	(13.38)	(10.44)
Interest Expenses	273.13	229.03
<b>Cash Generated Before Working Capital Changes</b>	<b>1,423.68</b>	<b>1,493.80</b>
<b>Movement In Working Capital</b>		
Increase / (Decrease) in Trade Payables	(447.73)	696.19
Increase / (Decrease) in Provisions	1.95	43.81
Increase / (Decrease) in Other Financial Liabilities	76.47	117.70
Increase / (Decrease) in Other Liabilities	77.68	33.30
(Increase) / Decrease in Trade Receivables	550.40	(484.60)
(Increase) / Decrease in Inventories	118.02	(742.31)
(Increase) / Decrease in Loans	5.88	(2.77)
(Increase) / Decrease in Other Financial Assets	62.70	(89.19)
(Increase) / Decrease in Other Assets	309.51	(100.08)
<b>Cash Generated From Operations</b>	<b>2,178.56</b>	<b>965.85</b>
(Direct Taxes Paid)/Refund Received (Net)	35.03	(17.37)
<b>Net Cash Flow From / (Used in) Operating Activities</b>	<b>2,213.59</b>	<b>948.48</b>
<b>B. CASH FLOW FROM / (USED IN) INVESTING ACTIVITIES</b>		
Purchase of Property Plant and Equipment including Capital Work in Progress (Net)	(2,185.97)	(1,557.82)
Proceeds from Sale of Property Plant and Equipments	5.86	17.11
Investment in Equity Shares	(0.05)	-
Receipt of Government Grants	50.00	50.00
Intangible Assets under Development	-	(27.00)
Interest Income Received	13.87	12.35
<b>Net Cash Flow From / (Used in) Investing Activities</b>	<b>(2,116.29)</b>	<b>(1,505.36)</b>
<b>C. CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES</b>		
Proceeds/ (Repayment) of Borrowings (Net)	380.93	146.54
Interest Paid	(274.56)	(231.08)
<b>Net Cash Flow From / (Used in) Financing Activities</b>	<b>106.37</b>	<b>(84.54)</b>
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	203.67	(641.42)
Cash and Cash Equivalents at the beginning of the year	139.60	781.02
<b>Cash and Cash Equivalents at the end of the year</b>	<b>343.27</b>	<b>139.60</b>



# Statement of Cash Flows

for the Year Ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

Particulars	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
<b>Components of Cash and Cash Equivalents</b>		
Cash and cheques on Hand	1.00	0.61
Balances with Banks	-	-
-On Current Accounts	0.88	5.89
-On EEFC Accounts	206.03	4.75
Cheques, Drafts on hand	135.36	128.35
<b>Cash and cash Equivalent (as per Note 11)</b>	<b>343.27</b>	<b>139.60</b>

Changes in Liabilities arising from Financing Activities including both changes arising from cash flow and non cash flow :

Particulars	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Long Term Borrowings	1,402.85	1,075.32
Short Term Borrowings	1,417.01	1,363.61
Interest accrued but not due on Borrowings	7.52	8.96
<b>Total</b>	<b>2,827.38</b>	<b>2,447.89</b>
D Total Movement	379.49	-
<b>E Non Cash Changes</b>		
Interest Charged	(273.13)	-
<b>Changes in Financing Cash Flow</b>	<b>106.37</b>	-

The Statement of Cash Flows has been prepared under the indirect method as set out in Indian Accounting Standard 7 (Ind AS 7) Statement of Cash Flows

The accompanying notes form an integral part of the Financial Statements  
In Terms of our Report of even date

**For Brahmayya & Co.**  
Chartered Accountants  
Firm Regn No. 000511S

For and on behalf of Board of  
**Bafna Pharmaceuticals Limited**

**S. Hemalatha**  
Whole Time Director  
DIN : 02714329

**Vinayak Dinesh Dendukuri**  
Whole Time Director  
DIN : 07601309

**Bafna Mahaveer Chand**  
Chief Executive Officer

**Lokesh Vasudevan**  
Partner  
M.No. 222320

**Melagiri Sridhar**  
Chief Financial Officer

**Mohanachandran A**  
Company Secretary  
M.No.65827

Place: Chennai  
Date: 26<sup>th</sup> May 2025

Place: Chennai  
Date: 26<sup>th</sup> May 2025



# Statement of Changes in Equity

for the Year Ended 31<sup>st</sup> March 2025

(Amount are in INR Lakhs unless specified)

## A. EQUITY SHARE CAPITAL

Particulars	No. of Shares (in Lakhs)	Amount
Balance as at 1 <sup>st</sup> April, 2023	236.56	2,365.63
Changes in Equity Share Capital During 2023-24	-	-
<b>Balance as at 31<sup>st</sup> March, 2024</b>	<b>236.56</b>	<b>2,365.63</b>
Changes in Equity Share Capital During 2024-25	-	-
<b>Balance as at 31<sup>st</sup> March, 2025</b>	<b>236.56</b>	<b>2,365.63</b>

## B. OTHER EQUITY

Particulars	Reserves and Surplus				Total
	Capital Reserve	Securities Premium Account	General Reserve	Retained earnings	
Balance as at 1 <sup>st</sup> April, 2023	2,698.14	7,537.65	192.35	(5,448.31)	4,979.83
Current year profit	-	-	-	734.79	734.79
Other Comprehensive Income after tax	-	-	-	3.65	3.65
<b>Balance as at 31<sup>st</sup> March, 2024</b>	<b>2,698.14</b>	<b>7,537.65</b>	<b>192.35</b>	<b>(4,709.87)</b>	<b>5,718.27</b>
Current year profit	-	-	-	415.25	415.25
Other Comprehensive Income after tax	-	-	-	(18.50)	(18.50)
<b>Balance as at 31<sup>st</sup> March, 2025</b>	<b>2,698.14</b>	<b>7,537.65</b>	<b>192.35</b>	<b>(4,313.12)</b>	<b>6,115.02</b>

The accompanying notes form an integral part of the Financial Statements

In Terms of our Report of even date

**For Brahmaya & Co.**  
Chartered Accountants  
Firm Regn No. 000511S

For and on behalf of Board of  
**Bafna Pharmaceuticals Limited**

**S. Hemalatha**  
Whole Time Director  
DIN : 02714329

**Vinayak Dinesh Dendukuri**  
Whole Time Director  
DIN : 07601309

**Bafna Mahaveer Chand**  
Chief Executive Officer

**Lokesh Vasudevan**  
Partner  
M.No. 222320

**Melagiri Sridhar**  
Chief Financial Officer

**Mohanachandran A**  
Company Secretary  
M.No.65827

Place: Chennai  
Date: 26<sup>th</sup> May 2025

Place: Chennai  
Date: 26<sup>th</sup> May 2025

## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

### 1. Corporate Information

BAFNA PHARMACEUTICALS LIMITED ('Bafna pharma' or 'the Company') is a Public Limited Company domiciled and incorporated in India, having its registered office at New No. 68 Old No. 299, Thambu Chetty Street, Chennai – 60001. The Company's shares are listed and traded on BSE Limited and National Stock Exchange of India Limited. The Company is engaged in the business of Manufacturing of finished pharmaceutical formulations. These Financial Statements were authorized for issue by the Company's Board of Directors on 26<sup>th</sup> May 2025.

#### 2.1. Basis of Preparation

These notes provide the list of the material accounting policies adopted in the preparation of these Financial Statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

##### a) Compliance with Ind AS

The Financial Statements of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as notified under section 133 of the Companies Act, 2013 ("the Act") read with prescribed rules therein. The Company has uniformly applied the accounting policies during the periods presented.

##### b) Historical Cost Convention

The Financial Statements have been prepared on a historical cost basis, except for the following:

- Certain financial assets and liabilities (including derivative instruments) and contingent consideration that are measured at fair value or amortized cost;
- Assets held for sale – measured at lower of carrying amount and fair value less cost to sell;
- Defined benefit plans – plan assets measured at fair value; and
- Share-based payments – measured at fair value of options at the grant date.

##### c) Current / Non – Current Classification

Any asset or liability is classified as current if it satisfies any of the following conditions:

- Asset / Liability is expected to be realised / settled in the Company's normal operating cycle
- Asset is intended for sale or consumption

- Asset / Liability is held primarily for the purpose of trading

- Asset is a cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date

- In case of a Liability, the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date

For the purpose of this classification, the Company has ascertained its normal operating cycle as twelve months, which is based on the nature of business and time between acquisition of assets and their realisation in cash and cash equivalents.

Deferred Tax Assets and Liabilities are classified as non current.

#### 2.2. Use of Material Accounting Estimates and Judgements

Estimates, assumptions concerning the future and judgements are made in the preparation of the Financial Statements. They affect the application of the Company's accounting policies, reporting amounts of assets, liabilities, income and expense and disclosures made. Although these estimates are based on management's best knowledge of current events and actions, actual result may differ from those estimates.

The critical accounting estimates and assumptions used and areas involving a high degree of judgements are described below:

##### A. Use of estimation and assumption

In the process of applying the Company's accounting policies, management had made the following estimation and assumptions that have the significant effect on the amounts recognized in the Financial Statements. The estimates and assumptions used in accompanying Financial Statements are based upon management's evaluation of the relevant facts and circumstances as on the date of the Financial Statements, reviewed on an ongoing basis. Any revision to accounting estimates is recognized prospectively in current and future periods.

##### a) Property, Plant and Equipment & Intangible Assets

Key estimates related to long-lived assets (property, plant and equipment and intangible assets) include useful lives, recoverability of carrying values and the existence of any retirement obligations. As a result of future decisions, such estimates could be significantly modified. The useful lives as mentioned in Note 2.3 (A) and Note 2.3 (B) is applied as per



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

Schedule II of Companies Act, 2013 and estimated based upon our historical experience, technical estimation and industry information. These estimates include an assumption regarding periodic maintenance and an appropriate level of annual capital expenditures to maintain the assets.

### b) Employee Benefits - Measurement of Defined Benefit Obligation (DBO)

Management assesses post-employment and other employee benefit obligations using the projected unit credit method based on actuarial assumptions which represent management's best estimates of the variables (such as standard rates of inflation, medical cost trends, mortality, discount rate and anticipation of future salary increases) that will determine the ultimate cost of providing post-employment and other employee benefits. Variation in these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.

### c) Income Taxes

The Company recognizes tax liabilities based upon self-assessment as per the tax laws. When the final tax outcome of these matters is different from the amounts that were initially recognized, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

## B. Critical Judgements Made in Applying Accounting Policies

### a) Revenue

The Company recognizes revenue from contracts with customers based on a five-step model as per Ind AS 115 (Refer Note 2.3 (R)) which involves judgements such as identification of distinct performance obligation involves judgement to determine the deliverables and the ability of the customer to benefit independently from such deliverables. The management exercises judgement in determining whether the performance obligation is satisfied at a point in time or over a period of time It considers indicators such as how customer consumes benefits as services are rendered or who controls the asset as it is being created or existence of enforceable right to payment for performance to date and alternate use of such product or service, transfer of significant risks and rewards to the customer, acceptance of delivery by the customer, etc.

### b) Recognition of Deferred Tax Assets

The extent to which deferred tax assets can be recognized is based on an assessment of the probability of the future taxable income against

which the deferred tax assets can be utilized. In addition, significant judgement is required in assessing the impact of any legal or economic limits or uncertainties in various tax jurisdictions.

### c) Evaluation of Indicators for Impairment of Assets

The evaluation of applicability of indicators of impairment of assets requires assessment of several external and internal factors which could result in deterioration of recoverable amount of the assets.

### d) Expected Credit Losses

Expected credit losses of the Company are based on an evaluation of the collectability of receivables. A considerable amount of judgment is required in assessing the ultimate realization of these receivables, including their current credit worthiness, past collection history of each customer and ongoing dealings with them. If the financial conditions of the counterparties with which the Company contracted were to deteriorate, resulting in an impairment of their ability to make payments, additional expected credit loss may be required.

### e) Useful Life of Depreciable/Amortizable Assets

Management reviews its estimate of the useful lives of depreciable/amortizable assets at each reporting date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical and economic obsolescence that may change the utility of certain software, customer relationships, IT equipment and other plant and equipment.

### f) Fair Value Measurements

Management applies valuation techniques to determine the fair value of financial instruments (where active market quotes are not available) and non-financial assets. This involves developing estimates and assumptions consistent with how market participants would price the instrument. Management uses the best information available. Estimated fair values may vary from the actual prices that would be achieved in an arm's length transaction at the reporting date.

### g) Provisions

At each reporting date basis the management judgement, changes in facts and legal aspects, the Company assess the requirement of the provisions. However, the actual future outcome may be different from this judgement.

### h) Leases

The Company determines the lease term as the non-cancellable term of the lease, together with any



# Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The Company has certain lease contracts that include extension and termination options. The Company applies judgement in evaluating whether it is reasonably certain or not to exercise the option to renew or terminate the lease. That considers all relevant factors that create an economic incentive for it to exercise either the renewal or termination. After the commencement date, the Company reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to renew or to terminate.

## C. Recent Pronouncements

Ministry of Corporate Affairs ("MCA") notifies new standard or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On 7<sup>th</sup> May 2025, MCA notifies the Companies (Indian Accounting Standards) Amendment Rules, 2025, applicable from 1<sup>st</sup> April 2025 as below:



### Ind AS 21 The Effects of Changes in Foreign Exchange Rates

The amendment provides guidance on determining the exchange rate when a currency is not exchangeable into another currency. Where exchangeability is lacking, entities are required to estimate the spot exchange rate that would be used in an orderly transaction under prevailing economic conditions and disclose the estimation process, key inputs, and associated risks.

The Company does not expect this amendment to have any significant impact on its Financial Statements.

The Company has not early adopted any amendment that have been notified but are not yet effective.

## 2.3 Material Accounting Policies

### A. Property, Plant and Equipment and Depreciation

#### Initial Recognition

All items of property, plant and equipment are initially measured at cost. The cost of an item of property, plant and equipment is recognized as an asset if, and only if, it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

Cost includes its purchase price (after deducting trade discounts and rebates), import duties & non-refundable purchase taxes, any costs directly attributable to bringing the asset to the location & condition necessary for it

to be capable of operating in the manner intended by management, borrowing costs on qualifying assets and asset retirement costs. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

The activities necessary to prepare an asset for its intended use or sale extend to more than just physical construction of the asset. It may also include technical (DPR, environmental, planning, Land acquisition and geological study) and administrative work such as obtaining approvals before the commencement of physical construction.

The cost of replacing a part of an item of property, plant and equipment is capitalized if it is probable that the future economic benefits of the part will flow to the Company and that its cost can be measured reliably. The carrying amount of the replaced part is derecognized.

Costs of day to day repairs and maintenance costs are recognized into the Statement of Profit and Loss as incurred.

#### Subsequent measurement

Subsequent to recognition, property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses.

The carrying values of property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

The residual values, estimated useful lives and depreciation method are reviewed at each financial year-end, and adjusted prospectively, if appropriate.

#### Depreciation

Depreciation is provided on Straight Line Method, as per the provisions of Schedule II of the Companies Act, 2013 or based on useful life estimated on the technical assessment. Asset class wise useful lives are as under:

Type of Assets	Useful Life
Building	30 Years
Plant and Machinery	15 Years
Furniture and Fixtures	10 Years
Office Equipments	5 - 10 Years
Vehicles	8 Years
Laboratory Equipments	10 Years
Computers	3 Years



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

In respect of additions / deletions to the Property Plant and Equipment, depreciation is charged from the date the asset is ready to use / up to the date of deletion.

Depreciation methods, useful lives and residual values are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

### De-recognition

An item of plant and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de recognition of the asset is recognized in the Statement of Profit and Loss in the year the asset is derecognized.

### Capital Work in Progress and Capital Advances

Cost of asset not ready for intended use and assets under installation or under construction as at the Balance Sheet date are shown as Capital Work in Progress. Advances given towards acquisition of property, plant and equipment outstanding at each Balance Sheet date are disclosed as Other Non-Current Asset in accordance with Schedule III to the Companies Act, 2013.

## B. Intangible Assets & Amortization

### Initial Recognition

Intangible assets acquired separately are initially measured at cost. Intangible assets are recognized if, it is probable that the future economic benefits that are attributable to the asset will flow to the Company and the cost of the asset can be measured reliably.

Software for internal use, which is primarily acquired from third-party vendors including consultancy charges for implementing the software, is capitalized. Subsequent costs associated with maintaining such software are recognized as expense as incurred. The capitalized costs are amortized over a period of the estimated useful life of the software.

Cost of separately acquired intangible asset includes its purchase price (after deducting trade discounts and rebates), import duties & non-refundable purchase taxes, any costs directly attributable to preparing the asset for its intended use.

Intangible assets acquired in a business combination are recognized at fair value at the acquisition date. Subsequently, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any.

### Subsequent measurement and amortization

Intangible assets are stated at cost of acquisition less accumulated amortization and accumulated impairment losses, if any. Subsequent expenditure related to an item of intangible assets are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance.

The carrying values of intangible assets are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

The residual values, estimated useful lives and amortization method are reviewed at each financial year-end, and adjusted prospectively, if appropriate.

The useful lives of intangible assets are assessed as either finite or indefinite. Finite-life intangible assets are amortized on a straight-line basis over the period of their estimated useful lives.

The amortization expense is recognized in the Statement of Profit and Loss unless such expenditure forms part of carrying value of another asset.

Indefinite-life intangible assets comprises of those assets for which there is no foreseeable limit to the period over which they are expected to generate net cash inflows. These are considered to have an indefinite life, given the strength and durability of the Company and the level of marketing support.

For indefinite life intangible assets, the assessment of indefinite life is reviewed at each financial year end, to determine whether it continues, if not, it is impaired or changed prospectively based on revised estimates.

### De-recognition

An item of Intangible Assets is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de recognition of the asset is recognized in the Statement of Profit and Loss in the year the asset is derecognized.

## C. Inventories

Inventories consisting of raw materials, consumables, stores and spares, work in progress and finished goods are measured at the lower of cost and net realizable value. The cost of all categories of inventories is based on the weighted average method.

Cost of raw materials, consumables, stores and spares includes cost of purchases and other costs incurred

## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

in bringing the inventories to its present location and condition.

Cost of work-in-progress and finished goods comprises direct material, direct labour and an appropriate proportion of variable and fixed overhead expenditure. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and costs necessary to make the sale.

The factors that the Company considers in determining the allowance for slow moving, obsolete and other non-saleable inventory include estimated shelf life, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Company's business and markets. The Company considers all these factors and adjusts the inventory provision to reflect its actual experience on a periodic basis.

### D. Impairment of Non – Financial Assets

At each reporting date, the Company assesses whether there is any indication that an asset may be impaired. Where an indicator of impairment exists, the Company makes a formal estimate of recoverable amount. Where the carrying amount of an asset exceeds its recoverable amount the asset is considered impaired and is written down to its recoverable amount.

Recoverable amount is the greater of fair value less costs to sell and value in use. It is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets, in which case, the recoverable amount is determined for the Cash Generating Unit ("CGU") to which the asset belongs.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre- tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

Impairment losses of continuing operations, including impairment on inventories, are recognized in the Statement of Profit and Loss, except for properties previously revalued with the revaluation surplus taken to Other Comprehensive Income ("OCI"). For such properties, the impairment is recognized in OCI up to the amount of any previous revaluation surplus.

After impairment, depreciation or amortization is provided on the revised carrying amount of the asset over its remaining useful life.

The impairment assessment for all assets is made at each reporting date to determine whether there is an indication that previously recognized impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in prior years. Such reversal is recognized in the Statement of Profit and Loss.

### E. Financial Assets

Financial assets comprise of investments in equity and debt securities, mutual funds, loans, trade receivables, cash and cash equivalents and other financial assets.

#### Initial recognition

All financial assets except investments in subsidiaries, associates and jointly controlled entities are recognized initially at fair value. However, trade receivables that do not contain a significant financing component are measured at transaction price. Purchases or sales of financial asset that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the assets.

#### Subsequent Measurement

##### a) Financial assets measured at amortized cost:

Financial assets held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding are measured at amortized cost using effective interest rate (EIR) method. The EIR amortization is recognized as finance income in the Statement of Profit and Loss.

The Company while applying above criteria has classified the following at amortized cost:

- a) Loans
- b) Trade Receivable
- c) Cash and Cash Equivalents
- d) Other Financial Assets



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

### b) Financial assets at Fair Value through Other Comprehensive Income (FVTOCI):

Financial assets held within a business model whose objective is to hold financial assets in order to collect contractual cash flows, selling the financial assets and the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding are measured at FVTOCI. Fair Value movements in financial assets at FVTOCI are recognized in other comprehensive income. Equity instruments held for trading are classified at Fair Value through Profit or Loss (FVTPL). For other equity instruments the Company classifies the same either at FVTOCI or FVTPL on instrument to instrument basis. The classification is made on initial recognition and is irrevocable. Fair value changes on equity investments at FVTOCI, excluding dividends are recognized in Other Comprehensive Income (OCI).

### c) Financial Assets at Fair Value through Profit or Loss (FVTPL)

Financial asset are measured at fair value through profit or loss if it does not meet the criteria for classification as measured at amortized cost or at fair value through other comprehensive income. All fair value changes are recognized in the Statement of Profit and Loss.

### d) Investment in subsidiaries, joint ventures & associates are carried at cost in the Financial Statements. However, a provision for diminution in value is made to recognize a decline other than temporary in value of the investments.

### Impairment

Financial assets are tested for impairment based on the expected credit losses in accordance with Ind AS 109 on the following financial assets:

#### a) Trade Receivables

An impairment analysis is performed at each reporting date. The expected credit losses over life time of the asset are estimated by adopting the simplified approach using a provision matrix on its portfolio of trade receivables. which is based on historical loss rates reflecting current condition and forecasts of future economic conditions. In this approach assets are grouped on the basis of similar credit characteristics such as customer segment, past due status and other factors which are relevant to estimate the expected cash loss from these assets. As a practical expedient, the Company

uses a provision matrix to determine impairment loss allowance on portfolio of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

#### b) Other Financial Assets

Other Financial Assets are tested for impairment based on significant change in credit risk since initial recognition and impairment is measured based on probability of default over the life time when there is significant increase in credit risk.

### De-recognition

A financial asset is de recognized only when:

- The Company has transferred the rights to receive cash flows from the financial asset, or
- The contractual right to receive cash flows from financial asset is expired, or
- Retains the contractual rights to receive the cash flows of the financial asset, but assumes a contractual obligation to pay the cash flows to one or more recipients.

Where the entity has transferred an asset and transferred substantially all risks and rewards of ownership of the financial asset, in such cases the financial asset is derecognized. Where the entity has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is also derecognized if the Company has not retained control of the financial asset.

### F. Cash and Cash Equivalents

Cash and cash equivalents comprises of bank balances (including deposits with banks with original maturity of three months or less) and cash in hand and short-term investments with an original maturity of three months or less. Deposits with banks are subsequently measured at amortized cost and short term investments are measured at fair value through Statement of Profit and Loss.

### G. Non-current Assets held for sale

Non-current assets or disposal groups comprising of assets and liabilities are classified as 'held for sale' when all the following criteria are met:

- (i) decision has been made to sell,

## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

- (ii) the assets are available for immediate sale in its present condition,
- (iii) the assets are being actively marketed and
- (iv) sale has been agreed or is expected to be concluded within 12 months of the Balance Sheet date.

Subsequently, such non-current assets and disposal groups classified as 'held for sale' are measured at the lower of its carrying value and fair value less costs to sell. Non-current assets held for sale are no longer depreciated or amortized.

### H. Share Capital

Equity Shares are classified as equity.

### I. Financial Liabilities

#### Initial Recognition

Financial liabilities are recognized when, and only when, the Company becomes a party to the contractual provisions of the financial instrument. The Company determines the classification of its financial liabilities at initial recognition. All financial liabilities are recognized initially at fair value plus any directly attributable transaction costs, such as loan processing fees and issue expenses.

#### Subsequent Measurement - at amortized cost

After initial recognition, financial liabilities are subsequently measured at amortized cost using the effective interest rate (EIR) method. Gains and losses are recognized in the Statement of Profit and Loss when the liabilities are de-recognized, and through the amortization process.

#### De-recognition

A financial liability is de-recognized when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a de-recognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognized in the Statement of Profit and Loss.

#### Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on

a net basis, to realize the assets and settle the liabilities simultaneously.

### J. Borrowing Costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective asset. Capitalisation of borrowing cost is suspended in the period during which the active development is delayed due to other than temporary interruption. All other borrowing costs are expensed in the period they occur. Borrowing costs consist of interest, exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost and other costs that an entity incurs in connection with the borrowing of funds.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization.

### K. Employee benefits

Employee benefits are charged to the Statement of Profit and Loss for the year.

Retirement benefits in the form of Provident Fund are defined contribution scheme and such contributions are recognized, when the contributions to the respective funds are due. There are no other obligation other than the contribution payable to the respective funds.

Gratuity liability is defined benefit obligation and is provided for on the basis of actuarial valuation on projected unit credit method made at the end of each financial year. Re measurement in case of defined benefit plans gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur, directly in other comprehensive income and they are included in the statement of changes in equity.

Compensated absences are provided for on the basis of actuarial valuation on projected unit credit method made at the end of each financial year. Re-measurements as a result of experience adjustments and changes in actuarial assumptions are recognized in Statement of Profit and Loss.

The amount of Non-current and Current portions of employee benefits is classified as per the actuarial valuation at the end of each financial year.



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

### L. Income Taxes

Income tax expense is comprised of current and deferred taxes. Current and deferred tax is recognized in net income except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive income. Current income tax relating to items recognized outside profit and loss is recognized outside profit and loss (either in other comprehensive income or in equity). Current income taxes for the current period, including any adjustments to tax payable in respect of previous years, are recognized and measured at the amount expected to be recovered from or payable to the taxation authorities based on the tax rates that are enacted or substantively enacted by the end of the reporting period.

Deferred income tax assets and liabilities are recognized for temporary differences between the Financial Statement carrying amounts of existing assets and liabilities and their respective tax base using the tax rates that are expected to apply in the period in which the deferred tax asset or liability is expected to settle, based on the laws that have been enacted or substantively enacted by the end of reporting period.

Deferred tax assets and liabilities are not recognized if the temporary difference arises from goodwill or from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable income nor the accounting income. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable income will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and reduced accordingly to the extent that it is no longer probable that they can be utilized.

Deferred tax assets and liabilities are offset when there is legally enforceable right of offset current tax assets and liabilities when the deferred tax balances relate to the same taxation authority. Current tax asset and liabilities are offset where the entity has legally enforceable right to offset and intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously. Deferred Tax relating to items recognized outside profit or loss is recognized outside profit and loss (either in other comprehensive income or in equity).

### M. Leases

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

#### Company as a lessee

The Company assesses whether a contract is or contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether:

- (i) the contract involves the use of an identified asset
- (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease, and
- (iii) the Company has the right to direct the use of the asset

At date of commencement of leases, the Company recognizes a right of use asset (ROU) and a corresponding lease liability for all the lease arrangements, except for those with a term of twelve month or less (short term leases) and leases of low value assets. For these leases, the Company recognizes lease payments as an expense on straight line basis over the lease term.

#### Initial Measurement

ROU assets are initially measured at cost that comprises of the initial amount of lease liability adjusted for any lease payments made at or prior to the date of commencement, initial direct costs and lease incentives (if any).

Lease Liability is initially measured at the present value of future lease payments that are not paid at that date. The lease payments shall be discounted using the interest rate implicit in the lease or, if not readily determinable, incremental borrowing rate.

#### Subsequent Measurement

ROU assets are subsequently measured at cost less accumulated depreciation and impairment loss, if any. ROU is depreciated from the date of commencement on a straight line basis over the shorter of lease term or useful life of the underlying asset.

Lease Liability is subsequently measured by increasing the carrying amount to reflect interest and reducing the carrying amount to reflect the lease payments made.

The carrying amount of lease liability is remeasured to reflect any reassessment or lease modification such as change in lease term.



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

ROU asset and lease liability are separately presented in the balance sheet and lease payments have been classified as financing cash flows.

### Company as a lessor

Leases for which the Company is a lessor is classified as finance or operating lease. Leases in which the Company does not transfer substantially all the risks and rewards incidental to ownership of an asset are classified as operating leases. Lease income from operating leases is recognized in Statement of Profit and Loss on a straight line basis over the lease term unless the receipts are structured to increase in line with expected general inflation to compensate for the expected inflationary cost increases.

### N. Provisions

A provision is recognized if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are measured at the present value of management's best estimate of the expenditure required to settle the present obligation at the end of the reporting period.

Provisions are reviewed and adjusted, when required, to reflect the current best estimate at the end of each reporting period.

The Company recognizes decommissioning provisions in the period in which a legal or constructive obligation is incurred. A corresponding decommissioning cost is added to the carrying amount of the associated property, plant and equipment, and it is depreciated over the estimated useful life of the asset.

### O. Contingent Liabilities

Contingent liability is disclosed in case of:

- A present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation;
- A present obligation arising from past events, when no reliable estimate is possible;
- A possible obligation arising from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company where the probability of outflow of resources is not remote.

### P. Contingent Assets

Contingent assets are not recognized but disclosed in the Financial Statements when an inflow of economic benefits is probable. Contingent assets are assessed continually and, if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

### Q. Fair Value Measurements

Company follows the hierarchy mentioned underneath for determining fair values of its financial instruments:

- Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 – Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices); and
- Level 3 – Inputs for the asset or liability that are not based on observable market data.

The fair value of financial instruments traded in active markets is based on quoted market prices at the reporting dates. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis. The fair value for these instruments is determined using Level 1 inputs.

The fair value of financial instruments that are not traded in an active market (for example, over the counter derivatives) is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is fair valued using level 2 inputs.

If one or more of the significant inputs is not based on observable market data, the instrument is fair valued using Level 3 inputs. Specific valuation techniques used to value financial instruments include:

- Quoted market prices or dealer quotes for similar instruments
- The fair value of interest rate swaps is calculated as the present value of the estimated future cash flows based on observable yield curves



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

- The fair value of forward foreign exchange contracts is determined using forward exchange rates at the reporting dates, with the resulting value discounted back to present value
- Other techniques, such as discounted cash flow analysis, are used to determine fair value for the remaining financial instruments.

### R. Revenue Recognition

Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

The Company recognizes revenue from contracts with customers based on a five-step model, such as to, identifying the contracts with a customer, identifying the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation at a point in time or over time.

The Company satisfies a performance obligation and recognizes revenue over time, if one of the following criteria is met:

- The customer simultaneously receives and consumes the benefits provided by the Company performance as the Company performs; or
- The Company's performance creates or enhances an asset that the customer controls as the asset is created or enhanced; or
- The Company's performance does not create an asset with an alternative use to the Company and the entity has an enforceable right to payment for performance completed to date.

For performance obligations where one of the above conditions are not met, revenue is recognized at the point in time at which the performance obligation is satisfied.

### S. Other Income

#### Interest Income

For all debt instruments measured either at amortized cost or at fair value through other comprehensive income, interest income is recorded using the effective

interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortized cost of a financial liability. When calculating the effective interest rate, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example, prepayment, extension, call and similar options) but does not consider the expected credit losses. Interest income is included in finance income in the Statement of Profit and Loss.

Interest income on fixed deposits is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate.

#### Dividend income

Dividend income is recognized at the time when right to receive the payment is established, which is generally when the shareholders approve the dividend.

### T. Foreign Currency Transactions

#### Functional and Presentation Currency

The Financial statements are presented in Indian Rupee (INR/₹) which is also the functional and presentation currency of the Company.

#### Transactions and Balances

Transactions in foreign currencies are translated to the functional currency at exchange rates in effect on transaction date. At each reporting date, monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate in effect at the date of Financial Statement.

The translation for other non-monetary assets and liabilities are not updated from historical exchange rates unless they are carried at fair value.

### U. Government Grants

Government grants are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognized as income in equal amounts over the expected useful life of the related asset.



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

### V. Earnings per share

Basic earnings per share are calculated by dividing the profit attributable to owners of the Company by the weighted average number of equity shares outstanding during the financial year, adjusted for bonus elements in equity shares issued during the year and excluding treasury shares.

Diluted earnings per share adjust the figures used in the determination of basic earnings per share to take into account, the after income tax effect of interest and other financing costs associated with dilutive potential equity shares and the weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares.

### W. Segment Reporting

Operating segments are identified and reported in a manner consistent with the internal financial reporting provided to the chief operating decision makers, responsible for allocating resources and assessing performance of the operating segments.

### X. Events after reporting date:

Where events occurring after the Balance Sheet date provide evidence of conditions that existed at the end of the reporting period, the impact of such events is adjusted within the Financial Statements. Non Adjusting events after the Balance Sheet date which are material in size or nature are disclosed separately in the Financial Statements.





## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 3 PROPERTY, PLANT AND EQUIPMENT

Particulars	Freehold Land	Buildings	Plant and Equipment	Furniture and Fixtures	Laboratory Equipments	Electrical Installations	Vehicles	Office Equipment	Computers	Total
<b>Gross Block</b>										
As at 1 <sup>st</sup> April, 2023	19.32	2,507.76	5,015.15	185.15	1,074.04	339.12	52.71	50.17	222.29	9,465.69
Additions	-	7.38	387.83	15.67	67.56	6.09	-	13.25	10.47	508.25
Disposals	-	-	15.47	-	1.04	0.47	8.28	-	-	25.26
<b>As at 31<sup>st</sup> March, 2024</b>	<b>19.32</b>	<b>2,515.14</b>	<b>5,387.51</b>	<b>200.82</b>	<b>1,140.56</b>	<b>344.74</b>	<b>44.43</b>	<b>63.42</b>	<b>232.76</b>	<b>9,948.68</b>
Additions	-	555.17	1,258.62	77.19	274.45	278.60	-	6.17	54.01	2,504.21
Disposals	-	-	21.18	-	9.26	0.39	-	-	-	30.83
Assets Held for Sale	-	319.30	1,140.97	170.62	90.93	15.90	16.97	21.39	93.22	1,869.30
<b>As at 31<sup>st</sup> March, 2025</b>	<b>19.32</b>	<b>2,751.01</b>	<b>5,483.98</b>	<b>107.39</b>	<b>1,314.82</b>	<b>607.05</b>	<b>27.46</b>	<b>48.20</b>	<b>193.55</b>	<b>10,552.76</b>
<b>Depreciation</b>										
As at 1 <sup>st</sup> April, 2023	-	1,113.40	2,736.54	183.08	821.54	322.23	22.71	36.08	207.13	5,442.71
Charged for the Year	-	82.96	362.87	1.10	36.55	0.18	3.20	3.67	9.02	499.55
On Disposals	-	-	12.75	-	0.99	0.45	0.53	-	-	14.72
<b>As at 31<sup>st</sup> March, 2024</b>	<b>-</b>	<b>1,196.36</b>	<b>3,086.66</b>	<b>184.18</b>	<b>857.10</b>	<b>321.96</b>	<b>25.38</b>	<b>39.75</b>	<b>216.15</b>	<b>5,927.54</b>
Charged For the Year	-	91.62	278.50	8.32	58.58	21.89	3.20	4.88	21.97	488.96
On Disposals	-	-	14.34	-	2.82	0.39	-	-	-	17.55
Assets Held for Sale	-	303.34	1,016.08	170.47	89.72	15.18	16.62	20.04	92.73	1,724.18
<b>As at 31<sup>st</sup> March, 2025</b>	<b>-</b>	<b>984.64</b>	<b>2,334.74</b>	<b>22.03</b>	<b>823.14</b>	<b>328.28</b>	<b>11.96</b>	<b>24.59</b>	<b>145.39</b>	<b>4,692.32</b>
<b>Net Block</b>										
As at 31 <sup>st</sup> March, 2024	19.32	1,318.78	2,300.85	16.64	283.46	22.78	19.05	23.67	16.59	4,021.14
<b>As at 31<sup>st</sup> March, 2025</b>	<b>19.32</b>	<b>1,766.37</b>	<b>3,149.24</b>	<b>85.36</b>	<b>491.68</b>	<b>278.77</b>	<b>15.50</b>	<b>23.61</b>	<b>48.14</b>	<b>5,877.99</b>

### 4 CAPITAL WORK IN PROGRESS

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Capital Work in Progress	731.32	1,049.58
	<b>731.32</b>	<b>1,049.58</b>

#### Ageing of Capital Work in Progress as at 31st March, 2025

	Less than 1 Year	1-2 Years	2-3 Year	More than 3 Years	Total
Projects in Progress*	731.32	-	-	-	731.32
	<b>731.32</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>731.32</b>

#### Ageing of Capital Work in Progress as at 31st March, 2024

	Less than 1 Year	1-2 Years	2-3 Year	More than 3 Years	Total
Projects in Progress**	1,049.58	-	-	-	1,049.58
	<b>1,049.58</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,049.58</b>

\*Construction of Warehouse

\*\*Construction of Advance Quality Control Laboratory

## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 5 INTANGIBLE ASSETS UNDER DEVELOPMENT

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Intangible Assets under Development	-	177.00
	-	177.00

#### Ageing of Intangible Assets under Development as at 31st March, 2025

	Less than 1 Year	1-2 Years	2-3 Year	More than 3 Years	Total
Intangible Assets under Development	-	-	-	-	-
	-	-	-	-	-

#### Ageing of Intangible Assets under Development as at 31st March, 2024

	Less than 1 Year	1-2 Years	2-3 Year	More than 3 Years	Total
Intangible Assets under Development	27.00	150.00	-	-	177.00
	27.00	150.00	-	-	177.00

The Company had incurred certain identified expenditures towards procurement of certain market authorisations, which would be used to expand its product base and enable significant economic benefits. During the Financial Year ended 31<sup>st</sup> March 2025, Intangible Assets under development has been derecognised. (Refer Note 32).

### 6 INVESTMENTS

	No. of Shares		Amount	
	As at 31 <sup>st</sup> March , 2025	As at 31 <sup>st</sup> March, 2024	As at 31 <sup>st</sup> March , 2025	As at 31 <sup>st</sup> March, 2024
<b>Investment at Fair Value Through Other Comprehensive Income</b>				
<b>Unquoted</b>				
<b>Investment in Equity Shares of INR 100 each</b>				
Jimi Solar Private Limited	49.00	-	0.05	-
	49.00	-	0.05	-

### 7 OTHER FINANCIAL ASSETS

	Non Current		Current	
	As at 31 <sup>st</sup> March , 2025	As at 31 <sup>st</sup> March, 2024	As at 31 <sup>st</sup> March , 2025	As at 31 <sup>st</sup> March, 2024
Security Deposits with Government Departments	73.41	66.70	-	-
Security Deposits with Related Parties	6.75	6.75	-	-
Security Deposits with Landlords & Others	0.50	-	-	-
Accrued Interest	-	-	-	0.24
Bank Balances	-	69.93	-	-
	80.66	143.38	-	0.24



## Notes and other explanatory information to financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 8 INVENTORIES

(At lower of cost and net realisable value unless otherwise stated)	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Raw Materials	1,923.06	1,466.99
Consumables, Stores and Spares	310.79	277.78
Work-in-Progress	382.06	912.92
Finished Goods	192.70	306.49
	<b>2,808.61</b>	<b>2,964.18</b>

### 9 TRADE RECEIVABLES

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
<b>Unsecured</b>		
Considered Good	4,076.63	4,628.85
	<b>4,076.63</b>	<b>4,628.85</b>
Less: Provision for Expected Credit Losses	59.28	89.37
	<b>4,017.35</b>	<b>4,539.48</b>

Ageing for Trade receivables as at 31st March, 2025 is as follows:-

	Outstanding for following periods from Due date of Payment*					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables – considered good	3,835.97	128.60	2.13	88.27	21.66	4,076.63
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables– considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
	<b>3,835.97</b>	<b>128.60</b>	<b>2.13</b>	<b>88.27</b>	<b>21.66</b>	<b>4,076.63</b>
Less: Provision for Expected Credit Losses						59.28
						<b>4,017.35</b>



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

Ageing for Trade receivables as at 31st March, 2024 is as follows:-

	Outstanding for following periods from Due date of Payment*					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables – considered good	4,276.57	179.38	88.10	71.50	13.30	4,628.85
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade Receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables– considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
	<b>4,276.57</b>	<b>179.38</b>	<b>88.10</b>	<b>71.50</b>	<b>13.30</b>	<b>4,628.85</b>
Less: Provision for Expected Credit Losses						89.37
						<b>4,539.48</b>

\* Aging has been calculated from the date of transaction

### 10 LOANS



	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
<b>Unsecured, Considered Good</b>		
Loans and Advances to Employees	2.30	8.18
	<b>2.30</b>	<b>8.18</b>

### 11 CASH AND CASH EQUIVALENTS

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Cash on Hand	1.00	0.61
Balances with Banks		
-Current Accounts	0.88	5.89
-EEFC Accounts	206.03	4.75
-Deposit Accounts Less than 3 Months	135.36	128.35
	<b>343.27</b>	<b>139.60</b>

### 12 CURRENT TAX ASSETS (NET)

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Advance Tax (Net of Provision for Tax)	29.79	64.81
	<b>29.79</b>	<b>64.81</b>



## Notes and other explanatory information to financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 13 OTHER ASSETS

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
<b>Advances other than Capital Advances</b>		
Advances for services / goods	135.81	75.83
Prepaid Expense	52.06	46.12
Taxes Paid Under Protest	10.28	10.28
GST Receivables	1,152.91	1,528.34
Less: Provision for GST Receivables	(79.62)	-
	<b>1,271.44</b>	<b>1,660.57</b>

### 14 EQUITY SHARE CAPITAL

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
<b>Authorised</b>		
400 Lakhs (31 <sup>st</sup> March, 2024: 400 Lakhs) Equity Shares of INR10 each	4,000.00	4,000.00
	<b>4,000.00</b>	<b>4,000.00</b>
<b>Issued, Subscribed and Paid Up</b>		
<b>Equity Shares</b>		
236.56 Lakhs (31 <sup>st</sup> March, 2024: 236.56 Lakhs) Equity Shares of INR 10 each, fully paid up	2,365.63	2,365.63
<b>Total Equity Share Capital</b>	<b>2,365.63</b>	<b>2,365.63</b>

#### 14.1 Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

	As at 31 <sup>st</sup> March , 2025		As at 31 <sup>st</sup> March, 2024	
	Numbers in Lakhs	Amount	Numbers in Lakhs	Amount
Equity Shares of INR 10 Each, Fully paid up				
At the Beginning	236.56	2,365.63	236.56	2,365.63
Issued during the period	-	-	-	-
<b>At the end</b>	<b>236.56</b>	<b>2,365.63</b>	<b>236.56</b>	<b>2,365.63</b>

#### 14.2 Terms / Rights attached to Equity Shares (eg. Dividend rights, Voting Rights)

The Company has only one class of equity shares having a par value of INR 10 Per share. Each Holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts in the proportion to the number of equity shares held by the shareholders.

#### 14.3 Shares held by Holding Company

	As at 31 <sup>st</sup> March , 2025		As at 31 <sup>st</sup> March, 2024	
	Numbers in Lakhs	Amount	Numbers in Lakhs	Amount
<b>Equity Shares of INR 10 each fully paid up held by SRJR Life Sciences LLP, Holding Company</b>	176.40	1,764.00	207.85	2,078.53



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 14.4 Details of Shareholder holding more than 5% shares of the Company:

	As at 31 <sup>st</sup> March, 2025		As at 31 <sup>st</sup> March, 2024	
	No. Lakhs	% Holding	No. Lakhs	% Holding
<b>Equity Shares of INR 10 each Held By</b>				
SRJR Life Sciences LLP, Holding Company	176.40	74.57%	207.85	87.9%

### 14.5 Disclosure of Shareholding of Promoters

#### Shares held by promoters at the end of the year

	No. of shares (in Lakhs)	% of total shares	% Change
<b>Equity Shares of INR 10 each, fully paid up</b>			
P Paras Bafna	0.50	0.21%	-
Naveen Bafna M	0.42	0.18%	-
Bafna Mahaveer Chand	0.06	0.03%	-
Sasikala Bafna	0.02	0.01%	-
Paras Bafna*	0.00	0.00%	-
SRJR Lifesciences LLP	176.40	74.57%	(13.30)%
Amri Bai Bafna	0.02	0.01%	-
	<b>177.42</b>	<b>75.00%</b>	<b>13.30%</b>

\*less than 100 shares



The above information is as per register of share holders / members.

## 15 BORROWINGS

	Non Current		Current	
	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Rupee Loans and Advances				
Secured				
From Banks	1,252.78	925.25	559.97	362.49
	<b>1,252.78</b>	<b>925.25</b>	<b>559.97</b>	<b>362.49</b>
From Related Parties				
Un-secured				
From KMPs	150.07	150.07	-	-
	<b>150.07</b>	<b>150.07</b>	<b>-</b>	<b>-</b>
	<b>1,402.85</b>	<b>1,075.32</b>	<b>559.97</b>	<b>362.49</b>
Amount disclosed under the head "Short Term Borrowings" (Note 17)			(559.97)	(362.49)
	<b>1,402.85</b>	<b>1,075.32</b>	<b>-</b>	<b>-</b>

#### Terms of the Borrowings

The Company has availed the Working Capital Loan, Cash Credit Facility and Term Loan from ICICI Bank Limited. Working Capital Loans and are repayable in 48 and 60 equated monthly instalments. The loan carries interest rate of Repo Rate+Spread. The loans and cash credit facility from ICICI Bank are secured by Current Assets, Movable Fixed Assets and Immovable Fixed Assets of the Company. These loans are also guaranteed by the CVR Enterprise LLP and SRJR Lifesciences LLP (promoters of the Company).

The Company has availed car loan from Kotak Mahindra bank. The loan was secured by hypothecation of the respective vehicles. The Company had not registered the charge for the said hypothecation in the year of purchase. The Company has repaid the loan during the year.



## Notes and other explanatory information to financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

Loan received from related party is repayable after completion of one year from the end of the financial year at the option of the related party .

There is no default as on the balance sheet date in the repayment of borrowings and interest thereon.

The Company is generally regular in registering and filling of satisfaction of charges with ROC within the statutory period.

The quarterly returns or statements of current assets filed by the Company with the banks or financial institutions are not in agreement with the books of accounts tabulated as follows:

Name of the Bank	Quarter Ended	Particulars of Security Provided	Amount as per books of accounts	Amount as reported in Quarterly Return	Variance	Remarks
ICICI Bank	Jun-24	Inventory	3,067.26	2,572.51	494.75	The relevant statements have been provided pending reconciliation and book closure for the corresponding periods due to the valuation finished goods and work in progress.
		Books Debts	3,089.89	3,188.40	(98.51)	
		Sundry Creditors	2,361.15	2,025.82	335.33	
	Sep-24	Inventory	2,747.12	2,126.02	621.10	
		Books Debts	3,371.50	3,410.05	(38.55)	
		Sundry Creditors	2,287.00	1,889.73	397.27	
	Dec-24	Inventory	2,965.33	2,320.67	644.66	
		Books Debts	3,157.95	3,287.46	(129.51)	
		Sundry Creditors	2,411.63	2,035.98	375.65	
	Mar-25	Inventory	2,808.61	2,183.34	625.27	
		Books Debts	4,017.35	4,095.44	(78.09)	
		Sundry Creditors	3,094.52	2,892.15	202.37	

### 16 GOVERNMENT GRANTS

	Non Current		Current	
	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Government Grants	191.42	161.47	16.55	9.88
	<b>191.42</b>	<b>161.47</b>	<b>16.55</b>	<b>9.88</b>

### 17 SHORT TERM BORROWINGS

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Current maturities of Long Term Borrowings	559.97	362.49
Cash Credits	857.04	1,001.12
	<b>1,417.01</b>	<b>1,363.61</b>

### 18 TRADE PAYABLES

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Trade Payables (including acceptances)		
(a) total outstanding dues of micro enterprises and small enterprises	930.21	1,304.46
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	2,164.31	2,237.77
	<b>3,094.52</b>	<b>3,542.23</b>

## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### Ageing for Trade Payables as at 31st March, 2025

Particulars	Outstanding for following Periods from Due Date of Payment*				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
MSME	930.22	-	-	-	930.22
Others	2,145.49	1.58	-	17.24	2,164.31
Disputed Dues- MSME	-	-	-	-	-
Disputed Dues- Other Than MSME	-	-	-	-	-
	<b>3,075.71</b>	<b>1.58</b>	<b>2.78</b>	<b>14.46</b>	<b>3,094.53</b>

### Ageing for Trade Payables as at 31st March, 2024

Particulars	Outstanding for following Periods from Due Date of Payment*				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
MSME	1,304.46	-	-	-	1,304.46
Others	1,867.75	-	355.06	14.96	2,237.77
Disputed Dues- MSME	-	-	-	-	-
Disputed Dues- Other Than MSME	-	-	-	-	-
	<b>3,172.21</b>	<b>-</b>	<b>355.06</b>	<b>14.96</b>	<b>3,542.23</b>

\*Ageing has been calculated from the date of transaction.

## 19 OTHER FINANCIAL LIABILITIES

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Interest accrued but not due on Borrowings	7.52	8.96
Other Payables	250.88	174.41
	<b>258.40</b>	<b>183.37</b>

## 20 OTHER LIABILITIES

	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Salaries and other benefits Payable	146.47	129.92
Advance from Customers	84.04	16.26
Taxes Payable (Other than Income Tax)	16.47	21.58
Employee Contributions Payable	13.41	14.96
	<b>260.39</b>	<b>182.72</b>

## 21 PROVISIONS

	Non Current		Current	
	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Provision for Leave Encashment	47.82	39.17	13.18	12.61
Provision for Bonus	-	-	76.14	65.86
Provision for Gratuity	-	-	48.98	48.02
	<b>47.82</b>	<b>39.17</b>	<b>138.30</b>	<b>126.49</b>



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 22 REVENUE FROM OPERATIONS

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
Domestic Sales	7,203.41	5,673.92
Export Sales	7,297.80	9,419.81
Analytical Income	84.49	152.84
	<b>14,585.70</b>	<b>15,246.57</b>

### 23 OTHER INCOME

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
<b>Interest Income</b>		
-From Bank	7.98	10.13
-From Others	5.66	2.40
Gain/(Loss) on Foreign Exchange Difference (Net)	134.44	167.18
Rent	0.57	1.07
Freight Income	44.83	23.20
Sale of MEIS Script	16.78	9.70
Claim Received from Insurance	23.27	-
Profit on Sale of Assets	-	6.57
Deferred Income-Government Grants	13.38	10.44
Management Consultancy Fees	-	87.33
Misc. Income	27.31	34.22
	<b>274.22</b>	<b>352.24</b>

### 24 COST OF MATERIALS CONSUMED

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
Consumption of Raw Material, Chemicals and Packing Materials	7,448.56	7,901.24
	<b>7,448.56</b>	<b>7,901.24</b>

### 25 PURCHASE OF TRADED GOODS

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
Purchases - Trading Materials	-	1,256.91
	<b>-</b>	<b>1,256.91</b>



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 26 MANUFACTURING EXPENSES

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
Manufacturing Expenses	458.77	364.63
Consumables	115.30	129.34
Analytical Expenses	139.58	108.80
<b>Repairs and Maintenance</b>		
-Machinery Maintenance	133.77	244.63
-Lab Equipment Maintenance	147.13	43.41
-Factory Maintenance	77.39	60.33
-Others	172.67	214.88
Chemical Expenses	120.60	105.60
Security Charges	22.11	21.32
Power and Fuel	767.44	669.15
Freight Charges	58.13	55.66
	<b>2,212.89</b>	<b>2,017.75</b>

### 27 CHANGE IN INVENTORIES OF WORK IN PROGRESS AND FINISHED GOODS

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
<b>Opening Stock:</b>		
-Work-in-Progress	912.92	514.78
-Finished Goods	306.49	219.45
	<b>1,219.41</b>	<b>734.23</b>
<b>Closing Stock:</b>		
-Work-in-Progress	382.06	912.92
-Finished Goods	192.70	306.49
	<b>574.76</b>	<b>1,219.41</b>
<b>(Increase)/ Decrease in Closing Stock</b>	<b>644.65</b>	<b>(485.18)</b>

### 28 EMPLOYEE BENEFITS EXPENSES

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
Salaries, allowances and benefits to employees	1,905.38	1,728.33
Contribution to Provident Fund and Other Funds	121.24	116.81
Staff Welfare Expense	76.35	57.60
	<b>2,102.97</b>	<b>1,902.74</b>

### 29 FINANCE COST

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
Interest	256.21	193.75
Other Borrowing Cost (Upfront Fees, Commitment Charges etc.)	16.92	35.28
	<b>273.13</b>	<b>229.03</b>



## Notes and other explanatory information to financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 30 DEPRECIATION AND AMORTIZATION EXPENSE

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
Depreciation on PPE	488.97	499.54
	<b>488.97</b>	<b>499.54</b>

### 31 OTHER EXPENSES

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
Rent	22.53	20.99
Rates and taxes	90.81	103.27
Liquidated Damages	-	1.64
<b>Repairs and Maintenance:</b>		
-Computer Software	27.03	24.46
-Others	10.71	9.86
Packing Expenses	1.16	0.56
Freight and Transportation	282.24	220.01
Insurance	26.26	31.79
Research and Registration Expenses	145.41	26.65
Donations	18.00	21.83
Business Promotion and Advertisement	34.94	47.18
Directors Sitting Fees	6.78	4.84
Electricity Charges	4.58	3.90
Marketing and Selling Expenses	-	12.92
Postage and Courier	4.84	4.76
Printing and Stationery	28.71	23.99
Legal and Professional Fees	221.99	828.82
<b>Remuneration to auditors (As Auditor):</b>		
-Audit Fee	12.00	8.00
-Reimbursement of Expenses to Auditors	1.58	0.56
Provision for Expected Credit Loss	(30.09)	52.51
Provision on Recoverability of Non Financial Assets (Net)	79.62	-
Travelling and conveyance	51.43	57.54
Bad Debts written off	1.82	7.47
Loss on Sale of Assets	7.44	-
Communication expenses	6.50	6.15
Miscellaneous expenses	2.65	22.29
	<b>1,058.94</b>	<b>1,541.99</b>

### 32 EXCEPTIONAL ITEM

Exceptional items for the year ended 31<sup>st</sup> March 2025 represents

- Derecognition of certain inventory items amounting to INR 37.56 Lakhs
- Derecognition of Intangible Asset under Development amounting to INR 177 Lakhs. The management has derecognised the Intangible Asset under Development as it does not foresee that any future economic benefit would accrue to the Company in respect of the expenditure incurred in the earlier financial years towards obtaining certain product registrations.



## Notes and other explanatory information to financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 33 EARNING PER SHARE

The Company's Earnings Per Share ("EPS") is determined based on the net profit attributable to the shareholders of the Company. Basic earnings per share is computed using the weighted average number of shares outstanding during the year. Diluted earnings per share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the year including share options, except where the result would be anti-dilutive.

		For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
<b>Total Operations for the year</b>			
Net Profit Attributable to Equity Shareholders for calculation of Basic Earnings Per Share		415.25	734.79
<b>Net Profit/(Loss) for calculation of Basic EPS</b>	<b>(A)</b>	<b>415.25</b>	<b>734.79</b>
<b>Net Profit as above</b>		<b>415.25</b>	<b>734.79</b>
Add : Dividends on convertible preference shares & tax thereon		-	-
Add : Interest on bonds/Debentures/Loan convertible into equity shares (Net of tax)		-	-
<b>Net Profit/(Loss) for calculation of Diluted EPS</b>	<b>(B)</b>	<b>415.25</b>	<b>734.79</b>
<b>Weighted Average Number of Equity Shares for Basic EPS</b>	<b>(C)</b>	236.56	236.56
<b>Weighted average number of Equity Shares for Diluted EPS</b>	<b>(D)</b>	236.56	236.56
<b>Basic EPS</b>	<b>(A) / (C)</b>	1.76	3.11
<b>Diluted EPS</b>	<b>(B) / (D)</b>	1.76	3.11

Diluted Earnings Per Share, when anti dilutive is restricted to Basic Earnings Per Share

### 34 EMPLOYEE BENEFITS

#### Leave of absence and encashment:

The Company has different leave plans including paid leave of absence plans and encashment of leave plans for employees at different grades and provision has been made in accordance with Ind AS-19. The total amount of provision available for the unavailed leave balances as at 31<sup>st</sup> March 2025 is INR 61 Lakhs (as at 31<sup>st</sup> March 2024 INR 51.78 Lakhs). Liability has been created based on actuarial valuation done during the year, with the Discount rate of 6.71% (Prev. Year 7.21%)

#### Defined Benefit Plans

The Company has a defined benefit gratuity plan, which is regulated as per the provisions of Payment of Gratuity Act, 1972. Employees who are in continuous service for a period of 5 years are eligible for gratuity. The amount of gratuity payable on retirement/ termination is the employee's last drawn basic salary per month computed proportionately for 15 days salary multiplied for the number of years of service. The scheme is funded by the Company. The liability for the same is recognized on the basis of actuarial valuation

		For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
<b>Net Employee Benefit Expense recognized in the Employee Cost in Statement of Profit &amp; Loss Account</b>			
Current Service Cost		34.83	34.93
Interest Cost on Benefit Obligation		23.91	21.49
Interest Income		(20.45)	(16.83)
<b>Sub Total</b>		<b>38.29</b>	<b>39.59</b>



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
<b>Recognised in Other Comprehensive Income</b>		
Net Actuarial (Gain)/Loss recognized in the year		
i. Actuarial (Gains)/Loss on Obligation For the Period	17.10	4.35
ii. Return on Plan Assets, Excluding Interest Income	1.40	(8.00)
<b>Sub Total</b>	<b>18.50</b>	<b>(3.65)</b>
<b>Net Benefit Expense</b>	<b>56.79</b>	<b>35.94</b>
<b>Balance Sheet</b>		
	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
<b>Benefit Asset / Liability</b>		
Present value of Defined Benefit Obligation	(386.94)	(340.95)
Fair Value of Plan Assets	337.96	292.93
Funded Status (Surplus/ (Deficit))	(48.98)	(48.02)
<b>Assets / (Liability) recognized in the Balance Sheet</b>	<b>(48.98)</b>	<b>(48.02)</b>
<b>Change in the Present Value of the Defined Benefit Obligation</b>		
Opening Defined Benefit Obligation	340.95	290.07
Benefits Paid	(29.87)	(9.90)
<b>Expenses Recognised in Statement of Profit and Loss Account</b>		
Current Service Cost	34.83	34.93
Interest cost on Benefit Obligation	23.91	21.49
<b>Recognised in Other Comprehensive Income</b>		
Actuarial (Gain)/Loss on Obligation	17.10	4.35
<b>Closing Defined Benefit Obligation</b>	<b>386.94</b>	<b>340.94</b>
<b>Change in the Fair Value of Plan Assets</b>		
Opening Fair Value of Plan Assets	292.93	227.16
Interest Income	20.45	16.83
Contributions by Employer	55.84	50.83
Return on Plan Assets	(1.40)	8.01
Benefits Paid	(29.87)	(9.90)
<b>Closing Fair Value of Plan Assets</b>	<b>337.96</b>	<b>292.93</b>
<b>Investment Details of the Plan Assets</b>		
Insurance Fund	333.15	278.02
Cash And Cash Equivalentents	4.81	14.91
Special Deposits	-	-
<b>Assumptions</b>		
Discount Rate (%)	7.21	7.41
Attrition Rate (%)	10.00	10.00
Expected rate of salary increase (%)	8.00	8.00

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

Amounts of Defined benefit plan for the current and three previous year are as follows

	Present value of Defined benefit obligation	Surplus / (deficit)	Experience adjustments on plan assets	Experience adjustments on plan liabilities
31 <sup>st</sup> March, 2025	(386.94)	(48.98)	1.40	17.10
31 <sup>st</sup> March, 2024	(340.95)	(48.02)	(8.00)	4.35
31 <sup>st</sup> March, 2023	(290.07)	(62.91)	(7.73)	(7.58)
31 <sup>st</sup> March 2022	(276.99)	(156.06)	(1.38)	3.78

Sensitivity analysis of the defined benefit obligation

Particulars	1% Increase		1% Decrease	
	31 <sup>st</sup> March, 2025	31 <sup>st</sup> March, 2024	31 <sup>st</sup> March, 2025	31 <sup>st</sup> March, 2024
Impact of the change in discount rate	(20.23)	(16.58)	22.82	18.66
Impact of the change in salary increase	21.22	17.59	(19.54)	(16.11)
Impact of the change in rate of Employee Turnover	(2.53)	(1.40)	2.74	1.50

**Note :** Sensitivity due to mortality and withdrawals are not material and hence impact of change not calculated.

### Defined Contribution Plans

In respect of the defined contribution plan (Provident fund), an amount of INR 76.28 Lakhs (31<sup>st</sup> March 2024: INR 70.66 Lakhs) has been recognized as expenditure in the Statement of Profit and Loss.

In respect of the State Plans (Employee State Insurance), an amount of INR 6.54 Lakhs (31<sup>st</sup> March 2024: INR 6.29 Lakhs) has been recognized as expenditure in the Statement of Profit and Loss.

During the year the Company has provided Bonus and incentive of INR 107.18 Lakhs (31<sup>st</sup> March 2024: INR 118.54 Lakhs) as expenditure in the Statement of Profit & Loss.

## 35 CONTINGENT LIABILITIES AND PENDING LITIGATIONS

A	Contingent Liabilities	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
a.	Letter of Credit and Bank Guarantees	833.66	833.66
b.	Bonds executed in favour of Customs Authorities for the purchase of materials and capital goods without payment of duty.	200.00	200.00
B	Claims Not Acknowledged as Debt	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
	Income Tax Act, 1961- Tax Deducted at Source	40.61	41.73
C	Pending Litigations	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
i.	Provident Fund*	33.67	33.67
ii.	Sales tax*	25.26	25.26
iii.	Service tax*	22.31	22.31
iv.	DGFT*	20.00	20.00
v.	Income Tax *	342.19	342.19
vi.	Goods & Service Tax**	235.47	235.47

\*The amounts referred herein above corresponds to the claims made by the relevant statutory authorities pertaining to pre - Corporate Insolvency Resolution Process ("CIRP") period. By virtue of Honourable NCLT order approving the resolution plan,



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

the relevant claims stands extinguished. The Company has also filed writ petitions before the Honourable Madras High Court requesting the demand to be quashed.

\*The Income Tax Refund amounting to INR 45.17 Lakhs has been adjusted against the previous years demand by the Income Tax Department. The Company has filed the writ petition in Honourable Madras High Court against such demands which has been issued by the Centralized Processing Centre ("CPC"). The management of the Company is of the view that post completion of CIRP, no such demands is payable by the Company. Based on the writ petition filed by the Company, the management is confident of obtaining a favourable outcome in this regard.

\*\*The Company has received the demand of INR 265.42 Lakhs including penalties for the period FY 2017-18 to FY 2020-21 against which a liability of INR 29.95 Lakhs has been paid by the Company. The Company has disputed INR 235.47 Lakhs and filed the appeal with CGST Appeals. Based on the management assessment, the Company is of the opinion that said demand will be set aside and there will be no liability.

**36** The Company has received communications from BSE Limited and National Stock Exchange of India Limited regarding the non-compliance with respect to certain regulations including Minimum Public Shareholding ("MPS") requirements specified in Rule 19 (2) and Rule 19A of the Securities Contracts (Regulations) Rules, 1957, as amended and Regulation 38 of the Listing Obligations and Disclosure Requirements Regulations of Securities Exchange Board of India ("SEBI") ("Listing Regulations"). The Company has created a provision of INR 163.68 Lakhs as on 31<sup>st</sup> March 2025 (as on 31<sup>st</sup> March 2024: INR 88.39 Lakhs) towards penalties and also the Company has requested waiver for such penalties and also subsequently met the MPS criteria. Based on the internal assessment and communication with the BSE Limited and National Stock Exchange of India Limited, the management is confident of obtaining waiver from such penalties.

### 37 SEGMENT REPORTING



The Company is engaged in the business of manufacturing and trading of pharmaceuticals products. The Chief Operating Decision Maker monitors the operating results of its business for the purpose of making decisions about resource allocation and performance. Manufacturing and trading of pharmaceuticals products is considered as only segment.

### 38 RELATED PARTY DISCLOSURE

#### a) Name of Related parties and description of relationship

Name of the Related Parties	Designation	Close Family Members
SRJR Lifesciences LLP	Holding Company	
S. Hemalatha	Whole Time Director	
P K Sundaresan	Independent & Non Executive Director	
B. Kamlesh Kumar	Independent & Non Executive Director (upto 9 <sup>th</sup> September, 2023)	
R. Chitra	Chairperson, Independent & Non Executive Director	
Akila C Raju	Non Executive Director	
Upendar Mekala Reddy	Non Executive Director (with effect from 26 <sup>th</sup> June 2023)	
Krishna Yeachuri	Independent & Non Executive Director (with effect from 26 <sup>th</sup> June 2023 and upto 31 <sup>st</sup> March, 2025)	
Vinayak Dinesh Dendukuri	Whole Time Director (with effect from 26 <sup>th</sup> June 2023)	
Bafna Mahaveer Chand	Chief Executive Officer	Sasikala Bafna- Wife Navin Bafna- Son Ruchika Saraf- Daughter-in-Law
Melagiri Sridhar	Chief Financial Officer	
Vishnu V Kuppa	Company Secretary (with effect from 7 <sup>th</sup> April 2023 till 23 <sup>rd</sup> April 2024)	
Mohan Chandran	Company Secretary (with effect from 29 <sup>th</sup> May 2024)	



## Notes and other explanatory information to financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### Enterprises owned or significantly influenced by key management personnel or their relatives (either individually or with others)

Bhansilal & Co

Saffolco Pharmachem LLP

SMN Pharma Private Limited

### b) Transactions During the Year with Related Parties

Name of the Related Parties	Nature of Transactions	For the Year Ended 31 <sup>st</sup> March 2025	For the Year Ended 31 <sup>st</sup> March 2024
Bafna Mahaveer Chand	Remuneration	72.00	75.18
Navin Bafna	Remuneration	26.40	25.20
Navin Bafna	Salary Advance Paid/ (Recovered)	2.17	-
Navin Bafna	Salary Advance Paid/ (Recovered)	(0.87)	-
S. Hemalatha	Remuneration	19.29	17.79
S. Hemalatha	Salary Advance Paid/ (Recovered)	-	(1.08)
Vinayak Dinesh Dendukuri	Remuneration	33.12	22.07
Vinayak Dinesh Dendukuri	Salary Advance Paid/ (Recovered)	(0.58)	0.58
Melagiri Sridhar	Remuneration	14.75	13.73
Melagiri Sridhar	Salary Advance Paid/ (Recovered)	(2.00)	2.75
Vishnu V Kuppa	Remuneration	0.17	9.59
Mohan Chandran	Remuneration	9.27	-
Sasikala Bafna	Rent	17.70	17.70
Bafna Mahaveer Chand	Loan Repaid/ (Taken)	-	0.60
P K Sundaresan	Sitting Fees	1.67	1.21
B. Kamlesh Kumar	Sitting Fees	-	0.88
R. Chitra	Sitting Fees	1.56	1.10
Krishna Yechuri	Sitting Fees	0.89	0.22
Akila C Raju	Sitting Fees	1.11	0.88
Upendar Mekala Reddy	Sitting Fees	1.56	0.55
Bhansilal & Co	Rent	0.12	0.12

### c) Year End Balances

Name of the Related Parties	Nature of Transactions	As at 31 <sup>st</sup> March, 2025	As at 31 <sup>st</sup> March, 2024
Bafna Mahaveer Chand	Loan Payable	150.07	150.07
Navin Bafna	Salary Advance Receivable	1.30	-
Melagiri Sridhar	Salary Advance Receivable	-	2.00

## 39 CAPITAL MANAGEMENT

The objective of the Company's capital management structure is to ensure sufficient liquidity to support its business, to ensure the Company's ability to continue as a going concern and provide adequate return to shareholders.

The Company monitors capital and the long term cash flow requirements including externally imposed capital requirements of the business on the basis of the carrying amount of equity less cash and cash equivalents as presented on the face.

Management assesses the Company's capital requirements in order to maintain an efficient overall financing structure while avoiding excessive leverage. This takes into account the subordination levels of the Company's various classes of debt. The



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets.

Particulars	As at	As at
	31 <sup>st</sup> March, 2025	31 <sup>st</sup> March, 2024
Net Debts (Net of Cash and Cash Equivalents) (A)	2,476.59	2,299.33
Total Equity (B)	8,480.65	8,083.90
Net Debt to Equity Ratio (Times) (C)=(A)/(B)	0.29	0.28

### 40 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

#### Financial Risk Management Framework

Company's principal financial liabilities comprises of borrowings, trade payables and Other financial liabilities. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include trade receivables, loans, cash and bank balances and other financial assets.

#### Risk Exposures and Responses

The Company is exposed to market risk, credit risk and liquidity risk. The Board of Directors reviews policies for managing each of these risks, which are summarised below.

#### i) Market risk

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from a change in the price of a financial instrument. The value of a financial instrument may change as a result of changes in the interest rates, foreign currency exchange rates, commodity prices, equity prices and other market changes that affect market risk sensitive instruments. Market risk is attributable to all market risk sensitive financial instruments including investments and deposits, foreign currency receivables, payables and borrowing.

#### Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's borrowing with floating interest rates. The Company constantly monitors the credit markets and rebalances its financing strategies to achieve an optimal maturity profile and financing cost. The Company's exposure to interest rate risk relates primarily to interest bearing financial liabilities. Interest rate risk is managed by the Company on an on-going basis with the primary objective of limiting the extent to which interest expense could be affected by an adverse movement in interest rates.

There are no hedging instruments to mitigate this risk.

#### Sensitivity Analysis

An increase/decrease of 100 basis points in interest rate at the end of the reporting period for the variable financial instruments would increase/(decrease) profit before taxation for the year by the amounts shown below. This analysis assumes all other variables remain constant.

	Profit / (Loss) before taxation	
	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
<b>Financial Liabilities - Borrowings</b>		
+1% (100 basis points)	(22.25)	(17.09)
-1% (100 basis points)	22.25	17.09



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### Foreign currency risk

Foreign currency risk is the risk that the fair value of future cash flows of a financial instruments will fluctuate because of changes in foreign exchange rates. The Company is exposed to foreign exchange risk arising from transactions i.e. import and export of materials, recognised assets and liabilities denominated in a currency that is not the Company's functional currency. The Company's foreign currency risks are identified, measured and managed at periodic intervals in accordance with the Company's policies.

### Company's Foreign Currency Exposures\*

As at 31<sup>st</sup> March, 2025

	Currency	Exchange Rate	Amount in Foreign Currency (in Lakhs)	Amount
Trade Receivables	USD	85.62	15.04	1,287.73
Trade Receivables	AUD	53.55	9.77	523.18
Trade Receivables	GBP	110.55	2.93	323.91
Advance from Customers	EUR	92.6	(0.04)	(3.36)

As at 31<sup>st</sup> March, 2024

	Currency	Exchange Rate	Amount in Foreign Currency (in Lakhs)	Amount
Trade Receivables	USD	82.25	9.21	757.82
Trade Receivables	AUD	53.85	8.38	451.31
Trade Receivables	GBP	104.65	7.17	750.68
Advance from Customers	EUR	89.35	(0.45)	(40.53)

\* Total Foreign currency exposure as on 31<sup>st</sup> March 2025 and 31<sup>st</sup> March 2024 is unhedged.

### Sensitivity

If foreign currency rates had moved as illustrated in the table below, with all other variables held constant, currency fluctuations on unhedged foreign currency denominated financial instruments, Pre- Tax Profit/ (Loss) would have been affected as follows:

	Profit / (Loss) before taxation	
	For the Year Ended 31 <sup>st</sup> March, 2025	For the Year Ended 31 <sup>st</sup> March, 2024
<b>USD sensitivity</b>		
INR/USD- increase by 5%	64.39	37.89
INR/USD- decrease by 5%	(64.39)	(37.89)
<b>AUD sensitivity</b>		
INR/AUD- increase by 5%	26.15	22.57
INR/AUD- decrease by 5%	(26.15)	(22.57)
<b>GBP sensitivity</b>		
INR/GBP- increase by 5%	16.17	37.53
INR/GBP- decrease by 5%	(16.17)	(37.53)
<b>EUR sensitivity</b>		
INR/EUR- increase by 5%	(0.17)	(2.03)
INR/EUR- decrease by 5%	0.17	2.03



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### Commodity Risk

Exposure to market risk with respect to commodity prices primarily arises from the Company's purchases of Active Pharmaceutical Ingredients and other direct materials, whose prices are exposed to risk of fluctuation over a period of time. The prices of the Company's raw materials generally fluctuate in line with commodity cycles, although the prices of raw materials used in the Company's active pharmaceutical ingredients business are generally more volatile. Cost of raw materials forms the largest portion of the Company's cost. Commodity price risk exposure is evaluated and managed through operating procedures and sourcing policies. As of 31<sup>st</sup> March, 2025, the Company had not entered into any material derivative contracts to hedge exposure to fluctuations in commodity prices.

### ii. Credit risk

Credit risk is the risk of financial loss to the Company if the customer or that counterparty to the financial instrument fails to meet its contractual obligations and arises principally from the Company's receivables from customers, loans and investments. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of counterparty to which the Company grants credit terms in the normal course of business.

#### Credit risk management

The finance function of the Company assesses and manages credit risk based on internal credit rating system. Internal credit rating is performed for each class of financial instruments with different characteristics. The Company assesses the credit risk for each class of financial assets based on the assumptions, inputs and factors specific to the class of financial assets.

The risk parameters are same for all financial assets for all periods presented. The Company considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk on an on-going basis throughout each reporting period. In general, it is presumed that credit risk has significantly increased since initial recognition if the payments are more than 30 days past due. A default on a financial asset is when the counterparty fails to make contractual payments when they fall due. This definition of default is determined by considering the business environment in which entity operates and other macro-economic factors.

**Trade Receivables:** The Company has exposure to credit risk from trade receivables on sale of pharmaceuticals products and related services. The Company has used Expected Credit Loss (ECL) model for assessing the impairment loss. For that purpose, the Company uses a provision matrix to compute the ECL amount. The provision matrix takes into account external and internal risk factors and historical data of credit losses from various customers. The Company ensures concentration of credit does not significantly impair the financial assets since the customers to whom the exposure of credit is given are well established and reputed industries engaged in their respective field of business. The creditworthiness of customers to which the Company grants credit in the normal course of the business is monitored regularly. The Company provides for expected credit loss under simplified approach.



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

	Loans	Trade Receivables	Other Financial Assets
<b>Loss allowance as on 1<sup>st</sup> April, 2023</b>	-	36.86	-
<b>Add / (less)</b>			
Modification of contractual cash-flows that did not result in de-recognition	-	-	-
Expected Credit Loss	-	52.51	-
Recoveries	-	-	-
Impairment	-	-	-
<b>Loss allowance on 31<sup>st</sup> March, 2024</b>	-	<b>89.37</b>	-
<b>Add / (less)</b>			
Modification of contractual cash-flows that did not result in de-recognition	-	-	-
Expected Credit Loss	-	(30.09)	-
Recoveries	-	-	-
Impairment	-	-	-
<b>Loss allowance on 31<sup>st</sup> March, 2025</b>	-	<b>59.28</b>	-

### iii. Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation. Prudent liquidity risk management implies maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due. Due to the nature of the business, the Company maintains flexibility in funding by maintaining availability under committed facilities. The Company's treasury team is responsible for liquidity, funding as well as settlement management. In addition, processes and policies related to such risks are overseen by senior management. Management monitors the Company's liquidity position through rolling forecasts on the basis of expected cash flows.

The table below provides details regarding the remaining contractual maturities of the Company's financial liabilities at the end of the reporting date, which are based on the contractual undiscounted cash flows and the earliest date the Company is required to pay:

Particulars	Less than 1 year	1-2 year	2-3 year	More than 3 years	Total
<b>As at 31<sup>st</sup> March, 2025</b>					
Borrowings	1,417.01	503.61	393.61	355.56	2,669.79
Borrowings from Related Parties	-	150.07	-	-	150.07
Trade Payables & Other Financial Liabilities	3,352.92	-	-	-	3,352.92
<b>Total</b>	<b>4,769.93</b>	<b>653.68</b>	<b>393.61</b>	<b>355.56</b>	<b>6,172.78</b>
<b>As at 31<sup>st</sup> March, 2024</b>					
Borrowings	1,363.61	353.02	296.67	275.56	2,288.86
Borrowings from Related Parties	-	150.07	-	-	150.07
Trade Payables & Other Financial Liabilities	3,725.60	-	-	-	3,725.60
<b>Total</b>	<b>5,089.21</b>	<b>503.09</b>	<b>296.67</b>	<b>275.56</b>	<b>6,164.53</b>



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### Financial instruments by category

For amortised cost instruments, carrying value represents the best estimate of fair value.

	As at 31 <sup>st</sup> March , 2025		
	FVTPL	FVTOCI	Amortised Cost
<b>Financial assets</b>			
Trade receivables	-	-	4,017.35
Non current invesments		0.05	-
Loans	-	-	2.30
Cash and cash equivalents	-	-	343.27
Other Financial Assets (Non Current and Current)	-	-	80.66
<b>Total</b>	<b>-</b>	<b>0.05</b>	<b>4,443.58</b>
<b>Financial liabilities</b>			
Borrowings (Non Current and Current)	-	-	2,819.86
Trade payables	-	-	3,094.52
Other Financial Liabilities	-	-	258.40
<b>Total</b>	<b>-</b>	<b>-</b>	<b>6,172.78</b>

	As at 31 <sup>st</sup> March, 2024		
	FVTPL	FVTOCI	Amortised Cost
<b>Financial assets</b>			
Trade receivables	-	-	4,539.48
Loans	-	-	8.18
Cash and cash equivalents	-	-	139.60
Other Financial Assets (Non Current and Current)	-	-	143.62
<b>Total</b>	<b>-</b>	<b>-</b>	<b>4,830.64</b>
<b>Financial liabilities</b>			
Borrowings (Non Current and Current)	-	-	2,438.93
Trade payables	-	-	3,542.23
Other Financial Liabilities	-	-	183.37
<b>Total</b>	<b>-</b>	<b>-</b>	<b>6,164.53</b>

## 41 FAIR VALUE MEASUREMENTS

### (i) Fair value hierarchy

Financial assets and Financial Liabilities measured at fair value in the Financial Statements are grouped into three Levels of a fair value hierarchy. The three Levels are defined based on the observability of significant inputs to the measurement, as follows:

**Level 1:** Quoted prices (unadjusted) in active markets for identical assets or liabilities.

**Level 2:** Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (prices) or indirectly (derived from prices).

**Level 3:** Inputs for the asset or liability that are not based on observable market data.



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

(ii) Financial Assets and Liabilities Measured at Fair Value - Recurring Fair Value Measurements at:

As at 31 <sup>st</sup> March, 2025	Level 1	Level 2	Level 3	Total
<b>Financial Assets</b>				
Investments at FVTOCI				
Investment in Equity Shares	-	-	0.05	0.05
<b>Total Financial Assets</b>	-	-	<b>0.05</b>	<b>0.05</b>
As at 31 <sup>st</sup> March, 2024	Level 1	Level 2	Level 3	Total
<b>Financial Assets</b>				
Investments at FVTOCI				
Investment in Equity Shares	-	-	-	-
<b>Total Financial Assets</b>	-	-	-	-

(iii) Assets and Liabilities which are measured at Amortised Cost for which Fair Values are Disclosed

As at 31 <sup>st</sup> March, 2025	Level 1	Level 2	Level 3	Total
<b>Financial Assets</b>				
Other Financial Assets (Non Current and Current)	-	-	80.66	80.66
Trade Receivables (Net of ECL)	-	-	4,017.35	4,017.35
Loans	-	-	2.30	2.30
Cash and Cash Equivalents	-	-	343.27	343.27
<b>Total Financial Assets</b>	-	-	<b>4,443.63</b>	<b>4,443.63</b>
<b>Financial Liabilities</b>				
Borrowings- Non Current	-	-	1,402.85	1,402.85
Borrowings-Current	-	-	1,417.01	1,417.01
Trade Payables	-	-	3,094.52	3,094.52
Other Financial Liabilities	-	-	258.40	258.40
<b>Total Financial Liabilities</b>	-	-	<b>6,172.78</b>	<b>6,172.78</b>

As at 31 <sup>st</sup> March, 2024	Level 1	Level 2	Level 3	Total
<b>Financial Assets</b>				
Other Financial Assets (Non Current and Current)	-	-	143.62	143.38
Trade Receivables (Net of ECL)	-	-	4,539.48	4,539.48
Loans	-	-	8.18	8.18
Cash and Cash Equivalents	-	-	139.60	139.60
<b>Total Financial Assets</b>	-	-	<b>4,830.64</b>	<b>4,830.64</b>
<b>Financial Liabilities</b>				
Borrowings- Non Current	-	-	1,075.32	1,075.32
Borrowings-Current	-	-	1,363.61	1,363.61
Trade Payables	-	-	3,542.23	3,542.23
Other Financial Liabilities	-	-	183.37	183.37
<b>Total Financial Liabilities</b>	-	-	<b>6,164.53</b>	<b>6,164.53</b>



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### Valuation Process and Technique Used to Determine Fair Value

Specific valuation techniques used to value financial instruments include:

- (a) The use of quoted market prices or dealer quotes for similar instruments
- (b) The fair value of the remaining financial instruments is determined based on the following methods:
  - i. Net assets value method
  - ii. Valuation of investment in unquoted equity shares has been made using the Discounted cash-flow method and Net assets value method, as deemed fit by the Company's management.

Risk adjustments specific to the counterparties (including assumptions about credit default rates) are derived from credit risk grading determined by the Company's internal credit risk management group.

## 42 ANALYTICAL RATIOS

Ratio	Numerator	Denominator	As at 31 <sup>st</sup> March 2025	As at 31 <sup>st</sup> March 2024	% Variance	Reasons for Variance
Current Ratio (in times)	Total Current Assets	Total Current Liabilities	1.63	1.75	-6.63%	
Debt- Equity Ratio (in times)	Debt consists of borrowings and lease liabilities	Total equity	0.33	0.30	10.21%	
Debt service coverage ratio (in times)	Earning for Debt Service = Net Profit after taxes + Non-cash operating expenses (Dep and Amortization) + Interest + Other non-cash adjustments (loss on sale of Fixed Assets)	Debt service = Interest and lease payments + Principal repayments	0.40	0.95	-58.04%	Increase in Borrowings for Capital Expenditure
Return on equity ratio (in %)	Profit for the year less Preference dividend (if any)	Average total equity	5.01%	9.52%	-47.33%	Due to write off of Intangible Assets and increase in Borrowings
Inventory Turnover Ratio	Sales	Average Inventory	5.05	5.88	-14.06%	
Trade receivables turnover ratio (in times)	Revenue from operations	Average trade receivables	3.41	3.52	-3.15%	
Trade payables turnover ratio (in times)	Cost of rendering of Services + Other expenses	Average trade payables	2.91	3.50	-16.81%	
Net capital turnover ratio (in times)	Revenue from operations	Average Working capital (i.e. Total current assets less Total current liabilities)	4.02	3.75	7.20%	
Net profit ratio (in %)	Profit for the year	Total Income	2.79%	4.71%	-40.68%	Due to write off of Intangible Assets and increase in Borrowings
Return on capital employed (in %)	Profit before tax + finance costs - interest income	Capital employed = Net worth + Borrowings + Lease liabilities + Deferred tax liabilities - Current Investment - Cash and Cash Equivalents - Other Bank Balances	6.21%	9.18%	-32.39%	Due to write off of Intangible Assets and increase in Borrowings



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

Ratio	Numerator	Denominator	As at 31 <sup>st</sup> March 2025	As at 31 <sup>st</sup> March 2024	% Variance	Reasons for Variance
Return on investment (in %)	Net Profit after taxes	Average Total Assets = Average of Opening Total Assets and Closing Total Assets excluding revaluation impact	2.76%	5.30%	-47.90%	Due to write off of Intangible Assets and increase in Borrowings

### 43 LEASES

#### Company as lessee

The Company has entered into certain cancellable lease agreements mainly for office premises, land and infrastructure facilities' which are renewable on mutual agreement with the parties. At the date of commencement of the lease, the Company recognises a right of use asset and a corresponding lease liability for all lease arrangements in which it is a lessee, except for short-term leases and low value leases. The Company applies the "short term lease" & "low value leases" recognition exemptions for these leases. Rent Expenses recorded for Short term and Low value lease was INR 22.53 Lakhs (31<sup>st</sup> March, 2024: INR 20.99 Lakhs).

### 44 INCOME TAX

The Company has opted for the new tax regime U/s 115BAA of the Income Tax Act from Financial Year ended 31<sup>st</sup> March 2023. The Company has carried forward losses and unabsorbed depreciation of earlier years. Therefore, the Company has not accounted any Income Tax on the profits earned during the year.

### 45 DEFERRED TAX

Deferred Tax assets arises on account of carried forward losses and unabsorbed tax depreciation. As a prudent measure DTA is not recognised since it is not probable that future taxable profits will be available against which carried forward losses and unabsorbed tax depreciation can be utilised.

### 46 CORPORATE SOCIAL RESPONSIBILITY (CSR)

(a) As per Section 135 of the Companies Act, 2013, a CSR committee has been formed by the Company. The areas for CSR activities are promoting education, preventive healthcare, special education and employment enhancing vocation skills, rural /nationally recognised/ Paralympic and Olympic sports, and Rural Development.

(b) Details of Corporate Social Responsibility (CSR) Expenditure:

Particulars	31 <sup>st</sup> March 2025	31 <sup>st</sup> March 2024
Amount Required to be Spent as per Section 135 of the Act	17.10	15.71
Amount Spent During the Year	17.11	3.00
Shortfall at the end of the year	-	12.71
Reason for shortfall	-	Other than on going projects
<b>Total spent during the year</b>	<b>17.11</b>	<b>3.00</b>

For the year ended 31<sup>st</sup> March 2024, the Company has transferred the unspent amount to the specified funds within the the time period for such transfer i.e. six months from the end of the Financial Year ended 31<sup>st</sup> March 2024.

### 47 DISCLOSURES OF THE TRANSACTIONS WITH STRUCK OFF COMPANIES

The Company did not have any transactions with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the financial year.



## Notes and other explanatory information to Financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 48 ADDITIONAL REGULATORY INFORMATION REQUIRED BY SCHEDULE III TO THE COMPANIES ACT, 2013

- (i) The Company does not have any Benami property held in its name. No proceedings have been initiated on or are pending against the Company for holding benami property under the Prohibition of Benami Property Transactions Act, 1988 and Rules made thereunder.
- (ii) The Company has not been declared wilful defaulter by any bank or financial institution or other lender or government or any government authority.
- (iii) The Company does not hold any investments in any subsidiary(ies), therefore, the provisions for compliance with the number of layers prescribed under clause (87) of section 2 of the Companies Act, 2013 read with the Companies (Restriction on number of Layers) Rules, 2017 (as amended) are not applicable.
- (iv) **Details of transactions of advances or loans or investments of funds (either from the borrowed funds or share premium or any other sources or kind of funds), as prescribed to any other person(s) or entity (ies), including foreign entities (intermediaries)**
  - A The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
    - (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
    - (b) Provide any guarantee, security or the loan to or on behalf of the ultimate beneficiaries
  - B The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
    - (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
    - (b) Provide any guarantee, security or the loan on behalf of the ultimate beneficiaries
- (v) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
- (vi) The Company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.
- (vii) No Scheme of Arrangements have been approved by the Competent Authority in terms of Sections 230 to 237 of the Act, during the year.

- 49 The Company has foreign currency receivables as on 31<sup>st</sup> March, 2025 of INR 120 Lakhs (31<sup>st</sup> March 2024: INR 174 Lakhs) which are outstanding beyond the stipulated time period permitted under the RBI Master Direction on Export of Goods and Services vide FED Master Direction No. 16/2015-16 dated 1<sup>st</sup> January, 2016 (as amended), issued by the Reserve Bank of India (RBI) as of 31<sup>st</sup> March, 2025. The management of the Company is in the process of obtaining approval for extension of time limits for realization and also in process of receiving the payment and in regular discussion with the Customers. The Management of the Company is confident of obtaining the approval for time extension and recovery of the amount within such extended time period.



## Notes and other explanatory information to financial Statements

for the year ended 31<sup>st</sup> March, 2025

(Amount are in INR Lakhs unless specified)

### 50 DISCLOSURES REQUIRED UNDER SECTION 22 OF MSMED ACT 2006 UNDER THE CHAPTER ON DELAYED PAYMENTS TO MICRO, SMALL AND MEDIUM ENTERPRISES

As at Balance Sheet date, amounts aggregating to INR 930.21 Lakhs were due to Micro, Small Enterprises as per the provisions of the Micro, Small and Medium Enterprises Development Act, 2006.

Particulars	As at	As at
	31 <sup>st</sup> March, 2025	31 <sup>st</sup> March, 2024
(a) The principal amount remaining unpaid to any supplier at the end of each accounting year;	930.21	1,304.46
(b) The interest payable	9.53	-
(c) The amount of interest paid by the buyer along with the amount of the payment made to the supplier beyond the due date (as per PO or 45 days whichever is earlier) during each accounting year;	-	-
(d) The amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006;"	-	-
(e) The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
(f) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006	9.53	-

**51** The Board of Directors of the Company, at its meeting held on 13<sup>th</sup> August 2024, had approved the sale of assets of the manufacturing unit of the Company located at Madhavaram, subject to regulatory approvals, which was also approved by the shareholders at Annual General Meeting held on 25<sup>th</sup> September 2024. Accordingly, the assets of the Madhavaram unit is classified as "Non Current Assets Held for Sale". The management expects the sale process to be concluded in the ensuing periods.

**52** Previous year figures have been regrouped/reclassified where ever necessary, to conform to those of the current year.

**53** As allowed under Schedule III of the Companies Act, 2013, Financial Statements are prepared in Lakhs and rounded off to two decimals. The amounts / numbers below one thousands are appearing as zero.

In Terms of our Report of even date

**For Brahmayya & Co.**  
Chartered Accountants  
Firm Regn No. 000511S

**Lokesh Vasudevan**  
Partner  
M.No. 222320

Place: Chennai  
Date: 26<sup>th</sup> May 2025

For and on behalf of the Board  
**Bafna Pharmaceuticals Limited**

**S. Hemalatha**  
Whole Time Director  
DIN : 02714329

**Melagiri Sridhar**  
Chief Financial Officer

Place: Chennai  
Date: 26<sup>th</sup> May 2025

**Vinayak Dinesh Dendukuri**  
Whole Time Director  
DIN : 07601309

**Mohanachandran A**  
Company Secretary  
M.No.65827

**Bafna Mahaveer Chand**  
Chief Executive Officer

Notes

A series of horizontal dashed lines for writing notes.



Notes

A series of horizontal dashed lines for writing notes.



Notes

A series of horizontal dashed lines for writing notes.







## **BAFNA PHARMACEUTICALS LTD.**

Regd. Office: New No. 68, Old No. 299, Thambu Chetty Street, Chennai - 600001

Ph: 044 42677555, Fax: 044 42677599

Email: [info@bafnapharma.com](mailto:info@bafnapharma.com)

Web: [www.bafnapharma.com](http://www.bafnapharma.com)